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ABSTRACT
Measuring the Interactions and Cooperativity Between Ionic, Aromatic, and Nonpolar Amino
Acids in Protein Structure
Mason Scott Smith
Department of Chemistry and Biochemistry, BYU
Doctor of Philosophy
Protein folding studies have provided important insights about the key role of noncovalent interactions in protein structure and conformational stability. Some of these interactions
include salt bridges, cation- π, and anion-π interactions. Understanding these interactions is
crucial to developing methods for predicting protein secondary, tertiary, quaternary structure
from primary sequence and understanding protein-protein interactions and protein-ligand
interactions. Several studies have described how the interaction between two amino acid side
chains have a substantial effect on protein structure and conformational stability. This is under
the assumption that the interaction between the two amino acids is independent of surrounding
interactions. We are interested in understanding how salt bridges, cation- π, and anion-π
interactions affect each other when they are in close proximity.
Chapter 1 is a brief introduction on noncovalent interactions and noncovalent interaction
cooperativity. Chapter 2 describes the progress we have made measuring the cooperativity
between noncovalent interactions involving cations, anions and aromatic amino acids in a coiledcoil alpha helix model protein. Chapter 3 describes cooperativity between cation, anion, and
nonaromatic hydrophobic amino acids in the context of a coiled-coil alpha helix. In chapter 4 we
describe a strong anion-π interaction in a reverse turn that stabilizes a beta sheet model protein.
In chapter 5 we measure the interaction between a cysteine linked maleimide and two lysines in a
helix and show that it is a general strategy to stabilize helical structure.

Key words: cation-𝛑, anion-𝛑, noncovalent interaction, coiled coil, protein
structure, conformational stability
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1.1

INTRODUCTION

Noncovalent interaction cooperativity

Covalent bonds are strong interactions between atoms where the electrons are shared
between atoms (10-100 kcal mol-1).1 When two atoms form a covalent bond but one atom is more
electronegative then the other the two atoms do not share the electrons equally, consequently
leaving one atom electron rich and the other electron poor. This results in the tendency for
molecules to have weaker noncovalent interactions with other molecules.

Noncovalent

interactions do not share electrons but are governed by a dispersive electronic interactions between
atoms or molecules where electron rich atoms or molecules interact with electron poor atoms or
molecules.2-3 Generally these interactions are weaker than covalent bonds (0-5 kcal mol-1), but are
important for the formation of supramolecular structure found in biological macromolecules such
as DNA, RNA, proteins, carbohydrates and lipids.4 Noncovalent interactions include hydrogen
bonding, cation-π, anion-π, London dispersion, π-π, CH-π, hydrophobic along with several others.
Hydrogen bonding is an interaction between an electron poor hydrogen, bound to an
electronegative atom, interacting with a lone pair of an adjacent atom. Now consider a waterwater hydrogen bond (3-8 kcal mol-1) which when in solution with other waters form dimers,
trimer, or even a dodecamer hydrogen bonding networks.5 As more molecules associate with the
hydrogen bonding network each individual hydrogen bond becomes stronger energetically almost
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doubling once ten waters are in the bonding network.6-8 This shows that the energy found in a
hydrogen bonding network is not additive, or when 1 interaction + 1 interaction ≠ sum of the
interactions.

When multiple noncovalent interactions are non-additive this is due to cooperativity or
non-cooperativity. When two noncovalent interactions strengthen each other in a non-additive
way we define that energy as cooperative, and when two interactions weaken each other it is anticooperative. Cooperativity has historically been studied in hydrogen bonding systems but there
are fewer experimental measurements of cooperativity in ionic, aromatic and nonpolar systems.
Most commonly found are quantum computational methods that predict cooperativity between
these interactions.

Figure 1-1. schematic of arene ion and arene-arene interactions. (A) electronic configuration of benzene
with electron density above and below the ring and positively dipoled edges of the ring. (B) cation-π
interaction. (C) anion-π interaction. (D) π- π interactions with both the parallel stacking and “t-shaped”
configurations.

1.1.1

Cation-π, anion-π, and π-π interactions
Electron-rich arenes like benzene have large amounts of electron density in the center of

the ring due to the electronegative sp2 hybridized carbons, leaving the less electronegative
hydrogens on the ring edges electron poor, this electronic configuration is referred to as a
quadrupole (Figure 1-1A). The large electron density in the center of the ring is able to form a
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strong interaction with cations, where the cation is positioned above or below the electron
density in the ring (Figure 1-1B). This is called a cation-π interaction which has been extensively
reviewed elsewhere.9-14 The edges of electron rich rings are electron poor and able to interact
with anions (Figure1-1C).15-18 π-π interactions form when two arene quadrupoles interact with
each other forming either “offset stacked” or “edge to face” orientations. Both orientations
position the electron rich portion of the arene over the electron poor portion (Figure 1-1D).19-21
Almost forty years ago, gas phase studies demonstrated the binding of a potassium cation
with benzene is stronger than the binding of a potassium cation with a water molecule.22 This
result suggested that cation-π interactions could be energetically important in aqueous solution.
Computational analysis predict that the interaction is stronger when the cation is positioned
perpendicular to the plane of the ring, and it has a distance dependence relative to R-n where R is
the distance between the cation and the center of the arene and n is less than 2. This indicates
that a cation can be moved from its optimal position without significant cost to the strength of
the interaction, with a distance limit being 6-7 angstroms.14, 23 A probe of 600 nonhomologous
proteins show that there are over 3,000 energetically significant cation-π interactions.9 The study
indicates that there is on average 1 cation-π for every 77 amino acids in the PDB. Figure 1-2
highlights some of the cation-π examples from this PDB screen. First, an aromatic box in
glucoamylase where a Lys108 is surrounded by four aromatic amino acids. Second, the cation-π
ladder in the human growth hormone where there is an alternating pattern of aromatic and
positively charged amino acids along two strands of a beta sheet (Figure 1-2A, 1-2B) 9, 24-28
Subsequent biological studies show that several protein-protein, protein-DNA, and
protein-ligand interactions are mediated through cation-π interactions.29-33 Figure 1-3C
Highlights the VWF protein domain binding to its target gene which has a conserved cation π
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interaction between Arg 632 and an adenine, misregulation with VWF-DNA protein complex
has been associated with a blood clotting disorder called Von Willebrand disease.34 Histone
effector proteins, which help regulate gene activation, bind histone methylated lysines. The PHD
domain, a common trimethyl lysine effector protein, has two conserved aromatics at positions
215 and 238 which are critical to the protein-histone interactions and specificity (Figure 1-2D).
Acetylcholine receptors, important for proper neural function, binds its positively charged
ligands with aromatic amino acids (Figure 1-3E). 14, 35-39 Figure 1-2F shows Trp123 of lysozyme
binding to a sodium cation, an example of a protein side chain binding to a metal cation.40-43

Figure 1-2. Examples of cation-π interactions found the PBD (A) The aromcatic box of glucoamylase
with a cation π interaction found in between lys108 and Tyr 120, Tyr116, Trp52, and Trp120. (B) the
cation-π ladder in human growth hormome. (C) Cation-π at the interface of the VWF domain and it’s
DNA binding partner. (D) PHD domain interacting with trimethyllysine on Histone 3. (E) Acetylcholine
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receptor mediation by Tyr185, Tyr192, Trp54, and Trp143 all participating in a cation π with the
trimethylammonium of acetylcholine. (F) Cation π between a sodium atom and Trp 123.

Unlike cation-π interactions, anion-π interactions are believed to be unfavorable when
positioned at the face of an electron rich arene.18, 44-45 Anions are positioned close to the
positively dipoled edges of electron rich arenes.46 In biology, probes for anion-π interactions in
the PDB show that Glu and Asp side chains tend to be oriented to the edges of Phe, Tyr, Trp.46-47
An example can be found in the enzyme keto steroid isomerase where a conserved Glu 38 forms
a edgewise anion-π interaction with both Phe 116, and Phe 54 (Figure1-4A).47-48 Unsurprisingly,
changing the electronic character of benzene to hexaflourobenzene shows that the electron poor
face can tolerate a facewise interaction with an anion.44, 49-50 Other ion-arene interaction studies
indicate that modifications in the electronic character of an arene can change its facewise
preference from a cation to an anion.51-54 Interestingly Chakravarty et. al. searched the PDB for
face-wise anion-π interactions both in protein structure and at protein-DNA interfaces.55 They
probed 1500 non-homologous structures and searched for anions that were less 4.5 angstroms
from the center of the aromatic ring and were within 15° perpendicular to the plane of the ring.
Although less common than edgewise anion-π interactions, they unambiguously found face-wise
interactions in the pdb and showed that the interactions were conserved within protein families
suggesting importance to protein folding or function. A facewise interaction found in the
enzyme tranketolase, which catalyzes the formation of glyceraldehyde-3-phosphate, shows
Glu102 directly above Tyr105 (Figure 1-3B). Additionally, anion\- π interactions have been
shown useful for engineering active sites for enzymes.56 Stabilizing the conformation of proteins
and beta sheet peptides,57-59 and significant anion-π interactions at the interface of proteins and
DNA suggesting an importance for DNA regulation and transcription.17, 60-61
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Figure 1-3. Anion π interactions. (A) Anion π interactions found in Ketosteroid Isomerase, Glu 38 forms
an edgewise anion π with Phe 116, and Phe 54. (B) Facewise anion π interactions in Transketolase
between Glu 102 and Tyr 105.

π-π interactions are usually weaker than ion-arene interactions but have still been used to
stabilize coiled-coil peptides, specify protein oligermization, and stabilize protein conformation
(Figure 1-4).62-66 The rings can form the “offset stacked” orientation where the planes of the rings
are parallel and the center of one ring is positioned over the edge of another ring. Two arenes can
also form a “edge to face” orientation where the positive edge of one ring forms a favorable
interaction with the center of the second ring. π- π stacking has been used to engineer a interesting
pentameric coiled-coil where the interior of the coil is a tight packing of Trp residues (Figure 14A).65 Other studies show that this pentamer can tolerate other aromatic amino acids and has shed
light on how tetrameric, pentameric, and hexameric coiled coils form.67-68 A de novo helix-loophelix dimer (alpha 2 delta) designed by Degrado et al. has a π π interaction between Phe29, and
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Phe 10 that contributes substantially to the dimer association state, mutation of either Phe causes
the dimer to not fold (Figure 1-4B).69-70 In DNA and RNA structure π-π stacking contributes to
the supramolecular structure mainly when the aromatic components of the nucleic acids stack on
top of each other (Figure1-4C).71-72 π-π interactions are also critical to protein tertiary structure,
and protein-ligand interactions.66, 69, 73-75

Figure 1-4. (A) Trp π-π interactions in the core of a pentameric coiled coil. (B) Helical homodimer
mediated by a Phe29, Phe10, Trp 14 π-π interaction. (C)

1.1.2

Cooperativity between arenes and ions.
Cation-π interactions have been computationally shown to affect π-π, anion-π interactions.

Cation-π interactions have been shown to enhance π-π stacking interactions by 5-fold.76-77
Included in these studies was a PDB search of protein structures showing that metal-π-π
interactions occur just as frequently as do metal-π interactions. They indicated that a T-shaped ππ orientation was preferred where the metal bound the face of one ring with another ring edge
binding the opposite face. Anion-π interactions also can have cooperative interactions with π-π
interactions where the arenes are electron difficient.49, 78 Interestingly there appears to be a fourway cooperative effect when a cation was positioned on one face of a stacked π-π interaction and
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an anion positioned on the other face.50 These studies indicate that ions have extensive cooperative
effects with arenes.

Figure 1-5. Schematic of the cooperativity predicted for a cation-π-anion interaction

Cation-π interactions can have an interesting effect on anion-π interactions. It is believed
that face-wise anion-π interactions with electron rich arenes should be destabilizing but
computational and supramolecular work show that facewise anion-π interactions are possible if
the electronics of the ring are changed. Interesting studies show if a cation is positioned on the
opposing face of the ring then the ring electron density is polarized towards the cation leaving the
opposing face electron poor (figure 1-5).79-81 Dougherty et al. also show that synthetic aromatic
host systems that bind cations are more effective if anionic carboxylates are engineered on the
opposing face of the aromatic rings. They confirmed these results by computationally modelling
a chlorine atom on one face of a benzene and showed that the benzene indeed was more
predisposed to interact with a sodium cation on the opposite face.81 Binding of anionic guests

8

within the internal arene-lined cavities of calixarenes, cryptophanes, and cyclotriveratrylenes
increases substantially when the exterior surfaces of these hosts are bound by transition metal
cations.82-86 A more recent bioinformatics probe by of the PDB protein structures showed that
about 3% of anion-π interactions show that the aromatic side chains is also participating in a cationπ interaction.48 The same paper describes how the anion-π-cation interaction is prevalent at
protein-protein interfaces, this seems reasonable due to polar amino acids being very prevalent at
the surface of proteins instead of the interior. Figure 1-6 highlights six examples of cation-π-anion
motifs found in protein structure and between protein-protein interfaces.

Figure 1-6. Examples described in a bioinformatics probe for cation π anion interactions in protein
structure.48 Differing colors represent different protein chains within the crystal structure. The six
examples include (A) adenylsuccinate lysase, (B) D:alanine :Dlactate ligase, (C) Green fluorescence
protein tetramer, (D) PHD domain binding to H3K4 hisone peptide, (E) MAGE G1 protein, and (F)
Alpha-Glucosidase.
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1.2

Protein Folding Cooperativity

Proteins are polymers of amino acids that form complex structural conformations. The
structure of the protein governs the protein function and biological purpose, so much so that several
disease states are associated with protein structural misfolding.87-92 Protein structure is mostly
governed by noncovalent interactions with the exception of covalently linked disulfide bonds,
because of this some proteins are only marginally stable at room temperature. Due to the low
energy barrier between a folded protein and its unfolded state no type of molecular interaction
within the protein is unimportant.
Two main determinants in protein folding are hydrophobic amino acids packing in the
interior of the protein isolated from solvent and hydrogen bonding.93-94 Hydrophobic packing
stabilizes proteins in two ways: Hydrophobic amino acids form London dispersion forces, and
isolating the hydrophobic amino acids from water solvent allows water to form a hydrogen
bonding network where water has more entropy than when bound to nonpolar amino acids. The
two main secondary structures of proteins are alpha helices and beta sheets, these two structures
form extensive hydrogen bonding networks between the main chain carbonyls and amides giving
the secondary structure stability and direction.94-96
Some labs have proposed that protein folding is mostly cooperative in nature.97-103 Dill et
al. propose a hydrophobic “zipper” hypothesis where initial hydrophobic contacts bring additional
contacts in close proximity further contributing to the hydrophobic cooperativity of a protein core
and allowing water to form a cooperative network in the solvent.93, 101, 103 Baker et al. suggest that
the observed cooperativity on protein folding is a result of natural selection and supports this
conclusion by creating de novo protein folds, or folds that are not observed in nature and therefore
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cannot be subject to natural selection. They suggest that biology over the years has selected
pathways for proteins that fold cooperatively.102, 104 A recent experimental study showed that
cooperativity between already folded domains contribute to the folded tertiary structure of a
protein.99
Although cooperativity is established in protein folding, there are limited examples of
experimental measurements of cooperativity between specific amino acids side chains. As
described in section 1.1.2 several labs predict extensive cooperativity between cations, anions, and
arenes. To our knowledge experimental measurements of the cooperativity between anions,
cations, and aromatics have not been measured in the context of protein structure. This dissertation
describes the first experimental measurements of the cooperative interaction between negatively
and positively charged amino acids with aromatic amino acids.
1.2.1

Measuring non-covalent interactions in proteins
Specific noncovalent interactions, in addition to hydrogen bonds and hydrophobic

interactions, are critical to protein function and structure. These interactions include cation-π,
anion-π, π-π, and n-π*, along with other interactions. Understanding these interactions is crucial
to developing methods for predicting protein secondary, tertiary, quaternary structure from
primary sequence, especially for proteins with no known function and with little homology with
known proteins.105-108
To measure the contributions of noncovalent interactions to protein conformational
stability, labs have developed double mutant cycle, and triple mutant cycle analysis.2, 109-112 This
approach has led to insights into the impact of non-covalent interactions on protein folding and
stability. A great example of a double mutant cycle was done by Ferst et. al where they
measured a salt bridge interaction between an arginine at position 69 and an aspartate at position
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93 found in the protein barnase (Figure 1-7A).113-114 To measure the interaction Ferst et. al. made
four barnase variants, wild-type, R69S, D93N, and R69S D93N double mutant. This group
folded and unfolded each barnase variant using chemical denaturants and monitored the folding
process using a stop-flow fluorimeter. They extrapolated folded free energies for each variant
and calculated the interaction between R69 and D93 (Figure 1-7B). The partially buried salt
bridge was estimated to contribute around 3 kcal mol-1 of energy to the folded conformation of
the wildtype barnase.

Figure 1-7. Structure of a partially buried salt bridge between Asp93 and Arg 69 (Left). Double mutant
cycle measuring the interaction energy between Asp 93 and Arg 69 (Right).

To measure the impact of a third side chain on the binary non-covalent interaction two
double mutant cycles can be combined to form a triple mutant cycle cube. Ferst et. al. were
interested in salt bridge cooperativity and continued using the protein barnase as a model
system.115 In the protein structure they noticed two salt bridges formed by Asp8, Asp12, and
Arg110 (Figure 1-8A). They made eight barnase variants and measured each variant’s folded
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free energy then calculated the triple mutant cycle analysis (figure 1-8B). Each side of the triple
mutant cycle cube is a double mutant cycle which measures the interaction between two amino
acids in the presence of a control side chain (usually alanine) and again in the presence of a side
chain of interest. When you compare opposite cube faces, you measure the effect of a third
amino acid position on a double mutant cycle binary interaction. They showed the salt bridge
between Asp 8 and Arg110 was worth -0.22 kcal/mol while position 12 was an alanine (red
double mutant cycle in figure 1-8B). Then they showed the same salt bridge gained -0.77 kcal
mol-1 in interaction energy when position 12 was the wild-type aspartate (green double mutant
cycle in figure 1-8B). The Asp8:Arg110 salt bridge was enhanced by -0.77 kcal mol-1 if the
Arg110:Glu12 salt bridge is present in the structure (Figure 3C). This demonstrates a
cooperativity between the two salt bridges where one salt bridge enhances the second.
When doing double or triple mutant cycle analysis two main assumptions are made: 1.
All the protein variants must not have significant structural rearrangements 2. The control side
chains should not interact with each other. In this example, the group confirmed structural
integrity of each variant by NMR and protein crystallography. The group chose alanine as the
mutant side chain and assumed that the Ala8, Ala12, Ala110 would not have substantial
interaction. This example illustrates the power of double and triple mutant cycle analysis,
showing the strength of binary non-covalent interactions can have can be substantially influenced
by a third amino acid.
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Figure 1-8. Example of a triple mutant cycle analysis between Asp8, Asp12, and Arg110 in the protein
barnase (A) structural data representing positions 8, 12, and 110. (B) The eight barnase variants required
for the triple mutant cube analysis. (C) The two double mutant cycles that measure the cooperativity
between Asp8, Asp12, and Arg110.

1.2.2

Measuring ionic, aromatic, nonpolar cooperativity in protein structure.
Our lab is interested in measuring the cooperativity of interactions involving anion,

cation, and aromatic side chains found in protein structure. Chapter 2 describes the progress we
have made measuring the cooperativity of cations, anions and aromatic amino acids in a coiledcoil alpha helix model protein. Chapter 3 describes cooperativity between cation, anion, and
nonaromatic hydrophobic amino acids in the context of a coiled-coil alpha helix. In Chapter 4 we
were tested the strength of an anion-π interaction to a reverse turn found in a beta sheet model
system.

1.3
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2

MEASURING A HELICAL SALT BRIDGE ENHANCED BY AROMATIC AMINO
ACIDS.

2.1

Introduction
Salt bridges, or the interaction between negative and positive amino acids contribute

significant conformational stability to protein structure, especially when two ionic groups are in
close proximity (i.e., within ∼4 Å of each other).1-9 For example, placing complementarily charged
amino acid side chains three or four residues apart can substantially stabilize α-helical peptides
because they are on the same face of the helix and in close proximity.10 Analogous approaches
also promote helical conformations within β-peptides and other foldamers.11-13 Increasing the
distance between the positively and negatively charged residues causes the residues to be solvated
by water and ion molecules from the solvent, thereby attenuating the salt-bridge interaction.14
Several lines of evidence show that longer range salt bridges are possible when an arene is
positioned between the cation, and anion. (see Section 1.1.2).15-18
We set out to measure the impact of an arene on a Glu-Lys salt bridge in the protein 1CW.
1CW is a trimer α-helix coiled coil whose structure has been extensively characterized.9, 19-20 1CW
is a two state folder and is therefore amenable to detailed thermodynamic analysis.9, 21 The small
size of 1CW (33 amino acids) facilitates the chemical synthesis of the protein with complete
control of site specific mutations necessary for the measurement of noncovalent interactions.
Alanine 10, serine 14, and alanine 18 occupy the i, the i+4, and the i+8 positions along the solvent-
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exposed faces of each α-helix in 1CW (Figure 2-1). Several studies have shown that the i to i+3
or i to i+4 spacing in an α-helix facilitates favorable noncovalent interactions due to the close
proximity of these positions.5, 22-23

Figure 2-1. Coiled coil trimeric protein. The protein has three solvent exposed sites where we can
measure the interaction between anionic, aromatic, and cationic amino acids.

2.1

Results and discussion

Cooperativity between a long-range salt bridges mediated by Tryptophan.

We wondered to what extent Trp14 might enable a favorable long-range salt-bridge
interaction between Glu10 and Lys18. Assessing the contribution of an interaction between two
amino acid residues to peptide or protein conformational stability requires double mutant cycle
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analysis, in which each residue is mutated to a non-interacting surrogate, individually and then in
combination. For example, to determine whether a Glu10–Lys18 interaction contributes
substantially to the stability of the three-helix bundle formed by 1 (Figure 2-2), we mutated Glu10
to Ala to give peptide 2; Lys18 to Ala to give peptide 3; and both Glu10 and Lys18 to Ala to give
peptide 4. Like peptide 1, each of these variants forms a cooperatively folded helix-bundle
homotrimer (See Supporting information section 2.4.4). The difference in the folding free energies
of 2 vs. 1 is a measure of the energetic contribution of the putative Glu10–Lys18 interaction plus
the impact of the Glu10 to Ala mutation (i.e., ΔΔG21 = ΔΔΔGE·K + ΔΔGE10A). In contrast, no
Glu10–Lys18 interaction is possible within peptides 3 and 4, in which Ala occupies position 18.
Therefore, the difference in the folding free energies of 4 vs. 3 must only reflect the impact of the
Glu to Ala mutation (i.e., ΔΔG43 = ΔΔGE10A). Subtracting ΔΔG43 from ΔΔG21 therefore provides
a measure of the energetic contribution of the Glu10–Lys18 interaction to helix bundle stability:
ΔΔΔGE·K = ΔΔG21 − ΔΔG43 = −2.18 ± 0.09 kcal mol−1 for the three Glu10–Lys18 interactions
present in the helix-bundle formed by 1; −0.73 ± 0.02 kcal mol-1 per individual Glu10–Lys18
interaction. Despite the large distance between Glu10 and Lys18 (∼13 Å), the energetic
contribution of the Glu10–Lys18 interaction is similar in magnitude to that of many previously
characterized short-range salt bridges within proteins.1-2, 4-5, 8, 24
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Figure 2-2. Peptides 1-8 used to measure the cooperative interaction between a Glu10, Trp14, and Lys18.
The double mutant cycle that measure the interaction in the presence of Trp14 (bottom left) and the
double mutant cycle in the presence of Ser14 (bottom right) can be compared to quantify the impact of
Trp14 on the Glu10:Lys18 salt bridge. CD experiments were done in 20 mM phosphate buffer pH 7.0 at
30μM peptide concentration.

To assess the contribution of Trp14 to the long-range Glu10–Lys18 interaction in peptide
1, we prepared peptide 5, a derivative of 1 in which Trp14 has been replaced by Ser, which
occupies position 14 in the parent peptide from which 1 was derived; subsequent experiments
demonstrated that Ser is a reasonable mimic of Ala at this position (supporting information section
2.4.7). We then repeated the double mutant cycle analysis to assess the strength of the Glu10–
Lys18 interaction in the absence of Trp14 by comparing the stability of 5 with that of peptides 6,
7, and 8 (the Ser14 analogues of peptides 2, 3, and 4 respectively). Interestingly, when Ser occupies
position 14 the salt bridge interaction is unfavorable (ΔΔΔGE·K = ΔΔG65 – ΔΔG87 = 0.89 ± 0.06
kcal mol-1 for the three E·K interactions in the peptide 5). Comparing the contribution to
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conformational stability of the Glu10-Lys18 salt bridge in the presence of Trp14 vs. Ser14 shows
that the Trp14 enhances each salt bridge in 5 by -1.02± 0.09 kcal mol-1 per Glu10-Trp14-Lys18
interaction (Figure 2-2).

Table 2-1. Structure activity relationship of Glu10, Lys 18 salt bridge enhanced by Trp 14.a
Salt-bridge with Arene
Peptide
1
9
10
11
12
13

Sequence
•••KVEALEWKVQKLE•••
•••KVDALEWKVQKLE•••
•••KVEALEWKVQOLE•••
•••KVAELEWKVQKLE•••
•••KVKALEWKVQELE•••
•••KVEALEWMeKVQKLE•••

ΔΔΔGf (kcal/mol)
-2.25 ± 0.08
-0.74 ± 0.08
-0.23 ± 0.06
0.35 ± 0.11
1.01 ± 0.12
-0.79 ± 0.09

Salt-bridge with
Ser14
ΔΔΔGf (kcal/mol)

Impact of arene
on trimer ΔΔΔΔGf
(kcal/mol)

0.20 ± 0.06
0.46 ± 0.07
-0.25 ± 0.10
-0.86 ± 0.08
0.25 ± 0.10
0.20 ± 0.06

-2.45 ± 0.10
-1.21 ± 0.11
0.02 ± 0.08
1.21 ± 0.14
0.76 ± 0.15
-1.00 ± 0.11

Partial sequences given for 1, 9-13 from residue 8-20. Variable temperature CD experiments done in 20
mM sodium phosphate pH 7.0, 1M Urea, 343.15 K. Data are given as ± standard error for 30 μM peptide.
a

We next explored whether the large Trp-based enhancement of the Glu10–Lys18
interaction could tolerate changes in the position of the Glu10 carboxylate relative to the Lys18
ammonium group (Table 2-1). To that end, we performed triple mutant cycle analyses on peptides
9–12 and their sequence variants, in which we varied the identity and relative location of the
positive and negatively charged components of the salt bridge. Some of these variants were so
stable in 20 mM sodium phosphate buffer (pH 7) as to preclude direct assessment of their folding
free energies. To facilitate direct comparison among peptides 1, 9–12, we performed variable
temperature CD experiments on these compounds in 20 mM sodium phosphate buffer (pH 7) with
1 M urea, which adjusted helix-bundle stability such that we could reliably extract thermodynamic
parameters from the variable temperature CD data for each compound. Replacing Glu10 with Asp
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(peptide 9, Table 2-1) decreases the Trp-based enhancement in the salt-bridge interaction by 50%.
Replacing Lys18 with ornithine (peptide 10) abolishes the Trp-based enhancement completely.
This is an interesting contrast with earlier work by Waters and coworkers, who showed that Phe
interacts more favorable with an i+4 ornithine than an i+4 Lys.22 Moving Glu10 to position 11
(i.e., one residue closer to Trp14; peptide 11) interestingly causes the salt bridge to be favorable
in the presence of Ser14 and non-favorable with Trp14. Peptide 12 shows that Trp14 makes an
unfavorable Lys10-Glu18 salt bridge worse. We speculate that the failure of Trp to enhance a longrange salt-bridge between Lys10 and Glu18 (peptide 12) could reflect an unfavorable interaction
between the long-range salt bridge and the helical macrodipole, but the precise mechanism remains
unclear. These results suggest that the ability for Trp14 to enhance the interaction between Glu
and Lys is highly sensitive to the relative positions of the Glu carboxylate and the Lys ammonium.
We also show that the Trp-based enhancement of the Glu10-Lys18 salt bridge appears to have a
significant hydrogen bonding component because when methylating the indole nitrogen on Trp 14
side chain (Wme) decreases the Trp based stabilization by about 60% (Figure 2-3, peptide 13).

2.2.2

The structural influence of the arene on the long-range salt bridge.

We then tested the ability of other aromatic side chains to enhance the Glu10-Lys18 salt
bridge (Figure 2-3). Tyr (peptide 14) enhances the stability of the Glu10–Lys18 salt bridge to a
similar degree as Trp. However, as with Trp, methylation of the Tyr phenolic oxygen (peptide 15)
decreases Tyr-based stabilization by ∼65%, again suggesting a substantial hydrogen-bonding
component for Trp or Tyr based enhancement of the Glu10–Lys18 interaction. In agreement with
this conclusion, Phe (peptide 16) is substantially worse at enhancing the Glu10–Lys19 interaction
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than both Tyr and Trp. Interestingly, addition of 0.25M NaCl to the buffer increases the Phe-based
enhancement of the Glu10–Lys18 interaction (supporting information section 2.4.8), suggesting
that the enhanced long-range salt-bridge is resistant to screening by salt, possibly because the nonpolar residue excludes ions from the space immediately between Glu10 and Lys18; alternatively,
it is possible the the Phe-based enhancement of the Glu10-Lys18 interaction also has a
hydrophobic component.
We wondered whether the still sizeable ability of Phe to enhance the Glu10–Lys18
interaction (−1.25 ± 0.09 for the three Phe residues in 16; −0.42 ± 0.04 kcal mol−1 enhancement
per individual Phe) was related to a cation–π interaction between the positively charged Lys18 and
the electron-rich face of the Phe arene. To test this hypothesis, we replaced Phe with
pentafluorophenylalanine (f5Phe), in which the face of the aromatic ring is electron-poor instead
of electron-rich (peptide 17). Interestingly F5Phe enhances the stability of the Glu10–Lys18
interaction to a similar degree as does Phe. This observation agrees qualitatively with the
computational work of Deyá and his coworkers, who predicted that the two charges positioned
across hexaflourobenzene would still interact cooperatively.15 The similar impact f5Phe and Phe
on the Glu10-Lys18 salt bridge suggests that the electrostatic potential of the ring may not be a
major determinant of the observed salt-bridge stabalization. To further test this hypothesis, we
made peptides 18–21 along with their sequence variants and showed that p-fluorophenylalanine
(p-fPhe, Peptide 18), 3,4-difluorophenylalanine (3,4-f2Phe, peptide 19), and p-nitrophenylalanine
(p-NO2Phe, peptide 20) are each similar or superior to Phe14 in their ability to stabilize Glu10Lys18 salt bridge (Figure 2-3). An exception to this trend, for reasons that are still unclear, was
that 4-pyridinylalanine (PyrA, peptide 21) had a substantially smaller impact than that of Phe14.
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This may reflect perturbation of the pyridinium/pyridine acid-base equilibrium by Glu10 and/or
Lys18.

Figure 2-3. The effect of changing the arene side chain at position 14 on the strength of the Glu10:Lys18
salt bridge

2.2.3

Crystal structures of 1CW variants
Like small molecules, proteins can form crystals when they are supersaturated in

solution.25 Under saturated conditions individual protein molecules can pack in ordered arrays
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through noncovalent interactions between protein molecules. High-quality crystals are formed
when well-ordered packing arrangements are maintained throughout the crystal, the crystal has
little contamination, and is large enough to collect diffraction data.26-29 Initial crystallization
screens of 1 (EWK) indicated two crystal forms, or two differing packing arrangements occurred
depending on solution condition (crystal forms EWK1 and EWK2 are shown in Figure 2-4A,
details of each crystal packing lattice can be found in the supporting information 2.4.6). Each
crystal form folds into a homotrimeric helix bundle. As is typical for helix bundles, the primary
sequence of EWK is characterized by a repeating seven-residue sequence (i.e., a heptad), in
which hydrophobic residues occupy the first and fourth positions (positions a and d),
respectively, of an abcdefg heptad.19, 30-31 Each heptad spans two turns of the α-helix (at ∼3.5
residues per turn). Consequently, nonpolar a and d-position residues occupy the same face of the
helix; burial of these residues at the inter-helical interface generally provides the major driving
force for helix-bundle self-association.30 Similarly, polar residues at b, c, and f-positions in
peptide 1 occupy the solvent-exposed surface of the helix bundle; b-position Glu10 is two helical
turns away from b-position Lys18, with f-position Trp14 in between them. Figure 2-4B shows a
single helix from EWK1, and EWK2 superimposed, both crystal forms show the same rotamer for
tryptophan. We then measured the distances between the ammonium group on Lys18 and the Cδ
Glu10 on both EWK crystal forms (Figure 2-4C). The long Glu10:Lys18 distances (13.9Å,
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15.9Å) indicate the potential for a long-range salt bridge being enhanced by Trp14.

Figure 2-4 Representation of EWK trimer helical wheel where Glu10, Trp14, and Lys18 occupy the
solvent exposed b, f, and c positions within the heptad repeat.

Figure 2-5. (A) Two crystal forms for peptide 1 (EWK). (B) Glu10, Trp14, and Lys 18 overlaid from
each crystal form. (C) Distances between the lysine Nzeta center of the Trp ring and the distance between
the Glu 10 CEpsilon and the Trp14 Ring.
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The structure of peptide EWK2 (peptide 1) was overlaid with individual α-helices from
crystal structures of five derivatives of EWK, in which Tyr (EYK), Phe (EFK), p-FPhe (Ep-fFK),
3,4-F2Phe (E3,4-f2FK), p-NO2Phe (Ep-NO2FK), or PyrA (EPyrAK) occupy position 14 instead of
Trp (Figure 2-5). We wondered whether the side-chain conformations (i.e. rotamers) adopted by
Glu10, Lys18, or the i-position arenes would correlate with the ability of each arene to enhance
the Glu10-Lys18 salt-bridge. To explore this possibility, we measured dihedral angles χ1 (defined
by the atoms Nα, Cα, Cβ, and Cγ) and χ2 (Cα, Cβ, Cγ, and Cδ) for each side-chain, and described
each χ1 and χ2 in one of three possible ways: g+ (positive gauche) for angles between 0° and 120°;
g-(negative gauche) for angles between 0° and -120°; and t (trans) for angles between 120° and
180° or between -120° and -180° (the symmetry of the Phe, Tyr, F5Phe, p-fPhe, p-NO2Phe, and
PyrA side chains make it impossible to distinguish between g+ and g- for χ2; consequently, χ2
values between 0° and 120° or between 0° and -120° for these side-chains are simply described as
g.) . We observed no particular trend in the side-chain conformations of the Glu10 or Lys18 from
variant to variant. However, PyrA14 in EPyrAK adopted an unusual g-,t conformation, in contrast
to the more conventional t,g conformation adopted by EWK, EYK, EFK, Ep-fFK, E3,4-f2FK, and
Ep-NO2FK. PyrA14 had a much smaller impact on the Glu10-Lys18 salt bridge than did the other
arenes investigated here, and it seems possible that this effect could be related to the unusual g-,t
rotamer adopted by PyrA14.
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Figure 2-6. EWK, EYK, EFK, Ep-fFK, E3,4-f2FK, Ep-NO2FK, and EPyraAK structures overlayed with
the comparison of aromatic, Lys18, and Glu 14 side chain rotamers.

Each of these helix-bundle trimers crystallized in a dense lattice with extensive interbundle contacts between surface residues (Figure 2-6). These contacts are relevant to the
crystalline state, but not to solution, where each helix bundle trimer is surrounded by water and
does not interact closely with other trimers. Fig. 2-7 shows some of these inter-bundle contacts
involving Glu10, Lys18, and the i-position arenes. In most of these variants, Glu10 from one helix
is intimately interdigitated with the i-position arene from another helix within an adjacent bundle.
Moreover, the unusual rotamer adopted by PyrA14 in EPyrAK appears to facilitate an inter-bundle

33

salt bridge with Glu10 from another helix. These intimate crystal contacts suggest that we should
be cautious in using these structural data from the crystalline state to draw conclusions about the
behavior of the molecule in solution.

Figure 2-7. Peptide 1 (EWK) crystal packing lattice. Red X symbolized detectable water molecules in
the electron density map. Lys10 is colored in green, Trp14 in black, and Glu10 in cyan.
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Figure 2-8. Crystal packing interface for EWK, EYK, EFK, Ep-fFK, E3,4-f2FK, Ep-NO2FK, and
EPyraAK.

2.2.4

NMR model system

We next used NMR spectroscopy to explore the solution behavior of the i–4-position Glu,
an i-position Trp, and an i+4-position Lys within an α-helix. Peptide pA-EWK (Figure 2-8) is
derived from the parent α-helical model peptide pA (sequence: Ac-OO-AAAAA-AAAAAAAAAA-AAAA-OO-Y-NH2), which contains a 19-residue polyalanine segment (for high helix
propensity) flanked by two ornithine residues on either end (to increase solubility in aqueous
solution); a C-terminal tyrosine provides a spectroscopic handle for accurate concentration
determination.32-33 Ala12 is centrally located within the 19-residue polyalanine segment; Ala8 and
Ala16 occupy the i–4 and i+4 positions, respectively, relative to Ala12. We replaced Ala16 with
Lys, Ala12 with Trp, and Ala8 with Glu to give peptide pA-EWK. We obtained two-dimensional
TOCSY and ROESY spectra of a 5 mM solution of pA-EWK in 20 mM sodium phosphate (pH
7) and assigned the backbone and side-chain resonances for Glu8, Trp12, and Lys16 (see
supporting information section 2.4.9 for details). The ROESY spectrum of pA-EWK reveals
several non-sequential NOEs between backbone and side-chain protons of Glu8 and Trp12 and
between backbone and side-chain protons of Trp12 and Lys16 (Figure 2); normalized volumes of
these NOE peaks are given in the supporting information. Hδ1 and Hε1 on the indole ring of Trp12
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are each involved in multiple NOEs with protons on both Glu8 and Lys16: Trp12Hδ1 has NOEs
with Glu8Hβ, Glu8Hγ, Lys16Hα, Lys16Hγ, Lys16Hδ, and Lys16Hε, whereas Trp12Hε has NOEs
with Glu8Hβ, Glu8Hγ, Lys16Hγ, Lys16Hδ, and Lys16Hε, consistent with close contacts between
Glu8, Trp12, and Lys16 in pA-EWK, centered on the right-hand side of the Trp12 indole ring as
drawn in Figure 2-8. Moreover, chemical shifts of the Glu8 Hγ protons and of the Lys16 Hγ, Hδ,
and Hε protons appear upfield (∆δ = -0.15 to -0.30) relative to corresponding protons in random
coil reference compounds,34 suggesting that the Glu8 Hγ protons and the Lys16 Hγ, Hδ, and Hε
protons are within the shielding region of the Trp12 indole ring. These observations indicate that
in pA-EWK the Glu8 and Lys16 side chains are both on opposing sides of and in close proximity
to the Trp12 indole.
We further explored the structural impact of the interaction by preparing peptides pAAWK and pA-EWA (Figure 2-8), in which Ala replaces Glu8 or Lys16, respectively. As with
pA-EWK, the ROESY spectrum for pA-AWK shows many NOEs between Trp12 and Lys16
backbone and side-chain protons. However, several important differences between the ROESY
spectra of pA-EWK vs. pA-AWK highlight the impact of Glu8 vs. Ala8 on Trp-Lys contacts
(Figure

2-8).

For

example,

NOE

peaks

corresponding

to

Trp12Hζ3/Lys16Hα,

Trp12Hζ3/Lys16Hδ, and Trp12Hη2/Lys16Hδ are present in the spectrum of pA-AWK but not in
that

of pA-EWK.

In

contrast,

NOE

peaks

corresponding to

Trp12Hε1/Lys16Hγ,

Trp12Hε1/Lys16Hδ, and Trp12Hε1/Lys16Hε are present in the spectrum of pA-EWK but not in
that of pA-AWK. Moreover, normalized peak volumes for the Trp12Hε3/Lys16Hδ,
Trp12Hα/Lys16NH, and Trp12 Hδ1/Lys16Hδ NOEs are larger for pA-EWK than for pA-AWK,
whereas normalized peak volumes for the Trp12Hδ1/Lys16Hε and Trp12Hζ2/Lys16Hε NOEs are
smaller for pA-EWK than for pA-AWK. These changes suggest that replacing Ala8 with Glu8
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allows Lys16Hδ to move closer to Hδ1, Hε1, and Hε3 on the right-hand side of the Trp12 indole
ring (as drawn in Figure 2-8), whereas Lys16NH moves closer to Trp12Hα, possibly due to
localized overwinding of the α-helical backbone between Trp12 and Lys16 to allow for optimized
interaction geometry between Glu8, Trp12, and Lys16.

Figure 2-9. Observed NOEs for monomeric α-helical peptides pA-EWK, pA-AWK, and pA-EWA in 20
mM sodium phosphate buffer (pH 7). Lines tipped with asterisks indicate NOEs that are only present in
the indicated peptide. Dotted lines indicate NOEs that are weaker in pA-EWK than in pA-EWA or pAAWK. Bold lines indicate NOEs that are stronger in pA-EWK than in pA-EWA or pA-AWK.

Similarly, differences between the ROESY spectra of pA-EWK vs. pA-EWA highlight
impact of Lys16 vs. Ala16 on Glu8-Trp12 contacts. The Trp12Hδ1/Glu8Hα NOE is present in the
spectrum of pA-EWA, but not that of pA-EWK. Moreover, normalized peak volumes for the
Trp12Hδ1/Glu8Hβ, Trp12Hδ1/Glu8Hγ, Trp12Hε1/Glu8Hβ, and Trp12Hε1/Glu8Hγ NOEs are
smaller in pA-EWK than in pA-AWK. These observations indicate that the Glu8 side-chain
protons are close to Hδ1 and Hε1 of Trp12 (as is also the case for Hδ and Hε of Lys16, see above),
but that replacing Ala16 with Lys16 increases the distance between the Glu8 side chain and the
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right side of the Trp12 indole ring (as drawn in Figure 2-8), possibly to compensate for the
localized overwinding of the α-helical backbone between Trp12 and Lys16.

2.2.5

Exploring the Long-Range Salt-bridge within a dimeric helix bundle.

We wondered whether the ability of an i+4 aromatic amino acid to enhance the stability
of a long-range salt bridge between an i-position Glu and an i+8 position Lys might also apply in
other α-helices in addition to the homotrimeric model system described above. We decided to
explore this possibility in the context of the homodimeric α-helical coiled coil GCN4-p1. In the
native GCN4- p1 sequence, Lys18 already occupies the i+8-position relative to Glu10, with
Ser14 at i+4; all three of these residues lie along the solvent-exposed surface of the coiled-coil
homodimer, providing an ideal context for assessing the impact of a non-polar residue at position
14 on the long-range interaction between Glu10 and Lys18. However, we worried that Glu11
(adjacent to Glu10) might interfere with our ability to characterize the Glu10- Lys18 interaction.
Consequently, in preparing peptide 22 (in which Glu, Phe, and Lys occupy positions 10, 14, and
18, respectively), we also mutated Glu11 to Ala. Circular dichroism (CD) experiments and sizeexclusion chromatography experiments indicate that these mutations do not substantially disrupt
the homodimeric α-helical coiled-coil quaternary structure of 20 relative to GCN4-p1 (see
supporting info 2.4.4). We assessed the impact of Phe14 on the Glu10-Lys18 interaction by
replacing Glu10 with Ala; Phe14 with Ser; and/or Lys18 with Ala, in all possible combinations.
Comparing the folding free energies of 22-ESK, 22-ASK, 22-ESA, and 22-ASA reveals that
Glu10 and Lys18 do not interact favorably (ΔΔΔGf = 0.59 ± 0.09 kcal/mol) in the presence of
Ser14. In contrast with our previous observations described in the main text, placing Phe at
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position 14 in the GCN4 system does not substantially change the already unfavorable
interaction between Glu10 and Lys18 (ΔΔΔGf = 0.65 ± 0.07 kcal/mol), suggesting that Phe14
does not enhance a long-range salt-bridge between Glu10 and Lys18 (Table 2-2).

Table 2-1 Enhancement of Glu:Lys long range salt bridge in the GCN4-p1 Dimeric helix.

a

Peptide

Sequence

22

Ac–•••VEALEFKNYKL•••–CONH2

23

Ac–•••VAELEFKNYKL•••–CONH2

Salt-bridge with
Ser14
ΔΔΔGf (kcal/mol)
0.59 ± 0.09
1.20 ± 0.07

0.65 ± 0.07

Influence of
Phe14
ΔΔΔΔGf (kcal/mol)
0.06 ± 0.12

-0.38 ± 0.07

-1.58 ± 0.10

Salt-bridge with Phe14
ΔΔΔGf (kcal/mol)

Data are given ± standard error at 30 µM protein concentration in 20 mM sodium phosphate
buffer (pH 7) at 333.15 K.
It is possible that subtle geometric differences between the homodimeric system and the
homotrimeric system described above might move Glu10 far enough away from Phe14 and
Lys18 as to prevent any Phe-based enhancement in of a long-range Glu10-Lys18 interaction in
22. Position 11 occupies the same solvent-exposed face of the helix as Glu10, Phe14, and Lys18
but should be closer to Phe14 and Lys18 than position 10. We wondered whether placing Glu at
position 11 instead of position 10, might facilitate a favorable long-range i to i+7 salt bridge
between Glu11 and Lys18 in the presence of Phe14. To test this hypothesis, we prepared peptide
23, in which Glu, Phe, and Lys occupy positions 11, 14, and 18, respectively, with Ala at
position 10 instead of Glu (again, to avoid interference of Glu10 with any possible interaction
among Glu11, Phe14, and Lys18). We also prepared variants of 21 in which we replaced Glu11
with Ala; Phe14 with Ser; and/or Lys18 with Ala, in all possible combinations (names and
sequences of these variants are shown in supporting information section 2.4.1; some of these
combinations were already accounted for in peptides 22-AFK, 22-AFA, 22 ASK, and 22-ASA).
Comparing the folding free energies of peptides 23-ESK, 23-ESA, 22-ASK, and 22-ASA
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reveals that Glu11 and Lys18 do not interact favorably in the presence of Ser14 (ΔΔΔGf = 1.20 ±
0.07 kcal/mol). However, in the presence of Phe14 (compare peptides 21-EFK, 21-EFA, 21AFK, and 21-AFA), the Glu11-Lys18 interaction is substantially favorable (ΔΔΔGf = -0.38 ±
0.07 kcal/mol), a dramatic Phe-based shift of -1.58 ± 0.10 kcal/mol per trimer (figure 2-9).

2.3

Conclusions
Salt bridges are critical to protein stability and to protein function. Through double and

triple mutant cycle analysis we have shown that a long-range salt bridge can stabilize the
conformation of a helix bundle if an aromatic residue is positioned between the ions. The enhanced
salt bridge interaction, in the context of a helix, is strongly dependent on the precise location and
orientation of the ionic side-chains and involves a significant hydrogen-bonding component. The
three-way interaction is also independent of the electronic configuration of the aromatic side chain.
Crystal structures of the interaction show that the trimer packs in a dense crystal lattice and solvent
exposed positions of the trimer are likely to be involved in crystal contacts with other trimers and
therefore the side chain conformations of positions 10, 14, and 18 must be interpreted with caution
and might not correlate to solution thermodynamic data. In the crystal structures, it appears that
the Lys18 is packing closely to the arene at position 14 while the Glu 10 from one trimer is packing
close to the arene14 of an adjacent trimer. Although, not relevant to solution behavior, it is
tempting to speculate that this is potentially an enhanced salt bridge interaction between trimers in
the crystal lattice. Solution NMR data for a monomeric pA-EWK helix shows several NOE’s
between a the Glu8 and Trp12, and between the Lys16 and Trp12, indicating that the ionic side
chains are close to the Trp side chain although the exact geometry of the side chains is still unclear.
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2.4
2.4.1

Supporting Information
Protein Synthesis, Purification, and Characterization

Peptides pA-EWK, pA-AWK, pA-EWA, and 1-27, and their sequence variants
(sequences shown in Supplementary Table 1) were synthesized as C-terminal amides, by
microwave-assisted solid-phase peptide synthesis Fmoc-protected amino acids were activated by
2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU) and Nhydroxybenzotriazole hydrate (HOBt), all purchased from Advanced ChemTech. NovaSyn TGR
resin was purchased from EMD Biosciences. Peptides were synthesized on a 12.5 μmol scale. A
general protocol for manual solid-phase peptide synthesis follows: NovaSyn TGR resin (52.1
mg, 12.5 μmol at 0.24 mmol/g resin loading) was aliquotted into a fritted polypropylene syringe
and allowed to swell first in CH2Cl2, and then in dimethylformamide (DMF). Solvent was
drained from the resin using a vacuum manifold. To remove the Fmoc protecting group on the
resin-linked amino acid, 0.625 mL of 20% piperidine in DMF was added to the resin, and the
resulting mixture was allowed to sit at room temperature for 1 minute. The deprotection solution
was then drained from the resin with a vacuum manifold. An additional 1.25 mL of 20%
piperidine in DMF was then added to the resin, and the reaction vessel was placed in the
microwave. The temperature was ramped from room temperature to 80°C over the course of 2
minutes and held at 80°C for 2 minutes. The deprotection solution was drained from the resin
using a vacuum manifold, and the resin was rinsed five times with DMF. The Fmoc deprotection
solution was changed after an aspartate residue was coupled to avoid aspartimide formation. The
modified deprotection solution (0.625 mL of 5% m/v piperizine + 0.1 M HOBT in DMF) was
added to the resin, the resulting mixture was allowed to sit at room temperature for 1 minute. The
deprotection solution was drained from the resin with a vacuum manifold. An additional 0.625
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mL of modified deprotection solution was then added to the resin, and the reaction vessel was
placed in the microwave. The temperature was ramped from room temperature to 75°C over the
course of 2 minutes and held at 75°C for 3 minutes.
For coupling of an activated amino acid, we prepared a stock coupling solution of 100
mL NMP, 3.17 g HBTU (0.01 mol, 0.1 M) and 1.53 g HOBt (0.01 mol, 0.1 M) for a final
concentration of 0.1 M HBTU and 0.1 M HOBt. The desired Fmoc-protected amino acid (125
μmol, 5 eq) was dissolved by vortexing in 1.25 mL coupling solution (125 μmol, 5 eq HBTU;
125 μmol, 5 eq HOBt). To the dissolved amino acid solution was added 44 μL DIEA (250 μmol,
10 eq). The resulting mixture was vortexed briefly and allowed to react for at least 1 min. The
activated amino acid solution was then added to the resin, and the reaction vessel was placed in
the microwave. The temperature was ramped from room temperature to 70°C over 2 minutes and
held at 70°C for 4 minutes. Following the coupling reaction, the activated amino acid solution
was drained from the resin with a 2 vacuum manifold, and the resin was subsequently rinsed five
times with DMF. The cycles of deprotection and coupling were alternately repeated to give the
desired full-length protein.
Acid-labile side-chain protecting groups were globally removed and proteins were
cleaved from the resin by stirring the resin for ~4h in a solution of phenol (0.0625 g), water (62.5
μL), thioanisole (62.5 μL), ethanedithiol (31 μL) and triisopropylsilane (12.5 μL) in
trifluoroacetic acid (TFA, 1 mL). Following the cleavage reaction, the TFA solution was drained
from the resin, the resin was rinsed with additional TFA. Proteins were precipitated from the
TFA solution by addition of diethyl ether (~40 mL). Following centrifugation, the ether was
decanted, and the pellet was dissolved in ~40mL 1:1 H2O/MeCN, frozen and lyophilized to
remove volatile impurities. The resulting powder was stored at -20°C until purification.
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Immediately prior to purification, the crude protein was dissolved in 1:1 H2O/MeCN.
Proteins were purified by preparative reverse-phase high performance liquid chromatography
(HPLC) on a C18 column using a linear gradient of water in acetonitrile with 0.1% v/v TFA.
Fractions containing the desired protein product were pooled, frozen, and lyophilized. Proteins
were identified by electrospray ionization time of flight mass spectrometry (ESI-TOF); expected
and observed exact masses mass spectra appear in Table 1. Protein purity was assessed by
Analytical HPLC.

Table 2-2. Sequences for peptides 1-27, pA-EWK, pA-AWK, pA-EWA and their sequence
derivatives.
Peptide

Sequence

1CW
1
2
3
4
5
6
7
8

Ac–EVEALEKKVAALECKVQALEKKVEALEHGWDGR–CONH2
Ac–EVEALEKKVEALEWKVQKLEKKVEALEHGWDGR–CONH2
Ac–EVEALEKKVAALEWKVQKLEKKVEALEHGWDGR–CONH2
Ac–EVEALEKKVEALEWKVQALEKKVEALEHGWDGR–CONH2
Ac–EVEALEKKVAALEWKVQALEKKVEALEHGWDGR–CONH2
Ac–EVEALEKKVEALESKVQKLEKKVEALEHGWDGR–CONH2
Ac–EVEALEKKVAALESKVQKLEKKVEALEHGWDGR–CONH2
Ac–EVEALEKKVEALESKVQALEKKVEALEHGWDGR–CONH2
Ac–EVEALEKKVAALESKVQALEKKVEALEHGWDGR–CONH2

9
9-DWA
9-DSK
9-DSA

Ac–EVEALEKKVDALEWKVQKLEKKVEALEHGWDGR–CONH2
Ac–EVEALEKKVDALEWKVQALEKKVEALEHGWDGR–CONH2
Ac–EVEALEKKVDALESKVQKLEKKVEALEHGWDGR–CONH2
Ac–EVEALEKKVDALESKVQALEKKVEALEHGWDGR–CONH2

10
10-AWO
10-ESO
10-ASO

Ac–EVEALEKKVEALEWKVQOLEKKVEALEHGWDGR–CONH2
Ac–EVEALEKKVAALEWKVQOLEKKVEALEHGWDGR–CONH2
Ac–EVEALEKKVEALESKVQOLEKKVEALEHGWDGR–CONH2
Ac–EVEALEKKVAALESKVQOLEKKVEALEHGWDGR–CONH2

11
11-EWA
11-ESK
11-ESA

Ac–EVEALEKKVAELEWKVQKLEKKVEALEHGWDGR–CONH2
Ac–EVEALEKKVAELEWKVQALEKKVEALEHGWDGR–CONH2
Ac–EVEALEKKVAELESKVQKLEKKVEALEHGWDGR–CONH2
Ac–EVEALEKKVAELESKVQALEKKVEALEHGWDGR–CONH2

12
12-KWA
12-AWE
12-KSE

Ac–EVEALEKKVKALEWKVQELEKKVEALEHGWDGR–CONH2
Ac–EVEALEKKVKALEWKVQALEKKVEALEHGWDGR–CONH2
Ac–EVEALEKKVAALEWKVQELEKKVEALEHGWDGR–CONH2
Ac–EVEALEKKVKALESKVQELEKKVEALEHGWDGR–CONH2
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12-KSA
12-ASE
13
13-AWmeK
13-EWmeA
13-AWmeA
14
14-AYK
14-EYA
14-AYA
15
15-AYmeK
15-EYmeA
15-AYmeA
16
16-AFK
16-EFA
16-AFA

Ac–EVEALEKKVKALESKVQALEKKVEALEHGWDGR–CONH2
Ac–EVEALEKKVAALESKVQELEKKVEALEHGWDGR–CONH2
Ac–EVEALEKKVEALEWmeKVQKLEKKVEALEHGWDGR–CONH2
Ac–EVEALEKKVAALEWmeKVQKLEKKVEALEHGWDGR–CONH2
Ac–EVEALEKKVEALEWmeKVQALEKKVEALEHGWDGR–CONH2
Ac–EVEALEKKVAALEWmeKVQALEKKVEALEHGWDGR–CONH2
Ac–EVEALEKKVEALEYKVQKLEKKVEALEHGWDGR–CONH2
Ac–EVEALEKKVAALEYKVQKLEKKVEALEHGWDGR–CONH2
Ac–EVEALEKKVEALEYKVQALEKKVEALEHGWDGR–CONH2
Ac–EVEALEKKVAALEYKVQALEKKVEALEHGWDGR–CONH2
Ac–EVEALEKKVEALEYmeKVQKLEKKVEALEHGWDGR–CONH2
Ac–EVEALEKKVAALEYmeKVQKLEKKVEALEHGWDGR–CONH2
Ac–EVEALEKKVEALEYmeKVQALEKKVEALEHGWDGR–CONH2
Ac–EVEALEKKVAALEYmeKVQALEKKVEALEHGWDGR–CONH2
Ac–EVEALEKKVEALEFKVQKLEKKVEALEHGWDGR–CONH2
Ac–EVEALEKKVAALEFKVQKLEKKVEALEHGWDGR–CONH2
Ac–EVEALEKKVEALEFKVQALEKKVEALEHGWDGR–CONH2
Ac–EVEALEKKVAALEFKVQALEKKVEALEHGWDGR–CONH2

17
17-A(f5F)K
17-E(f5F)A
17-A(f5F)A

Ac–EVEALEKKVEALE(f5F)KVQKLEKKVEALEHGWDGR–CONH2
Ac–EVEALEKKVAALE(f5F)KVQKLEKKVEALEHGWDGR–CONH2
Ac–EVEALEKKVEALE(f5F)KVQALEKKVEALEHGWDGR–CONH2
Ac–EVEALEKKVAALE(f5F)KVQALEKKVEALEHGWDGR–CONH2

18
18-A(p-fF)K
18-E(p-fF)A
18-A(p-fF)A

Ac–EVEALEKKVEALE(P-fF)KVQKLEKKVEALEHGWDGR–CONH2
Ac–EVEALEKKVAALE(P-fF)KVQKLEKKVEALEHGWDGR–CONH2
Ac–EVEALEKKVEALE(P-fF)KVQALEKKVEALEHGWDGR–CONH2
Ac–EVEALEKKVAALE(P-fF)KVQALEKKVEALEHGWDGR–CONH2

19
19-A(3,4-f2F)K
19-E(3,4-f2F)A
19-A(3,4-f2F)A

Ac–EVEALEKKVEALE(3,4-f2F)KVQKLEKKVEALEHGWDGR–CONH2
Ac–EVEALEKKVAALE(3,4-f2F)KVQKLEKKVEALEHGWDGR–CONH2
Ac–EVEALEKKVEALE(3,4-f2F)KVQALEKKVEALEHGWDGR–CONH2
Ac–EVEALEKKVAALE(3,4-f2F)KVQALEKKVEALEHGWDGR–CONH2

20
20-A(p-NO2F)K
20-E(p-NO2F)A
20-A(p-NO2F)A

Ac–EVEALEKKVEALE(P-NO2F)KVQKLEKKVEALEHGWDGR–CONH2
Ac–EVEALEKKVAALE(P-NO2F)KVQKLEKKVEALEHGWDGR–CONH2
Ac–EVEALEKKVEALE(P-NO2F)KVQALEKKVEALEHGWDGR–CONH2
Ac–EVEALEKKVAALE(P-NO2F)KVQALEKKVEALEHGWDGR–CONH2

20
20-A(PyrA)K
20-E(PyrA)A
20-A(PyrA)A
22
22-AFK
22-EFA
22-AFA
22-ESK
22-ASK
22-ESA

Ac–EVEALEKKVEALE(PyrA)KVQKLEKKVEALEHGWDGR–CONH2
Ac–EVEALEKKVAALE(PyrA)KVQKLEKKVEALEHGWDGR–CONH2
Ac–EVEALEKKVEALE(PyrA)KVQALEKKVEALEHGWDGR–CONH2
Ac–EVEALEKKVAALE(PyrA)KVQALEKKVEALEHGWDGR–CONH2
Ac–RMKQLEDRVEALEFKNYKLENEVARLKKLVGER–CONH2
Ac–RMKQLEDRVAALEFKNYKLENEVARLKKLVGER–CONH2
Ac–RMKQLEDRVEALEFKNYALENEVARLKKLVGER–CONH2
Ac–RMKQLEDRVAALEFKNYALENEVARLKKLVGER–CONH2
Ac–RMKQLEDRVEALESKNYKLENEVARLKKLVGER–CONH2
Ac–RMKQLEDRVAALESKNYKLENEVARLKKLVGER–CONH2
Ac–RMKQLEDRVEALESKNYALENEVARLKKLVGER–CONH2
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22-ASA

Ac–RMKQLEDRVAALESKNYALENEVARLKKLVGER–CONH2

23
23-EFA
23-ESK
23-ESA

Ac–RMKQLEDRVAELEFKNYKLENEVARLKKLVGER–CONH2
Ac–RMKQLEDRVAELEFKNYALENEVARLKKLVGER–CONH2
Ac–RMKQLEDRVAELESKNYKLENEVARLKKLVGER–CONH2
Ac–RMKQLEDRVAELESKNYALENEVARLKKLVGER–CONH2

24
24-AFR
24-ESR
24-ASR

Ac–EVEALEKKVEALEFKVQRLEKKVEALEHGWDGR–CONH2
Ac–EVEALEKKVAALEFKVQRLEKKVEALEHGWDGR–CONH2
Ac–EVEALEKKVEALESKVQRLEKKVEALEHGWDGR–CONH2
Ac–EVEALEKKVAALESKVQRLEKKVEALEHGWDGR–CONH2

25
25-AAK
25-EAA
25-AAA

Ac–EVEALEKKVEALEAKVQKLEKKVEALEHGWDGR–CONH2
Ac–EVEALEKKVAALEAKVQKLEKKVEALEHGWDGR–CONH2
Ac–EVEALEKKVEALEAKVQALEKKVEALEHGWDGR–CONH2
Ac–EVEALEKKVAALEAKVQALEKKVEALEHGWDGR–CONH2

26
27

Ac–EVEALEKKVAALEEKVQALEKKVEALEHGWDGR–CONH2
Ac–EVEALEKKVAALEEKVQKLEKKVEALEHGWDGR–CONH2

pA-EWK
pA-EWA
pA-AWK

2.4.2

Ac–OOAAAAAEAAAWAAAKAAAAAOOY–CONH2
Ac–OOAAAAAEAAAWAAAAAAAAAOOY–CONH2
Ac–OOAAAAAAAAAWAAAKAAAAAOOY–CONH2

ESI-TOF data

Figure 2-10. ESI TOF spectrum for peptide 1
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Figure 2-11. ESI TOF spectrum for peptide 2

Figure 2-12. ESI TOF spectrum for peptide 3

Figure 2-13. ESI TOF spectrum for peptide 4.
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Figure 2-14. ESI TOF spectrum for peptide 5.

Figure 2-15. ESI TOF spectrum for peptide 6.

Figure 2-16. ESI TOF spectrum for peptide 7.
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Figure 2-17. ESI TOF spectrum for peptide 8.

Figure 2-18. ESI TOF spectrum for peptide 9.

Figure 2-19. ESI TOF spectrum for peptide 9-DWA
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Figure 2-20. ESI TOF spectrum for peptide 9-DSK.

Figure 2-21. ESI TOF spectrum for peptide 9-DSA.

Figure 2-22. ESI TOF spectrum for peptide 10.
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Figure 2-23. ESI TOF spectrum for peptide 10-AWO.

Figure 2-24. ESI TOF spectrum for peptide 10-ESO.

Figure 2-25. ESI TOF spectrum for peptide 10-ASO.
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Figure 2-26. ESI TOF spectrum for peptide 11.

Figure 2-27. ESI TOF spectrum for peptide 11-EWA.

Figure 2-28. ESI TOF spectrum for peptide 11-ESK.
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Figure 2-29. ESI TOF spectrum for peptide 11-ESA.

Figure 2-30. ESI TOF spectrum for peptide 12.

Figure 2-31. ESI TOF spectrum for peptide 12-KWA.
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Figure 2-32. ESI TOF spectrum for peptide 12-AWE.

Figure 2-33. ESI TOF spectrum for 12-KSE.

Figure 2-34. ESI TOF spectrum for 12-KSA.
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Figure 2-35. ESI TOF spectrum for 12-ASE.

Figure 2-36. ESI TOF spectrum for peptide 13.

Figure 2-37. ESI TOF spectrum for peptide 13-AWmeK.

54

Figure 2-38. ESI TOF spectrum for peptide 13-EWmeA.

Figure 2-39. ESI TOF spectrum for peptide 13-AWmeA.

Figure 2-40. ESI TOF spectrum for peptide 14.
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Figure 2-41. ESI TOF spectrum for peptide 14-AYK.

Figure 2-42. ESI TOF spectrum for peptide 14-EYA.

Figure 2-43. ESI TOF spectrum for peptide 14-AYA.
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Figure 2-44. ESI TOF spectrum for peptide 15.

Figure 2-45. ESI TOF spectrum for peptide 15-AYmeK.

Figure 2-46. ESI TOF spectrum for peptide 15-EYmeA.
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Figure 2-47. ESI TOF spectrum for peptide 15-AYmeA.

Figure 2-48. ESI TOF spectrum for peptide 16.

Figure 2-49. ESI TOF spectrum for peptide 16-AFK.
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Figure 2-50. ESI TOF spectrum for peptide 16-EFA.

Figure 2-51. ESI TOF spectrum for peptide 16-AFA.

Figure 2-52. ESI TOF spectrum for peptide 17.
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Figure 2-53. ESI TOF spectrum for peptide 17-A(f5Phe)K.

Figure 2-54. ESI TOF spectrum for peptide 17-E(f5Phe)A.

Figure 2-55. ESI TOF spectrum for peptide 17-A(f5Phe)A.
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Figure 2-56. ESI TOF spectrum for 18-A(p-fF)A.

Figure 2-57. ESI TOF spectrum for 18-A(p-fF)K.

Figure 2-58. ESI TOF spectrum for 18-E(p-fF)A.
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Figure 2-59. ESI TOF spectrum for 18.

Figure 2-60. ESI TOF spectrum for 19-A(3,4-f2F)A.

Figure 2-61. ESI TOF spectrum for 19-A(3,4-f2F)K.
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Figure 2-62. ESI TOF spectrum for 19-E(3,4-f2F)A.

Figure 2-63. ESI TOF spectrum for 19.

Figure 2-64. ESI TOF spectrum for 20-A(p-NO2F)A.
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Figure 2-65. ESI TOF spectrum for 20-A(p-NO2F)K.

Figure 2-66. ESI TOF spectrum for 20-E(p-NO2F)A.

Figure 2-67. ESI TOF spectrum for 20
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Figure 2-68. ESI TOF spectrum for 21-A(PyrA)A.

Figure 2-69. ESI TOF spectrum for 21-A(PyrA)K.

Figure 2-70. ESI TOF spectrum for 21-E(PyrA)A.
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Figure 2-71. ESI TOF spectrum for 21.

Figure 2-72. ESI TOF spectrum for peptide 22.

Figure 2-73. ESI TOF spectrum for peptide 22-AFK.
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Figure 2-74. ESI TOF spectrum for peptide 22-EFA.

Figure 2-75. ESI TOF spectrum for peptide 22-AFA.

Figure 2-76. ESI TOF spectrum for peptide 22-ESK.
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Figure 2-77. ESI TOF spectrum for peptide 22-ASK.

Figure 2-78. ESI TOF spectrum for peptide 22-ESA.

Figure 2-79. ESI TOF spectrum for peptide 22-ASA.
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Figure 2-80. ESI TOF spectrum for peptide 23

Figure 2-81. ESI TOF spectrum for peptide 23-EFA.

Figure 2-82. ESI TOF spectrum for peptide 23-ESK.
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Figure 2-83. ESI TOF spectrum for peptide 23-ESA.

Figure 2-84. ESI TOF spectrum for peptide 24.

Figure 2-85. ESI TOF spectrum for peptide 24-AFR.
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Figure 2-86. ESI TOF spectrum for peptide 24-ESR.

Figure 2-87. ESI TOF spectrum for peptide 24-ASR.

Figure 2-88. ESI TOF spectrum for 25.
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Figure 2-89. ESI TOF spectrum for peptide 25-AAK.

Figure 2-90. ESI TOF spectrum for 25-EAA.

Figure 2-91. ESI TOF spectrum for 25-AAA.
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Figure 2-92. ESI TOF spectrum for peptide 26.

Figure 2-93. ESI TOF spectrum for peptide 27.

Figure 2-94. ESI TOF spectrum for pA-EWK.
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Figure 2-95. ESI TOF spectrum for pA-EWA.

Figure 2-96. ESI TOF spectrum for pA-AWK.

2.4.3

Analytical HPLC data

Figure 2-97. Analytical HPLC Data for 1. Protein solution was injected onto a C18 analytical column and
eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over 50 minutes,
followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration (10% B) at 1 mL/min.
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Figure 2-98. Analytical HPLC Data for 2. Protein solution was injected onto a C18 analytical column and
eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over 50 minutes,
followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration (10% B) at 1 mL/min.

Figure 2-99. Analytical HPLC Data for 3. Protein solution was injected onto a C18 analytical column and
eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over 50 minutes,
followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration (10% B) at 1 mL/min.

Figure 2-100. Analytical HPLC Data for 4. Protein solution was injected onto a C18 analytical column
and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over 50
minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration (10% B) at 1
mL/min.
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Figure 2-101. Analytical HPLC Data for 5. Protein solution was injected onto a C18 analytical column
and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over 50
minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration (10% B) at 1
mL/min.

Figure 2-102. Analytical HPLC Data for 6. Protein solution was injected onto a C18 analytical column
and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over 50
minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration (10% B) at 1
mL/min.

Figure 2-103. Analytical HPLC Data for 7. Protein solution was injected onto a C18 analytical column
and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over 50
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minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration (10% B) at 1
mL/min.

Figure 2-104. Analytical HPLC Data for peptide 8. Protein solution was injected onto a C18 analytical
column and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over
50 minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration (10% B) at
1 mL/min.

Figure 2-105. Analytical HPLC Data for 9. Protein solution was injected onto a C18 analytical column
and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over 50
minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration (10% B) at 1
mL/min.

Figure 2-106. Analytical HPLC Data for 9-DWA. Protein solution was injected onto a C18 analytical
column and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over
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50 minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration (10% B) at
1 mL/min.

Figure 2-107. Analytical HPLC Data for 9-DSK. Protein solution was injected onto a C18 analytical
column and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over
50 minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration (10% B) at
1 mL/min.

Figure 2-108. Analytical HPLC Data for 9-DSA. Protein solution was injected onto a C18 analytical
column and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over
50 minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration (10% B) at
1 mL/min.

Figure 2-109. Analytical HPLC Data for 10. Protein solution was injected onto a C18 analytical column
and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over 50
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minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration (10% B) at 1
mL/min.

Figure 2-110. Analytical HPLC Data for 10-AWO. Protein solution was injected onto a C18 analytical
column and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over
50 minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration (10% B) at
1 mL/min.

Figure 2-111. Analytical HPLC Data for 10-ESO. Protein solution was injected onto a C18 analytical
column and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over
50 minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration (10% B) at
1 mL/min.

Figure 2-112. Analytical HPLC Data for 10-ASO. Protein solution was injected onto a C18 analytical
column and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over
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50 minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration (10% B) at
1 mL/min.

Figure 2-113. Analytical HPLC Data for 11. Protein solution was injected onto a C18 analytical column
and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over 50
minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration (10% B) at 1
mL/min.

Figure 2-114. Analytical HPLC Data for 11-EWA. Protein solution was injected onto a C18 analytical
column and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over
50 minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration (10% B) at
1 mL/min.
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Figure 2-115. Analytical HPLC Data for 11-ESK. Protein solution was injected onto a C18 analytical
column and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over
50 minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration (10% B) at
1 mL/min.

Figure 2-116. Analytical HPLC Data for 11-ESA. Protein solution was injected onto a C18 analytical
column and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over
50 minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration (10% B) at
1 mL/min.
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Figure 2-117. Analytical HPLC Data for 12. Protein solution was injected onto a C18 analytical column
and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over 50
minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration (10% B) at 1
mL/min. (this run was ended early)

Figure 2-118. Analytical HPLC Data for 12-KWA. Protein solution was injected onto a C18 analytical
column and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over
50 minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration (10% B) at
1 mL/min.

Figure 2-119. Analytical HPLC Data for 12-AWE. Protein solution was injected onto a C18 analytical
column and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over
50 minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration (10% B) at
1 mL/min.
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Figure 2-120. Analytical HPLC Data for 12-KSE. Protein solution was injected onto a C18 analytical
column and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over
50 minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration (10% B) at
1 mL/min.

Figure 2-121. Analytical HPLC Data for 12-KSA. Protein solution was injected onto a C18 analytical
column and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over
50 minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration (10% B) at
1 mL/min.

Figure 2-122. Analytical HPLC Data for 12-ASE. Protein solution was injected onto a C18 analytical
column and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over
50 minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration (10% B) at
1 mL/min.
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Figure 2-123. Analytical HPLC Data for 13. Protein solution was injected onto a C18 analytical column
and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over 50
minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration (10% B) at 1
mL/min.

Figure 2-124. Analytical HPLC Data for 13-AWmeK. Protein solution was injected onto a C18 analytical
column and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over
50 minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration (10% B) at
1 mL/min.

Figure 2-125. Analytical HPLC Data for 13-EWmeA. Protein solution was injected onto a C18 analytical
column and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over
50 minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration (10% B) at
1 mL/min.
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Figure 2-126. Analytical HPLC Data for 13-AWmeA. Protein solution was injected onto a C18 analytical
column and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over
50 minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration (10% B) at
1 mL/min.

Figure 2-127. Analytical HPLC Data for 14. Protein solution was injected onto a C18 analytical column
and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over 50
minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration (10% B) at 1
mL/min.

Figure 2-128. Analytical HPLC Data for 14-AYK. Protein solution was injected onto a C18 analytical
column and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over
50 minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration (10% B) at
1 mL/min.
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Figure 2-129. Analytical HPLC Data for 14-EYA. Protein solution was injected onto a C18 analytical
column and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over
50 minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration (10% B) at
1 mL/min.

Figure 2-130. Analytical HPLC Data for 14-AYA. Protein solution was injected onto a C18 analytical
column and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over
50 minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration (10% B) at
1 mL/min.

Figure 2-131. Analytical HPLC Data for 15. Protein solution was injected onto a C18 analytical column
and eluted using a linear gradient of 20-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over 40
minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration (10% B) at 1
mL/min.
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Figure 2-132. Analytical HPLC Data for 15-AYmeK. Protein solution was injected onto a C18 analytical
column and eluted using a linear gradient of 20-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over
40 minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration (10% B) at
1 mL/min.

Figure 2-133. Analytical HPLC Data for 15-EYmeA. Protein solution was injected onto a C18 analytical
column and eluted using a linear gradient of 20-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over
40 minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration (10% B) at
1 mL/min.

Figure 2-134. Analytical HPLC Data for 15-AYmeA. Protein solution was injected onto a C18 analytical
column and eluted using a linear gradient of 20-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over
40 minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration (10% B) at
1 mL/min.
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Figure 2-135. Analytical HPLC Data for 16. Protein solution was injected onto a C18 analytical column
and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over 50
minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration (10% B) at 1
mL/min.

Figure 2-136. Analytical HPLC Data for 16-AFK. Protein solution was injected onto a C18 analytical
column and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over
50 minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration (10% B) at
1 mL/min.

Figure 2-137. Analytical HPLC Data for 16-EFA. Protein solution was injected onto a C18 analytical
column and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over
50 minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration (10% B) at
1 mL/min.
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Figure 2-138. Analytical HPLC Data for 16-AFA. Protein solution was injected onto a C18 analytical
column and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over
50 minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration (10% B) at
1 mL/min.

Figure 2-139. Analytical HPLC Data for 17. Protein solution was injected onto a C18 analytical column
and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over 50
minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration (10% B) at 1
mL/min.

Figure 2-140. Analytical HPLC Data for 17-A(f5F)K. Protein solution was injected onto a C18 analytical
column and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over
50 minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration (10% B) at
1 mL/min.
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Figure 2-141. Analytical HPLC Data for 17-E(f5F)A. Protein solution was injected onto a C18 analytical
column and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over
50 minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration (10% B) at
1 mL/min.

Figure 2-142. Analytical HPLC Data for 17-A(f5F)A. Protein solution was injected onto a C18 analytical
column and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over
50 minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration (10% B) at
1 mL/min.
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Figure 2-143. Analytical HPLC Data for 18. Protein solution was injected onto a C18 analytical column
and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over 50
minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration (10% B) at 1
mL/min

Figure 2-144. Analytical HPLC Data for 18-A(p-fF)K. Protein solution was injected onto a C18
analytical column and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1%
TFA) over 50 minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration
(10% B) at 1 mL/min
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Figure 2-145. Analytical HPLC Data for 18-E(p-fF)A. Protein solution was injected onto a C18
analytical column and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1%
TFA) over 50 minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration
(10% B) at 1 mL/min

Figure 2-146. Analytical HPLC Data for 18-A(p-fF)A. Protein solution was injected onto a C18
analytical column and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1%
TFA) over 50 minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration
(10% B) at 1 mL/min
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Figure 2-147. Analytical HPLC Data for 19. Protein solution was injected onto a C18 analytical column
and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over 50
minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration (10% B) at 1
mL/min.

Figure 2-148. Analytical HPLC Data for 19-A(3,4-f2F)K. Protein solution was injected onto a C18
analytical column and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1%
TFA) over 50 minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration
(10% B) at 1 mL/min
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Figure 2-149. Analytical HPLC Data for 19-E(3,4-f2F)K. Protein solution was injected onto a C18
analytical column and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1%
TFA) over 50 minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration
(10% B) at 1 mL/min

Figure 2-150. Analytical HPLC Data for 19-A(3,4-f2F)A. Protein solution was injected onto a C18
analytical column and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1%
TFA) over 50 minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration
(10% B) at 1 mL/min
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Figure 2-151. Analytical HPLC Data for 20. Protein solution was injected onto a C18 analytical column
and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over 50
minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration (10% B) at 1
mL/min.

Figure 2-152. Analytical HPLC Data for 20-A(p-NO2F)K. Protein solution was injected onto a C18
analytical column and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1%
TFA) over 50 minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration
(10% B) at 1 mL/min
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Figure 2-153. Analytical HPLC Data for 20-E(p-NO2F)A. Protein solution was injected onto a C18
analytical column and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1%
TFA) over 50 minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration
(10% B) at 1 mL/min

Figure 2-154. Analytical HPLC Data for 20-A(p-NO2F)A. Protein solution was injected onto a C18
analytical column and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1%
TFA) over 50 minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration
(10% B) at 1 mL/min.
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Figure 2-155. Analytical HPLC Data for 21. Protein solution was injected onto a C18 analytical column
and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over 50
minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration (10% B) at 1
mL/min.

Figure 2-156. Analytical HPLC Data for 21-A(PyrA)K. Protein solution was injected onto a C18
analytical column and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1%
TFA) over 50 minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration
(10% B) at 1 mL/min.
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Figure 2-157. Analytical HPLC Data for 21-E(PyrA)A. Protein solution was injected onto a C18
analytical column and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1%
TFA) over 50 minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration
(10% B) at 1 mL/min.

Figure 2-158. Analytical HPLC Data for 21-A(PyrA)A. Protein solution was injected onto a C18
analytical column and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1%
TFA) over 50 minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration
(10% B) at 1 mL/min.
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Figure 2-159. Analytical HPLC Data for 22. Protein solution was injected onto a C18 analytical column
and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over 50
minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration (10% B) at 1
mL/min.

Figure 2-160. Analytical HPLC Data for 22-AFK. Protein solution was injected onto a C18 analytical
column and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over
50 minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration (10% B) at
1 mL/min.

Figure 2-161. Analytical HPLC Data for 22-EFA. Protein solution was injected onto a C18 analytical
column and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over
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50 minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration (10% B) at
1 mL/min.

Figure 2-162. Analytical HPLC Data for 22-AFA. Protein solution was injected onto a C18 analytical
column and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over
50 minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration (10% B) at
1 mL/min.

Figure 2-163. Analytical HPLC Data for 22-ESK. Protein solution was injected onto a C18 analytical
column and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over
50 minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration (10% B) at
1 mL/min.
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Figure 2-164. Analytical HPLC Data for 22-ASK. Protein solution was injected onto a C18 analytical
column and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over
50 minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration (10% B) at
1 mL/min.

Figure 2-165. Analytical HPLC Data for 22-ESA. Protein solution was injected onto a C18 analytical
column and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over
50 minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration (10% B) at
1 mL/min.

Figure 2-166. Analytical HPLC Data for 22-ASA. Protein solution was injected onto a C18 analytical
column and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over
50 minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration (10% B) at
1 mL/min.
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Figure 2-167. Analytical HPLC Data for 23. Protein solution was injected onto a C18 analytical column
and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over 50
minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration (10% B) at 1
mL/min

Figure 2-168. Analytical HPLC Data for 23-EFA. Protein solution was injected onto a C18 analytical
column and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over
50 minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration (10% B) at
1 mL/min.

Figure 2-169. Analytical HPLC Data for 23-ESK. Protein solution was injected onto a C18 analytical
column and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over
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50 minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration (10% B) at
1 mL/min.

Figure 2-170. Analytical HPLC Data for 23-ESA. Protein solution was injected onto a C18 analytical
column and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over
50 minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration (10% B) at
1 mL/min.

Figure 2-171. Analytical HPLC Data for 24. Protein solution was injected onto a C18 analytical column
and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over 50
minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration (10% B) at 1
mL/min.

Figure 2-172. Analytical HPLC Data for 24-AFR. Protein solution was injected onto a C18 analytical
column and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over
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50 minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration (10% B) at
1 mL/min.

Figure 2-173. Analytical HPLC Data for 24-ESR. Protein solution was injected onto a C18 analytical
column and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over
50 minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration (10% B) at
1 mL/min.

Figure 2-174. Analytical HPLC Data for 24-ASR. Protein solution was injected onto a C18 analytical
column and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over
50 minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration (10% B) at
1 mL/min.
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Figure 2-175. Analytical HPLC Data for 25. Protein solution was injected onto a C18 analytical column
and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over 50
minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration (10% B) at 1
mL/min.

Figure 2-176. Analytical HPLC Data for 25-AAK. Protein solution was injected onto a C18 analytical
column and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over
50 minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration (10% B) at
1 mL/min.

Figure 2-177. Analytical HPLC Data for 25-EAA. Protein solution was injected onto a C18 analytical
column and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over
50 minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration (10% B) at
1 mL/min.
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Figure 2-178. Analytical HPLC Data for 25-AAA. Protein solution was injected onto a C18 analytical
column and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over
50 minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration (10% B) at
1 mL/min.

Figure 2-179. Analytical HPLC Data for 26. Protein solution was injected onto a C18 analytical column
and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over 50
minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration (10% B) at 1
mL/min.
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Figure 2-180. Analytical HPLC Data for 27. Protein solution was injected onto a C18 analytical column
and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over 50
minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration (10% B) at 1
mL/min.

Figure 2-181. Analytical HPLC Data for pA-EWK. Protein solution was injected onto a C18 analytical
column and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over
50 minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration (10% B) at
1 mL/min.
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Figure 2-182. Analytical HPLC Data for pA-EWA. Protein solution was injected onto a C18 analytical
column and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over
50 minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration (10% B) at
1 mL/min.

Figure 2-183. Analytical HPLC Data for pA-AWK. Protein solution was injected onto a C18 analytical
column and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over
50 minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration (10% B) at
1 mL/min.

2.4.4

Size exclusion chromatography

Previously characterized peptide 1CW adopts a homotrimeric self-association state in
solution, whereas GCN4 adopts a homodimeric self-association state in solution. The large
number of peptides explored here (78 peptides including 1–27 and their sequence variants shown

108

in Supplementary Table 1) precluded the use of time and resource-intensive sedimentation
equilibrium experiments to characterize their self-association properties. Consequently, we used
the higher throughput size exclusion chromatography to characterize the self-association
properties of 1–27 (and their sequence variants) by comparing their retention times on a sizeexclusion column to the retention times of homotrimeric 1CW, homodimeric GCN4 and
monomeric α-helical PSBD36.9, 35-36
Size exclusion chromatography (SEC) was done on a Shimadzu HPLC instrument using a
Phenomenex yarra 3u sec-3000 column (batches 1 and 2) or a Zenix-C SEC 100 column (batches
3, 4, and 5). The columns were calibrated with internal 1CW, GCN4, and PSBD36 standards.
Previous characterization of 1CW, GCN4, and PSBD36 by sedimentation equilibrium analytical
ultracentrifugation under analogous buffer conditions demonstrates that 1CW adopts a trimeric
association state; that GCN4 adopts a dimeric state; and that PSBD36 is an α-helical monomer.
The retention times derived from SEC experiments on peptides 1-19 and 23-26 are very close to
that of trimeric 1CW, suggesting that these variants likewise adopt a trimeric association state.
Similarly, the retention times derived from SEC experiments on peptides 20-22 are close to that
of dimeric GCN4, suggesting that these variants likewise adopt a dimeric association state.
Moreover, published peptide coil-VaLd (which has the same sequence as peptide 5, except that 5
has four additional C-terminal residues) crystallizes as a trimer,19 as do other coiled-coil peptides
in which beta-branched non-polar residues (i.e. Ile and/or Val) occupy a-positions and Leu
occupies d-positions in the canonical heptad repeat.37 Therefore, we are reasonably confident that
1-19 and 23-24 adopt trimeric association states and that 20-22 adopt dimeric association states.
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Table 2-4 Size exclusion chromatography of variants 1-27 and sequence variants. Batches 1-2
were done on a Phenomenex yarra 3u sec-3000 column. Batches 3-5 were done on a Zenix-C
SEC 100 column.
Batch 1
Peptide

Trimer MW

Retention Time

(Da)

Inferred association
state

1CW (trimer
standard)

11017

10.50

8

11016

10.50

Trimer

16

11541

10.54

Trimer

16-EFA

11367

10.38

Trimer

16-AFK

11370

10.51

Trimer

5

11361

10.43

Trimer

6

11190

10.51

Trimer

7

11187

10.35

Trimer

16-AFA

11196

10.47

Trimer

14-AYA

11244

10.45

Trimer

14-EYA

11416

10.35

Trimer

14-AYK

11419

10.50

Trimer

14-EYA

11590

10.43

Trimer

4

11313

10.50

Trimer

3

11484

10.37

Trimer

2

11488

10.60

Trimer

1

11659

10.55

Trimer

22-AFR

11452

10.56

Trimer

22

11623

10.43

Trimer

22-ASR

11271

10.52

Trimer

22-ESR

11442

10.41

Trimer

11-EWA

11367

10.43

Trimer
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11

11541

10.56

Trimer

11-ESA

11187

10.41

Trimer

11-ESK

11361

10.52

Trimer

12-KSA

11190

10.60

Trimer

12-ASE

11187

10.38

Trimer

12-KSE

11361

10.47

Trimer

12-KWA

11488

10.76

Trimer

12-AWE

11484

10.44

Trimer

12

11659

10.51

Trimer

Batch 2
1CW

11017

10.19

Trimer

9-DSA

11325

10.08

Trimer

9-DSK

11496

10.26

Trimer

9-DWA

11622

10.21

Trimer

9

11793

10.34

Trimer

10-ASO

11322

10.33

Trimer

10-AWO

11619

10.49

Trimer

10-ESO

11496

10.21

Trimer

10

11793

10.29

Trimer

17-A(f5F)A

11652

10.20

Trimer

17-A(f5F)K

11823

10.28

Trimer

17-E(f5F)A

11826

10.08

Trimer

17

11997

10.22

Trimer

Batch 3
1CW(monomer
standard)

11199

8.83

Trimer

GCN4(dimer
standard)

8131

9.43

Dimer

111

PSBD36(monomer
standard)

4001

10.51

Monomer

15-AYmeA

11422

8.97

Trimer

15-EYmeA

11593

8.83

Trimer

15-AYmeK

11596

8.99

Trimer

15

11767

8.88

Trimer

13-AWmeA

11491

9.05

Trimer

13-EWmeA

11662

8.95

Trimer

13-AWmeK

11665

9.10

Trimer

13

11836

8.95

Trimer

25-AAA

11104

8.86

Trimer

25-EAA

11275

8.73

Trimer

25-AAK

11278

8.86

Trimer

25

11449

8.83

Trimer

22-ESA

7909

9.13

Dimer

22-ASA

7794

9.52

Dimer

22-ASK

7911

9.50

Dimer

22-AFA

7915

10.30

Dimer/Monomer

22-AFK

8031

10.23

Dimer/Monomer

22-ESK

8025

9.15

Dimer

22-EFA

8029

9.39

Dimer

22

8145

9.46

Dimer

23-ESA

7909

9.44

Dimer

23-ESK

8025

9.39

Dimer

23-EFA

8029

9.81

Dimer

23-EFK

8145

9.73

Dimer

Batch 4

112

1CW(trimer
standard)

11199

9.01

Trimer

26

11275

8.93

Trimer

27

11449

9.09

Trimer

Batch 5
Trimer standard

11151

9.15

Trimer

GCN4 (Dimer
Standard)

8131

10.31

Dimer

18-A(p-fF)A

11385

9.33

Trimer

18-E(p-fF)A

11556

9.16

Trimer

18-A(p-fF)K

11560

9.36

Trimer

18

11731

9.18

Trimer

19-A(3,4-f2F)A

11439

9.27

Trimer

19-E(3,4-f2F)A

11610

9.15

Trimer

19-A(3,4-f2F)K

11614

9.28

Trimer

19

11785

9.16

Trimer

21-A(PyrA)A

11340

9.28

Trimer

21-E(PyrA)A

11511

9.16

Trimer

21-A(PyrA)K

11515

9.25

Trimer

21

11686

9.19

Trimer

20

11809

9.22

Trimer

20-A(p-NO2F)K

11638

9.34

Trimer

20-A(p-NO2F)A

11463

9.28

Trimer

20-E(p-NO2F)A

11634

9.11

Trimer

2.4.5

Folded Free energy measurement, Circular Dichroism spectropolarimetry
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Measurements were made with an Aviv 420 Circular Dichroism Spectropolarimeter, using
quartz cuvettes with a path length of 0.1 cm. Protein solutions were prepared in 20 mM sodium
phosphate buffer, pH 7, and protein concentrations were determined spectroscopically based on
tyrosine and tryptophan absorbance at 280 nm in 6 M guanidine hydrochloride + 20 mM sodium
phosphate (εTrp = 5690 M-1cm-1, εTyr = 1280 M-1cm-1).38 Concentrations for variants containing pnitrophenylalanine (p-NO2F) were confirmed by analytical HPLC traces monitered at 220nm and
integrated and compared to standard 33 amino acid coiled coils(εp-NO2Phe = 4439 M-1cm-1).

CD

spectra of 30 μM solutions were obtained from 260 to 200 nm at 25°C. Variable temperature
CD data were obtained at least in triplicate by monitoring the molar ellipticity at 222 nm of 30 µM
solutions each protein variant (30 μM) in 20 mM sodium phosphate (pH 7) from 1 to 95°C at 2 °C
intervals, with 120 s equilibration time between data points and 30 s averaging time.
Triplicate variable temperature CD data for 1-20, and 24-27 and their individual variants
were fit globally to a two-state model for thermally-induced unfolding of helix-bundle trimers as
shown in equations S1—S9 (see below for sedimentation equilibrium evidence that these 1CW
variants are, in fact, trimers).
In this two state model, 3 peptide monomers M are in equilibrium with the helix-bundle
trimer T, where the position of equilibrium is determined by folding equilibrium constant K:

(S1)
In turn, K is defined by the equation S2:
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K=

[T]

(S2)

[M]3

where [T] and [M] are the concentrations of helix-bundle trimer and peptide monomer,
respectively. The total concentration of peptide in solution P is defined by the equation S3:

P = [M] + 3[T]

(S3)

P = [M] + 3K[M]3

(S4)

By combining equations S2 and S3, we can obtain an expression for P that depends only on [M]
and on Kf, as shown in equation S4:

In equation S4, P is a constant, K is a temperature-dependent function (that is constant at a given
temperature), and [M] is unknown. Rearranging equation S4 results in the following polynomial
equation that is cubic in [M]:

0 = [M]3 +

[M]
3K

−

P

(S5)

3K

Using MATLAB, we found the three roots of this polynomial, two of which are complex, whereas
the third is real. The real root of equation (S5) provides an expression for [M] that depends only
on P and Kf, as shown in equation (S6):

[M] = �

P

6K

+�

1

729K3

+

P2

36K2

1
2

1
3

� � −

1

1
1 3
2
2
P
1
P
9K� +�
+
� �
6K 729K3 36K2

(S6)

As described above, K is a temperature-dependent function that is constant at a given
temperature. K is related to the temperature-dependent folding free energy ∆Gf according to
equation S7:
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−∆Gf

K = exp �

RT

�

where R is the universal gas constant (0.0019872 kcal/mol/K).

(S7)
In turn, the temperature

dependence of ∆Gf can be defined by the following first order polynomial:

∆Gf = ∆Go + ∆G1 (T − To )

(S8)

where T is temperature in Kelvin; ∆G0 and ∆G1 are parameters to be determined via least-squares
regression; and T0 is an arbitrary reference temperature, ideally chosen to be near the midpoint of
the unfolding transition. By combining equations S6–S8, we now have an expression for [M] as
a function of temperature that depends only on ∆G0, ∆G1, P and reference temperature T0.
We can use this expression for [M] to fit the variable temperature CD data [θ] to equation
S9, using the actual protein concentration in solution for P; using a fixed arbitrary value for T0
(343.15 K); and then varying ∆G0 and ∆G1 as parameters of the fit so as to minimize the sum of
the squared residuals.

[θ] = (uo ) �1 −

3K[M]3
P

3K[M]3

� + (fo + f1 T) �

P

�

(S9)

In equation S9, T is the temperature in Kelvin; uo defines a horizontal post-transition baseline; and
fo and f1 are the intercept and slope of the pre-transition baseline, respectively. We fit the variable
trimer variable temperature CD data using distinct ∆G0 and ∆G1 values for each peptide; distinct
uo and fo values for each replicate data set of each peptide and a global value for f1 across all
replicate data sets and peptides.
Triplicate variable temperature CD data for each 22-23 and their individual variants were
fit globally to a two-state model for thermally-induced unfolding of helix-bundle dimers as shown
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in equations S10—S19 (see below for sedimentation equilibrium evidence that these GCN4-p1
variants are dimers).
In this two state model, 2 peptide monomers M are in equilibrium with the helix-bundle
dimer D, where the position of equilibrium is determined by folding equilibrium constant K:

(S10)
In turn, K is defined by the equation S11:

K=

[D]

[M]2

(S11)

where [T] and [M] are the concentrations of helix-bundle trimer and peptide monomer,
respectively. The total concentration of peptide in solution P is defined by the equation S3:

P = [M] + 2[D]

(S12)

P = [M] + 2K[M]2

(S13)

By combining equations S12 and S11, we can obtain an expression for P that depends only on [M]
and on Kf, as shown in equation S4:

In equation S13, P is a constant, K is a temperature-dependent function (that is constant at a given
temperature), and [M] is unknown. Rearranging equation S13 results in the following quadratic:

0 = [M]2 + [M] − P
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(S14)

The solution the the quadratic (S14) provides an expression for [M] that depends only on P and
K, as shown in equation (S15):

[M] =

√1+8KP+1
4𝐾𝐾

(S15)

As described above, K is a temperature-dependent function that is constant at a given
temperature. In turn, the temperature dependence of ∆Gf for the dimer can be defined by the
following second order polynomial:

∆Gf = ∆Go + ∆G1 (T − To ) + ∆G2 (T − To )2

(S17)

where T is temperature in Kelvin; ∆G0, ∆G1 and ∆G2 are parameters to be determined via leastsquares regression; and T0 is an arbitrary reference temperature, also chosen near the midpoint of
the unfolding transition. By combining equations, we now have an expression for [M] as a
function of temperature that depends only on ∆G0, ∆G1, P and reference temperature T0.
We can use this expression for [M] to fit the variable temperature CD data [θ] to equation
S9, using the actual protein concentration in solution for P; using a fixed arbitrary value for T0
(343.15 K); and then varying ∆G0 and ∆G1 as parameters of the fit so as to minimize the sum of
the squared residuals.

[θ] = (uo )(1 − Ffit) + (fo + f1 T)(Ffit)
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(S18)

In equation S18, T is the temperature in Kelvin; uo defines a horizontal post-transition
baseline; and fo and f1 are the intercept and slope of the pre-transition baseline, respectively. Ffit
is the fraction folded as defined by equation (S19) of the protein at temperature T.

Ffit = 1 + �

1

1

1

1

� − (2𝐾𝐾𝐾𝐾 + 16𝐾𝐾2𝑃𝑃2)2
4𝐾𝐾𝐾𝐾

(S19)

We fit the dimer variable temperature CD data using distinct ∆G0, ∆G1 and ∆G2 values for each
peptide; distinct uo and fo values for each replicate data set of each peptide and a global value for
f1 across all replicate data sets and peptides.
CD fit data for compounds 22-23 and their control variants are shown below.

Figure 2-184. CD spectra (lines, top left), variable temperature CD data (circles, top right) for 30 µM
solutions of proteins 1 in 20 mM sodium phosphate, pH 7. Parameters used to fit the variable temperature
CD data to equations S6–S9 are also shown, with standard errors as indicated.
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Figure 2-185. CD spectra (lines, top left), variable temperature CD data (circles, top right) for 30 µM
solutions of proteins 1 in 20 mM sodium phosphate, pH 7, 1M urea. Parameters used to fit the variable
temperature CD data to equations S6–S9 are also shown, with standard errors as indicated.

Figure 2-186. CD spectra (lines, top left), variable temperature CD data (circles, top right) for 30 µM
solutions of proteins 2 in 20 mM sodium phosphate, pH 7. Parameters used to fit the variable temperature
CD data to equations S6–S9 are also shown, with standard errors as indicated.
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Figure 2-187. CD spectra (lines, top left), variable temperature CD data (circles, top right) for 30 µM
solutions of proteins 2 in 20 mM sodium phosphate, pH 7, 1M urea. Parameters used to fit the variable
temperature CD data to equations S6–S9 are also shown, with standard errors as indicated

Figure 2-188. CD spectra (lines, top left), variable temperature CD data (circles, top right) for 30 µM
solutions of proteins 3 in 20 mM sodium phosphate, pH 7. Parameters used to fit the variable temperature
CD data to equations S6–S9 are also shown, with standard errors as indicated.
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Figure 2-189. CD spectra (lines, top left), variable temperature CD data (circles, top right) for 30 µM
solutions of proteins 3 in 20 mM sodium phosphate, pH 7, 1M urea. Parameters used to fit the variable
temperature CD data to equations S6–S9 are also shown, with standard errors as indicated.

Figure 2-190. CD spectra (lines, top left), variable temperature CD data (circles, top right) for 30 µM
solutions of proteins 4 in 20 mM sodium phosphate, pH 7. Parameters used to fit the variable temperature
CD data to equations S6–S9 are also shown, with standard errors as indicated.
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Figure 2-191. CD spectra (lines, top left), variable temperature CD data (circles, top right) for 30 µM
solutions of proteins 4 in 20 mM sodium phosphate, pH 7, 1M urea. Parameters used to fit the variable
temperature CD data to equations S6–S9 are also shown, with standard errors as indicated.

Figure 2-192. CD spectra (lines, top left), variable temperature CD data (circles, top right) for 30 µM
solutions of proteins 5 in 20 mM sodium phosphate, pH 7. Parameters used to fit the variable temperature
CD data to equations S6–S9 are also shown, with standard errors as indicated.
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Figure 2-193. CD spectra (lines, top left), variable temperature CD data (circles, top right) for 30 µM
solutions of proteins 5 in 20 mM sodium phosphate, pH 7, 1M urea. Parameters used to fit the variable
temperature CD data to equations S6–S9 are also shown, with standard errors as indicated.

Figure 2-194. CD spectra (lines, top left), variable temperature CD data (circles, top right) for 30 µM
solutions of proteins 5 in 20 mM sodium phosphate, pH 7, 0.25M NaCl. Parameters used to fit the
variable temperature CD data to equations S6–S9 are also shown, with standard errors as indicated.
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Figure 2-195. CD spectra (lines, top left), variable temperature CD data (circles, top right) for 30 µM
solutions of proteins 6 in 20 mM sodium phosphate, pH 7. Parameters used to fit the variable temperature
CD data to equations S6–S9 are also shown, with standard errors as indicated.

Figure 2-196. CD spectra (lines, top left), variable temperature CD data (circles, top right) for 30 µM
solutions of proteins 6 in 20 mM sodium phosphate, pH 7, 1M urea. Parameters used to fit the variable
temperature CD data to equations S6–S9 are also shown, with standard errors as indicated.
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Figure 2-197. CD spectra (lines, top left), variable temperature CD data (circles, top right) for 30 µM
solutions of proteins 6 in 20 mM sodium phosphate, pH 7, 0.25M NaCl. Parameters used to fit the
variable temperature CD data to equations S6–S9 are also shown, with standard errors as indicated.

Figure 2-198. CD spectra (lines, top left), variable temperature CD data (circles, top right) for 30 µM
solutions of proteins 7 in 20 mM sodium phosphate, pH 7. Parameters used to fit the variable temperature
CD data to equations S6–S9 are also shown, with standard errors as indicated.
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Figure 2-199. CD spectra (lines, top left), variable temperature CD data (circles, top right) for 30 µM
solutions of proteins 7 in 20 mM sodium phosphate, pH 7, 1M urea. Parameters used to fit the variable
temperature CD data to equations S6–S9 are also shown, with standard errors as indicated.

Figure 2-200. CD spectra (lines, top left), variable temperature CD data (circles, top right) for 30 µM
solutions of proteins 7 in 20 mM sodium phosphate, pH 7, 0.25M NaCl. Parameters used to fit the
variable temperature CD data to equations S6–S9 are also shown, with standard errors as indicated.
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Figure 2-201. CD spectra (lines, top left), variable temperature CD data (circles, top right) for 30 µM
solutions of protein 8 in 20 mM sodium phosphate, pH 7. Parameters used to fit the variable temperature
CD data to equations S6–S9 are also shown, with standard errors as indicated.

Figure 2-202. CD spectra (lines, top left), variable temperature CD data (circles, top right) for 30 µM
solutions of proteins 8 in 20 mM sodium phosphate, pH 7, 1M urea. Parameters used to fit the variable
temperature CD data to equations S6–S9 are also shown, with standard errors as indicated.
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Figure 2-203. CD spectra (lines, top left), variable temperature CD data (circles, top right) for 30 µM
solutions of proteins 8 in 20 mM sodium phosphate, pH 7, 0.25M NaCl. Parameters used to fit the
variable temperature CD data to equations S6–S9 are also shown, with standard errors as indicated.

Figure 2-204. CD spectra (lines, top left), variable temperature CD data (circles, top right) for 30 µM
solutions of proteins 9 in 20 mM sodium phosphate, pH 7, 1M Urea. Parameters used to fit the variable
temperature CD data to equations S6–S9 are also shown, with standard errors as indicated.
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Figure 2-205. CD spectra (lines, top left), variable temperature CD data (circles, top right) for 30 µM
solutions of proteins 9-DWA in 20 mM sodium phosphate, pH 7, 1M Urea. Parameters used to fit the
variable temperature CD data to equations S6–S9 are also shown, with standard errors as indicated.

Figure 2-206. CD spectra (lines, top left), variable temperature CD data (circles, top right) for 30 µM
solutions of proteins 9-DSK in 20 mM sodium phosphate, pH 7, 1M Urea. Parameters used to fit the
variable temperature CD data to equations S6–S9 are also shown, with standard errors as indicated.
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Figure 2-207. CD spectra (lines, top left), variable temperature CD data (circles, top right) for 30 µM
solutions of proteins 9-DSA in 20 mM sodium phosphate, pH 7, 1M Urea. Parameters used to fit the
variable temperature CD data to equations S6–S9 are also shown, with standard errors as indicated.

Figure 2-208. CD spectra (lines, top left), variable temperature CD data (circles, top right) for 30 µM
solutions of proteins 10 in 20 mM sodium phosphate, pH 7, 1M Urea. Parameters used to fit the variable
temperature CD data to equations S6–S9 are also shown, with standard errors as indicated.
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Figure 2-209. CD spectra (lines, top left), variable temperature CD data (circles, top right) for 30 µM
solutions of proteins 10-AWO in 20 mM sodium phosphate, pH 7, 1M Urea. Parameters used to fit the
variable temperature CD data to equations S6–S9 are also shown, with standard errors as indicated.

Figure 2-210. CD spectra (lines, top left), variable temperature CD data (circles, top right) for 30 µM
solutions of proteins 10-ESO in 20 mM sodium phosphate, pH 7, 1M Urea. Parameters used to fit the
variable temperature CD data to equations S6–S9 are also shown, with standard errors as indicated.
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Figure 2-211. CD spectra (lines, top left), variable temperature CD data (circles, top right) for 30 µM
solutions of proteins 10-ASO in 20 mM sodium phosphate, pH 7, 1M Urea. Parameters used to fit the
variable temperature CD data to equations S6–S9 are also shown, with standard errors as indicated.

Figure 2-212. CD spectra (lines, top left), variable temperature CD data (circles, top right) for 30 µM
solutions of proteins 11 in 20 mM sodium phosphate, pH 7. Parameters used to fit the variable
temperature CD data to equations S6–S9 are also shown, with standard errors as indicated.
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Figure 2-213. CD spectra (lines, top left), variable temperature CD data (circles, top right) for 30 µM
solutions of proteins 11-EWA in 20 mM sodium phosphate, pH 7. Parameters used to fit the variable
temperature CD data to equations S6–S9 are also shown, with standard errors as indicated.

Figure 2-214. CD spectra (lines, top left), variable temperature CD data (circles, top right) for 30 µM
solutions of proteins 11-ESK in 20 mM sodium phosphate, pH 7. Parameters used to fit the variable
temperature CD data to equations S6–S9 are also shown, with standard errors as indicated.
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Figure 2-215. CD spectra (lines, top left), variable temperature CD data (circles, top right) for 30 µM
solutions of proteins 11-ESA in 20 mM sodium phosphate, pH 7. Parameters used to fit the variable
temperature CD data to equations S6–S9 are also shown, with standard errors as indicated.

Figure 2-216. CD spectra (lines, top left), variable temperature CD data (circles, top right) for 30 µM
solutions of proteins 12 in 20 mM sodium phosphate, pH 7, 1M Urea. Parameters used to fit the variable
temperature CD data to equations S6–S9 are also shown, with standard errors as indicated.
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Figure 2-217. CD spectra (lines, top left), variable temperature CD data (circles, top right) for 30 µM
solutions of proteins 12-KWA in 20 mM sodium phosphate, pH 7, 1M Urea. Parameters used to fit the
variable temperature CD data to equations S6–S9 are also shown, with standard errors as indicated.

Figure 2-218. CD spectra (lines, top left), variable temperature CD data (circles, top right) for 30 µM
solutions of proteins 12-AWE in 20 mM sodium phosphate, pH 7. Parameters used to fit the variable
temperature CD data to equations S6–S9 are also shown, with standard errors as indicated.
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Figure 2-219. CD spectra (lines, top left), variable temperature CD data (circles, top right) for 30 µM
solutions of proteins 12-KSE in 20 mM sodium phosphate, pH 7. Parameters used to fit the variable
temperature CD data to equations S6–S9 are also shown, with standard errors as indicated.

Figure 2-220. CD spectra (lines, top left), variable temperature CD data (circles, top right) for 30 µM
solutions of proteins 12-KSA in 20 mM sodium phosphate, pH 7, 1M urea. Parameters used to fit the
variable temperature CD data to equations S6–S9 are also shown, with standard errors as indicated.
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Figure 2-221. CD spectra (lines, top left), variable temperature CD data (circles, top right) for 30 µM
solutions of proteins 12-ASE in 20 mM sodium phosphate, pH 7, 1M urea. Parameters used to fit the
variable temperature CD data to equations S6–S9 are also shown, with standard errors as indicated.

Figure 2-222. CD spectra (lines, top left), variable temperature CD data (circles, top right) for 30 µM
solutions of proteins 13 in 20 mM sodium phosphate, pH 7, 1M urea. Parameters used to fit the variable
temperature CD data to equations S6–S9 are also shown, with standard errors as indicated.
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Figure 2-223. CD spectra (lines, top left), variable temperature CD data (circles, top right) for 30 µM
solutions of proteins 13-AWmeK in 20 mM sodium phosphate, pH 7, 1M urea. Parameters used to fit the
variable temperature CD data to equations S6–S9 are also shown, with standard errors as indicated.

Figure 2-224. CD spectra (lines, top left), variable temperature CD data (circles, top right) for 30 µM
solutions of proteins 13-EWmeA in 20 mM sodium phosphate, pH 7, 1M urea. Parameters used to fit the
variable temperature CD data to equations S6–S9 are also shown, with standard errors as indicated.
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Figure 2-225. CD spectra (lines, top left), variable temperature CD data (circles, top right) for 30 µM
solutions of proteins 13-AWmeA in 20 mM sodium phosphate, pH 7, 1M urea. Parameters used to fit the
variable temperature CD data to equations S6–S9 are also shown, with standard errors as indicated.

Figure 2-226. CD spectra (lines, top left), variable temperature CD data (circles, top right) for 30 µM
solutions of proteins 14 in 20 mM sodium phosphate, pH 7. Parameters used to fit the variable
temperature CD data to equations S6–S9 are also shown, with standard errors as indicated.
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Figure 2-227. CD spectra (lines, top left), variable temperature CD data (circles, top right) for 30 µM
solutions of proteins 14-AYK in 20 mM sodium phosphate, pH 7. Parameters used to fit the variable
temperature CD data to equations S6–S9 are also shown, with standard errors as indicated.

Figure 2-228. CD spectra (lines, top left), variable temperature CD data (circles, top right) for 30 µM
solutions of proteins 14-EYA in 20 mM sodium phosphate, pH 7. Parameters used to fit the variable
temperature CD data to equations S6–S9 are also shown, with standard errors as indicated.
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Figure 2-229. CD spectra (lines, top left), variable temperature CD data (circles, top right) for 30 µM
solutions of proteins 14-AYA in 20 mM sodium phosphate, pH 7. Parameters used to fit the variable
temperature CD data to equations S6–S9 are also shown, with standard errors as indicated.

Figure 2-230. CD spectra (lines, top left), variable temperature CD data (circles, top right) for 30 µM
solutions of proteins 15 in 20 mM sodium phosphate, pH 7. Parameters used to fit the variable
temperature CD data to equations S6–S9 are also shown, with standard errors as indicated.
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Figure 2-231. CD spectra (lines, top left), variable temperature CD data (circles, top right) for 30 µM
solutions of proteins 15-AYmeK in 20 mM sodium phosphate, pH 7. Parameters used to fit the variable
temperature CD data to equations S6–S9 are also shown, with standard errors as indicated.

Figure 2-232. CD spectra (lines, top left), variable temperature CD data (circles, top right) for 30 µM
solutions of proteins 15-EYmeA in 20 mM sodium phosphate, pH 7. Parameters used to fit the variable
temperature CD data to equations S6–S9 are also shown, with standard errors as indicated.

143

Figure 2-233. CD spectra (lines, top left), variable temperature CD data (circles, top right) for 30 µM
solutions of proteins 15-AYmeA in 20 mM sodium phosphate, pH 7. Parameters used to fit the variable
temperature CD data to equations S6–S9 are also shown, with standard errors as indicated.

Figure 2-234. CD spectra (lines, top left), variable temperature CD data (circles, top right) for 30 µM
solutions of proteins 16 in 20 mM sodium phosphate, pH 7. Parameters used to fit the variable
temperature CD data to equations S6–S9 are also shown, with standard errors as indicated.
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Figure 2-235. CD spectra (lines, top left), variable temperature CD data (circles, top right) for 30 µM
solutions of proteins 16 in 20 mM sodium phosphate, pH 7, 0.25M NaCl. Parameters used to fit the
variable.

Figure 2-236. ESI TOF spectrum for peptide 3CD spectra (lines, top left), variable temperature CD data
(circles, top right) for 30 µM solutions of proteins 16-AFK in 20 mM sodium phosphate, pH 7.
Parameters used to fit the variable temperature CD data to equations S6–S9 are also shown, with standard
errors as indicated.
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Figure 2-237. CD spectra (lines, top left), variable temperature CD data (circles, top right) for 30 µM
solutions of proteins 16-AFK in 20 mM sodium phosphate, pH 7, 0.25M NaCl. Parameters used to fit the
variable temperature CD data to equations S6–S9 are also shown, with standard errors as indicated.

Figure 2-238. CD spectra (lines, top left), variable temperature CD data (circles, top right) for 30 µM
solutions of proteins 16-EFA in 20 mM sodium phosphate, pH 7. Parameters used to fit the variable
temperature CD data to equations S6–S9 are also shown, with standard errors as indicated.
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Figure 2-239. CD spectra (lines, top left), variable temperature CD data (circles, top right) for 30 µM
solutions of proteins 16-EFA in 20 mM sodium phosphate, pH 7, 0.25M NaCl. Parameters used to fit the
variable temperature CD data to equations S6–S9 are also shown, with standard errors as indicated.

Figure 2-240. CD spectra (lines, top left), variable temperature CD data (circles, top right) for 30 µM
solutions of proteins 16-AFA in 20 mM sodium phosphate, pH 7. Parameters used to fit the variable
temperature CD data to equations S6–S9 are also shown, with standard errors as indicated.
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Figure 2-241. CD spectra (lines, top left), variable temperature CD data (circles, top right) for 30 µM
solutions of proteins 16-AFA in 20 mM sodium phosphate, pH 7, 0.25M NaCl. Parameters used to fit the
variable temperature CD data to equations S6–S9 are also shown, with standard errors as indicated.

Figure 2-242. CD spectra (lines, top left), variable temperature CD data (circles, top right) for 30 µM
solutions of proteins 17 in 20 mM sodium phosphate, pH 7. Parameters used to fit the variable
temperature CD data to equations S6–S9 are also shown, with standard errors as indicated.
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Figure 2-243. CD spectra (lines, top left), variable temperature CD data (circles, top right) for 30 µM
solutions of proteins 17-A(Ff5F)K in 20 mM sodium phosphate, pH 7. Parameters used to fit the variable
temperature CD data to equations S6–S9 are also shown, with standard errors as indicated.

Figure 2-244. CD spectra (lines, top left), variable temperature CD data (circles, top right) for 30 µM
solutions of proteins 17-E(f5F)A in 20 mM sodium phosphate, pH 7. Parameters used to fit the variable
temperature CD data to equations S6–S9 are also shown, with standard errors as indicated.
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Figure 2-245. CD spectra (lines, top left), variable temperature CD data (circles, top right) for 30 µM
solutions of proteins 17-A(f5F)A in 20 mM sodium phosphate, pH 7. Parameters used to fit the variable
temperature CD data to equations S6–S9 are also shown, with standard errors as indicated.

Figure 2-246. CD spectrum (top right) and triplicate variable temperature CD data (top left) for a 30 µM
solution of protein 18-A(p-fF)A in 20 mM sodium phosphate (pH 7). Parameters used to fit the variable
temperature CD data to equations S6–S9 are also shown, with standard errors as indicated.

Figure 2-247. ESI TOF spectrum for peptide 3CD spectrum (top right) and triplicate variable temperature
CD data (top left) for a 30 µM solution of protein 18-A(p-fF)K in 20 mM sodium phosphate (pH 7).
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Parameters used to fit the variable temperature CD data to equations S6–S9 are also shown, with standard
errors as indicated.

Figure 2-248. CD spectrum (top right) and triplicate variable temperature CD data (top left) for a 30 µM
solution of protein 18-E(p-fF)A in 20 mM sodium phosphate (pH 7). Parameters used to fit the variable
temperature CD data to equations S6–S9 are also shown, with standard errors as indicated.

Figure 2-249. CD spectrum (top right) and triplicate variable temperature CD data (top left) for a 30 µM
solution of protein 18 in 20 mM sodium phosphate (pH 7). Parameters used to fit the variable temperature
CD data to equations S6–S9 are also shown, with standard errors as indicated.

Figure 2-250. CD spectrum (top right) and triplicate variable temperature CD data (top left) for a 30 µM
solution of protein 19-A(3,4-f2F)A in 20 mM sodium phosphate (pH 7). Parameters used to fit the
variable temperature CD data to equations S6–S9 are also shown, with standard errors as indicated.
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Figure 2-251. CD spectrum (top right) and triplicate variable temperature CD data (top left) for a 30 µM
solution of protein 19-A(3,4-f2F)K in 20 mM sodium phosphate (pH 7). Parameters used to fit the
variable temperature CD data to equations S6–S9 are also shown, with standard errors as indicated.

Figure 2-252. CD spectrum (top right) and triplicate variable temperature CD data (top left) for a 30 µM
solution of protein 19-E(3,4-f2F)A in 20 mM sodium phosphate (pH 7). Parameters used to fit the
variable temperature CD data to equations S6–S9 are also shown, with standard errors as indicated.

Figure 2-253. CD spectrum (top right) and triplicate variable temperature CD data (top left) for a 30 µM
solution of protein 19 in 20 mM sodium phosphate (pH 7). Parameters used to fit the variable temperature
CD data to equations S6–S9 are also shown, with standard errors as indicated.
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Figure 2-254. ESI TOF spectrum for peptide 3 CD spectrum (top right) and triplicate variable
temperature CD data (top left) for a 30 µM solution of protein 20-A(p-NO2F)A in 20 mM sodium
phosphate (pH 7). Parameters used to fit the variable temperature CD data to equations S6–S9 are also
shown, with standard errors as indicated.

Figure 2-255. CD spectrum (top right) and triplicate variable temperature CD data (top left) for a 30 µM
solution of protein 20-A(p-NO2F)K in 20 mM sodium phosphate (pH 7). Parameters used to fit the
variable temperature CD data to equations S6–S9 are also shown, with standard errors as indicated.

Figure 2-256. CD spectrum (top right) and triplicate variable temperature CD data (top left) for a 30 µM
solution of protein 20-E(p-NO2F)A in 20 mM sodium phosphate (pH 7). Parameters used to fit the
variable temperature CD data to equations S6–S9 are also shown, with standard errors as indicated.
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Figure 2-257. CD spectrum (top right) and triplicate variable temperature CD data (top left) for a 30 µM
solution of protein 20 in 20 mM sodium phosphate (pH 7). Parameters used to fit the variable temperature
CD data to equations S6–S9 are also shown, with standard errors as indicated.

Figure 2-258. CD spectrum (top right) and triplicate variable temperature CD data (top left) for a 30 µM
solution of protein 21-A(PyrA)A in 20 mM sodium phosphate (pH 7). Parameters used to fit the variable
temperature CD data to equations S6–S9 are also shown, with standard errors as indicated.

Figure 2-259. CD spectrum (top right) and triplicate variable temperature CD data (top left) for a 30 µM
solution of protein 21-A(PyrA)K in 20 mM sodium phosphate (pH 7). Parameters used to fit the variable
temperature CD data to equations S6–S9 are also shown, with standard errors as indicated.
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Figure 2-260. CD spectrum (top right) and triplicate variable temperature CD data (top left) for a 30 µM
solution of protein 21-E(PyrA)A in 20 mM sodium phosphate (pH 7). Parameters used to fit the variable
temperature CD data to equations S6–S9 are also shown, with standard errors as indicated.

Figure 2-261. CD spectrum (top right) and triplicate variable temperature CD data (top left) for a 30 µM
solution of protein 21in 20 mM sodium phosphate (pH 7). Parameters used to fit the variable temperature
CD data to equations S6–S9 are also shown, with standard errors as indicated.
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Figure 2-262. CD spectra (lines, top left), variable temperature CD data (circles, top right) for 30 µM
solutions of proteins 22 in 20 mM sodium phosphate, pH 7. Parameters used to fit the variable
temperature CD data to equations S6–S9 are also shown, with standard errors as indicated.

Figure 2-263. CD spectra (lines, top left), variable temperature CD data (circles, top right) for 30 µM
solutions of proteins 22-AFK in 20 mM sodium phosphate, pH 7. Parameters used to fit the variable
temperature CD data to equations S6–S9 are also shown, with standard errors as indicated.

Figure 2-264. CD spectra (lines, top left), variable temperature CD data (circles, top right) for 30 µM
solutions of proteins 22-EFA in 20 mM sodium phosphate, pH 7. Parameters used to fit the variable
temperature CD data to equations S6–S9 are also shown, with standard errors as indicated.
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Figure 2-265. CD spectra (lines, top left), variable temperature CD data (circles, top right) for 30 µM
solutions of proteins 22-AFA in 20 mM sodium phosphate, pH 7. Parameters used to fit the variable
temperature CD data to equations S6–S9 are also shown, with standard errors as indicated.

Figure 2-266. CD spectra (lines, top left), variable temperature CD data (circles, top right) for 30 µM
solutions of proteins 22-ESK in 20 mM sodium phosphate, pH 7. Parameters used to fit the variable
temperature CD data to equations S6–S9 are also shown, with standard errors as indicated.
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Figure 2-267. CD spectra (lines, top left), variable temperature CD data (circles, top right) for 30 µM
solutions of proteins 22-ASK in 20 mM sodium phosphate, pH 7. Parameters used to fit the variable
temperature CD data to equations S6–S9 are also shown, with standard errors as indicated.

Figure 2-268. CD spectra (lines, top left), variable temperature CD data (circles, top right) for 30 µM
solutions of proteins 22-ESA in 20 mM sodium phosphate, pH 7. Parameters used to fit the variable
temperature CD data to equations S6–S9 are also shown, with standard errors as indicated.
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Figure 2-269. CD spectra (lines, top left), variable temperature CD data (circles, top right) for 30 µM
solutions of proteins 22-ASA in 20 mM sodium phosphate, pH 7. Parameters used to fit the variable
temperature CD data to equations S6–S9 are also shown, with standard errors as indicated.

Figure 2-270. CD spectra (lines, top left), variable temperature CD data (circles, top right) for 30 µM
solutions of proteins 23 in 20 mM sodium phosphate, pH 7. Parameters used to fit the variable
temperature CD data to equations S6–S9 are also shown, with standard errors as indicated.
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Figure 2-271. CD spectra (lines, top left), variable temperature CD data (circles, top right) for 30 µM
solutions of proteins 23-EFA in 20 mM sodium phosphate, pH 7. Parameters used to fit the variable
temperature CD data to equations S6–S9 are also shown, with standard errors as indicated.

Figure 2-272. CD spectra (lines, top left), variable temperature CD data (circles, top right) for 30 µM
solutions of proteins 23-ESK in 20 mM sodium phosphate, pH 7. Parameters used to fit the variable
temperature CD data to equations S6–S9 are also shown, with standard errors as indicated.
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Figure 2-273. CD spectra (lines, top left), variable temperature CD data (circles, top right) for 30 µM
solutions of proteins 23-ESA in 20 mM sodium phosphate, pH 7. Parameters used to fit the variable
temperature CD data to equations S6–S9 are also shown, with standard errors as indicated.

Figure 2-274. CD spectra (lines, top left), variable temperature CD data (circles, top right) for 30 µM
solutions of proteins 24 in 20 mM sodium phosphate, pH 7. Parameters used to fit the variable
temperature CD data to equations S6–S9 are also shown, with standard errors as indicated.
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Figure 2-275. CD spectra (lines, top left), variable temperature CD data (circles, top right) for 30 µM
solutions of proteins 24-AFR in 20 mM sodium phosphate, pH 7. Parameters used to fit the variable
temperature CD data to equations S6–S9 are also shown, with standard errors as indicated.

Figure 2-276. CD spectra (lines, top left), variable temperature CD data (circles, top right) for 30 µM
solutions of proteins 24-ESR in 20 mM sodium phosphate, pH 7. Parameters used to fit the variable
temperature CD data to equations S6–S9 are also shown, with standard errors as indicated.
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Figure 2-277. CD spectra (lines, top left), variable temperature CD data (circles, top right) for 30 µM
solutions of proteins 24-ASR in 20 mM sodium phosphate, pH 7. Parameters used to fit the variable
temperature CD data to equations S6–S9 are also shown, with standard errors as indicated.

Figure 2-278. CD spectra (lines, top left), variable temperature CD data (circles, top right) for 30 µM
solutions of proteins 25 in 20 mM sodium phosphate, pH 7, 1M urea. Parameters used to fit the variable
temperature CD data to equations S6–S9 are also shown, with standard errors as indicated.
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Figure 2-279. CD spectra (lines, top left), variable temperature CD data (circles, top right) for 30 µM
solutions of proteins 25-AAK in 20 mM sodium phosphate, pH 7, 1M urea. Parameters used to fit the
variable temperature CD data to equations S6–S9 are also shown, with standard errors as indicated.

Figure 2-280. CD spectra (lines, top left), variable temperature CD data (circles, top right) for 30 µM
solutions of proteins 25-EAA in 20 mM sodium phosphate, pH 7, 1M urea. Parameters used to fit the
variable temperature CD data to equations S6–S9 are also shown, with standard errors as indicated.
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Figure 2-281. CD spectra (lines, top left), variable temperature CD data (circles, top right) for 30 µM
solutions of proteins 25-AAA in 20 mM sodium phosphate, pH 7, 1M urea. Parameters used to fit the
variable temperature CD data to equations S6–S9 are also shown, with standard errors as indicated.

Figure 2-282. CD spectra (lines, top left), variable temperature CD data (circles, top right) for 30 µM
solutions of proteins 26 in 20 mM sodium phosphate, pH 7. Parameters used to fit the variable
temperature CD data to equations S6–S9 are also shown, with standard errors as indicated.
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Figure 2-283. CD spectra (lines, top left), variable temperature CD data (circles, top right) for 30 µM
solutions of proteins 27 in 20 mM sodium phosphate, pH 7. Parameters used to fit the variable
temperature CD data to equations S6–S9 are also shown, with standard errors as indicated.

2.4.6

Single crystal X-ray Diffraction Data.

Freeze dried EWK was dissolved in milli Q water at concentration of 5mg/ml and screened
against Rigaku Wizard Cryo1 and 2 screens. EWK1 and EWK2 Crystals were briefly dipped in
cryoprotectant (25 % (v/v) glycerol in well solution), then cryo-cooled by plunging into liquid
nitrogen prior to data collection. Data were collected at 100 K with a copper rotating anode Xray source (Rigaku Micromax-007HF), with Varimax-HR confocal optics, and a Rigaku
Raxis4++ image plate detector. Each drop contained 2 µl well solution + 2 µl protein. Crystals
were cryo-cooled by plunging into liquid nitrogen prior to data collection. Data were collected at
100 K with a copper rotating anode X-ray source (Rigaku Micromax-007HF), with Varimax-HR
confocal optics, and a Rigaku Raxis4++ image plate detector.
Freeze dried peptides 14, 16, 18, 19, 20, and 21 were dissolved in milli Q water at a
concentration of 10 mg/ml and screened against the Rigaku Wizard Cryo 1 and 2 screens. Drops
were set with a TPP mosquito liquid handling robot with protein:condition ratios of 1:2, 1:1, and
2:1 at a total drop volume of 300nl. Crystals was harvested in ambient temperatures from sitting
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well plates with a nylon loop and immediately frozen in liquid N2. The crystal was mounted in a
stream of cold N2 and centered in the X-ray beam using a video camera. Low-temperature (100
K) X-ray diffraction data was collected using a MACH3 kappa goniometer coupled to a Bruker
Apex II CCD detector with a Bruker-Nonius FR591 rotating anode X-ray source producing Cu
Kα radiation (λ = 1.54178 Å). The Bruker Proteum-3 suite was used to process (integrate and
scale) the data
All Structures were determined by molecular replacement with Phaser (CCP4 program
suite) using the coordinates of the a coiled-coil trimer structure previously determined (1COI).19
The initial electron density map indicated two helices each being a helix in a coiled coil trimer;
side-chain density was clearly interpretable. Model building was carried out using COOT.39
Refinement was performed with Phenix.40 Crystal structure EWK1 was deposited in the protein
databank (PDB ID 5UXT).
Table 2-5 Conditions which produced diffractable crystals for each EXK coiled coil.
Peptide

EXK variant

Precipitant

EWK1

EWK

50% PEG 200

EWK2

EWK

19
14

pH

Salt

0.1 M Na/K Phosphate

6.2

200mM Sodium
Chloride

30% Jeffamine
ED-2001

0.1M HEPES

7.0

E(3,4-f2F)K

40% v/v PEG 300

100 mM Sodium cacodylate/
Hydrochloric acid

6.5

200 mM
Calcium acetate

EYK

30% v/v PEG 600

100 mM HEPES/ Sodium
hydroxide

7.5

50mM lithium
sulfate
200 mM
Calcium acetate

(10% glycerol)

Buffer

18

E(p-fPhe)K

40% v/v PEG 300

100 mM Sodium cacodylate/
Hydrochloric acid

6.5

16

EFK

40% v/v PEG 300

100 mM Sodium phosphate
dibasic/ Citric acid

4.2

21

E(PyrA)K

40% v/v PEG 300

100 mM Sodium phosphate
dibasic/ Citric acid

4.2
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20

E(p-NO2F)K

40% v/v PEG 300

100 mM Sodium phosphate
dibasic/ Citric acid

Table 2-6 Crystal Data and Refinement Statistics.
EWK1

EWK2

C2

R3

a, b, c

84.8, 38.5, 37.0

39.4, 39.4, 98.7

α,β,γ

90, 113.3, 90

90, 90, 120

Resolution

40-2.20

40-1.80

R merge (%)

7.3 (26.5)

2.8 (191.9)

I/σ(I)

4.0 (1.0)

5(0.5)

completeness

92 (62.7)

99.1(91.4)

Redundancy

3.9

7.3

Resolution

40-2.20

40-1.80

# of reflections

6128

5325

Rwork/Rfree

19.4/27.5

23.4/27.8

# of atoms

845

523

Ave B factor

44.6

55

Space group
Unit Cell

Data collection

Refinement

Rmsd
Bond lengths (Å) 0.007

0.007

Bond angles (°)

0.950

0.838

Table 2-7 Crystal Data and Refinement Statistics.
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4.2

E(3,4-f2F)K

EYK

E(p-fF)K

R3

R3

R3

a, b, c

39.28, 39.28, 98.71

38.04, 38.04, 104.28

39.07, 39.07, 98.62

α,β,γ

90, 90, 120

90, 90, 120

90, 90, 120

Resolution

32.91-2.10

33.28-1.80

32.88-2.15

R merge (%)

15.2 (38.7)

9.9(31.8)

16.3 (35.3)

I/σ(I)

17.1 (2.0)

12.7(1.4)

7.4 (1.4)

completeness

100 (98.9)

99.8(98.1)

99.7 (100)

Redundancy

4.6 (2.4)

4.7(3.0)

4.1 (2.5)

Resolution

32.91-2.10

33.28-1.80

32.88-2.15

# of reflections

3325

5361

3077

Rwork/Rfree

19.7/25.5

14.6/17.3

20.0/27.8

# of atoms

578

664

564

Ave B factor

28.8

18.8

26.7

Bond lengths (Å) 0.008

0.010

0.007

Bond angles (°)

1.11

0.98

Space group
Unit Cell

Data collection

Refinement

Rmsd
1.05
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Table 2-8 Crystal Data and Refinement Statistics.
EFK

E(PYRA)K

E(p-NO2F)K

R3

R3

R3

a, b, c

38.89, 38.89, 103.47

38.38, 38.38, 119.43

39.05, 39.05, 101.16

α,β,γ

90, 90, 120

90, 90, 120

90, 90, 120

Resolution

34.49-2.15

39.82-2.2

33.73-2.1

R merge (%)

19.3 (40.6)

17.7 (53.9)

22.0 (62.6)

I/σ(I)

9.4 (2.1)

7.5 (1.7)

10.7 (1.3)

completeness

99.7 (100)

100 (100)

100 (100)

Redundancy

7.7 (4.4)

4.9 (3.3)

10.9 (6.2)

Resolution

34.49-2.15

39.82-2.2

33.73-2.1

# of reflections

3180

3343

3366

Rwork/Rfree

17.6/24.4

18.7/26.8

20.9/27.5

# of atoms

604

595

586

Ave B factor

20.5

25.18

27.52

Bond lengths (Å) 0.008

0.008

0.007

Bond angles (°)

0.99

1.00

Space group
Unit Cell

Data collection

Refinement

Rmsd

2.4.7

0.96

Justification for using Ser at position 14 instead of Ala as a control for evaluating
Trp-based enhancement of the Glu10-Lys18 Interaction.
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In the main text, we demonstrated that placing Trp at position 14 enhances the strength of
a long-range i to i+8 Glu10-Lys18 salt bridge better than does Ser. We chose Ser as a negative
control because of its polar character and small size, and because it occupies this position in the
sequence of the original 1CW coiled coil from which our variants were derived. However, we
wondered whether the use of Ser as a negative control instead of the more conventional Ala
might have artificially inflated the observed impact of Trp on the Glu10-Lys18 interaction. To
explore this possibility, we prepared peptides 25, 25-AAK, 25-EAA, and 25-AAA, derivatives
of peptides 5-8 in which Ala occupies position 14 instead of Ser. Variable temperature CD
experiments revealed that peptides 25, 25-AAK, 25-EAA, and 25-AAA are too stable in 20 mM
sodium phosphate buffer (pH 7) to reliably identify a fully unfolded baseline, and therefore we
were unable to extract folding free energy values for these peptides under these conditions.
However, we were able to fit variable temperature CD data for peptides 25, 25-AAK, 25-EAA,
and 25-AAA in 20 mM sodium phosphate (pH 7) + 1 M urea; we have folding free energy data
for peptides 1-8 under identical conditions. We observed that impact of Trp relative to Ala on the
Glu10-Lys18 interaction is substantially larger than the impact of Trp relative to Ser
(Supplementary Table 13). These results indicate that using Ser as a negative control leads to a
smaller, more conservative estimate for Trp-based enhancement of the Glu10-Lys18 interaction
than when Ala is used as negative control, suggesting that our concerns were unfounded.

Table2- 9. Sequences and folding free energies of GCN4-p1 variants 20, 21, 22 and their derivatives.a
Peptide

Sequence

1
2

Ac–EVEALEKKVEALEWKVQKLEKKVEALEHGWDGR–CONH2
Ac–EVEALEKKVAALEWKVQKLEKKVEALEHGWDGR–CONH2
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ΔGf (kcal/mol)
in 1M Urea
-16.23 ± 0.05
-15.73 ± 0.04

3
4
5
6
7
8
25
25-AAK
25-EAA
25-AAA
aData

Ac–EVEALEKKVEALEWKVQALEKKVEALEHGWDGR–CONH2
Ac–EVEALEKKVAALEWKVQALEKKVEALEHGWDGR–CONH2
Ac–EVEALEKKVEALESKVQKLEKKVEALEHGWDGR–CONH2
Ac–EVEALEKKVAALESKVQKLEKKVEALEHGWDGR–CONH2
Ac–EVEALEKKVEALESKVQALEKKVEALEHGWDGR–CONH2
Ac–EVEALEKKVAALESKVQALEKKVEALEHGWDGR–CONH2
Ac–EVEALEKKVEALEAKVQKLEKKVEALEHGWDGR–CONH2
Ac–EVEALEKKVAALEAKVQKLEKKVEALEHGWDGR–CONH2
Ac–EVEALEKKVEALEAKVQALEKKVEALEHGWDGR–CONH2
Ac–EVEALEKKVAALEAKVQALEKKVEALEHGWDGR–CONH2

-14.04 ± 0.03
-15.78 ± 0.05
-13.42 ± 0.02
-14.74 ± 0.02
-14.18 ± 0.02
-15.30 ± 0.04
-14.78 ± 0.02
-16.66 ± 0.07
-16.31 ± 0.06
-17.32 ± 0.09

are given ± standard error at 30 µM protein concentration in 20 mM sodium phosphate buffer (pH 7) + 1 M urea at 343.15

K.

Table 2-10. Impact of Trp14 relative to Ser14 or Ala14 on the long-range interaction between Glu10 and
Lys18 in the homotrimeric 1CW coiled coil.a
Impact of Trp vs. Ser on the Glu10-Lys18 Interaction
Impact of Trp vs. Ala on the Glu10-Lys18 Interaction

a

ΔΔΔΔGf (kcal/mol)
-2.45 ± 0.10
-3.12 ± 0.15

Data are given ± standard error at 30 µM protein concentration in 20 mM sodium phosphate
buffer (pH 7) + 1M urea at 343.15 K. Triple mutant cycle analysis performed for peptides 1–4 in
comparison to Ser-containing peptides 5–8, vs. Ala-containing peptides 25-AAK, 25-EAA, 25AAA.
2.4.8

Impact of Salt on Phe based enhancement of Glu10:Lys18 salt bridge

We wondered whether the ability of Phe to enhance the long-range Glu10-Lys18 interaction
depends on the concentration of salt in the buffer. To explore this possibility, we performed
triplicate variable temperature CD experiments on peptides 5–8, 16, 16-AFK, 16-EFA, and 16AFA in 20 mM sodium phosphate (pH 7) and 0.25 M NaCl. The results of this analysis are shown
in Supplementary Tables 14 and 15. The impact of Phe on the Glu10-Lys18 interaction gets
stronger in the presence of 0.25 M NaCl, indicating that it is resistant to screening by salt.
Table 2-11. Sequences, expected and observed exact masses, and folding free energies peptides 5–8, 16,
16-AFK, 16-EFA, and 16-AFA.a
Peptide

5
6
7
8
16
16-AFK
16-EFA

Sequence

Ac–EVEALEKKVEALESKVQKLEKKVEALEHGWDGR–CONH2
Ac–EVEALEKKVAALESKVQKLEKKVEALEHGWDGR–CONH2
Ac–EVEALEKKVEALESKVQALEKKVEALEHGWDGR–CONH2
Ac–EVEALEKKVAALESKVQALEKKVEALEHGWDGR–CONH2
Ac–EVEALEKKVEALEFKVQKLEKKVEALEHGWDGR–CONH2
Ac–EVEALEKKVAALEFKVQKLEKKVEALEHGWDGR–CONH2
Ac–EVEALEKKVEALEFKVQALEKKVEALEHGWDGR–CONH2
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ΔGf (kcal/mol)
-14.60 ± 0.02
-16.12 ± 0.03
-15.77 ± 0.03
-17.08 ± 0.05
-15.37 ± 0.04
-15.91 ± 0.05
-15.55 ± 0.06

16-AFA
aData

Ac–EVEALEKKVAALEFKVQALEKKVEALEHGWDGR–CONH2

-17.87 ± 0.05

are given ± standard error at 30 µM protein concentration in 20 mM sodium phosphate buffer (pH 7) + 0.25 M NaCl at

343.15 K.

Table 2-12. Impact of Phe14 on the long-range interaction between Glu10 and Lys18 in the
homotrimeric 1CW coiled coil in 20 mM sodium phosphate (pH 7), with or without 0.25 M NaCl.a
Phe-based stabilization in 20 mM sodium phosphate (pH 7)
Phe-based stabilization in 20 mM sodium phosphate (pH 7) + 0.25 M NaCl

ΔΔΔΔGf (kcal/mol)
-1.25 ± 0.09
-2.00 ± 0.12

Data are given ± standard error at 30 µM protein concentration in 20 mM sodium phosphate buffer (pH 7)
+ 0.25 M NaCl at 343.15 K.
a

2.4.9

NMR Tocsy and Roesy data
As described in the main text, peptide pA-EWK (Table S1) is derived from a previously

reported

parent

α-helical

model

peptide

pA41

(sequence

Ac-

OOAAAAAAAAAAAAAAAAAAAOOY-NH2), which contains a 19-residue polyalanine
segment (for high helix propensity), flanked by two ornithine residues on either end (to increase
solubility in aqueous solution), and a C-terminal tyrosine (a spectrosocpic handle for accurate
concentration determination). In pA-EWK, Glu occupies position 8, Trp occupies position 12,
and Lys occupies position 16. Peptides pA-AWK and pA-EWA are derivatives of pA-EWK in
which Ala replaces Glu8 or Lys16, respectively (Table S1).
NMR samples for pA-EWA, pA-AWK, and pA-EWK were prepared at 5 mM peptide
concentration in 20 mM sodium phosphate (pH 7) with 10% D2O. Samples were transferred to a
Varian 500 MHz magnet and data was collect using vnmrJ software. Water suppression was
achieved using an excitation sculpting sequence. 2D TOCSY experiments were collected with 8
scans, 400 t1 increments, and 80 ms mixing time. 2D adiabatic ROESY experiments were collected
with 64 scans, 256 t1 increments, and 200 ms mixing time. Data was processed using vnmrJ
followed by ccpNMR software. Examples of the 2D spectra for pA-EWA, pA-AWK, and pAEWK are shown in figures S77-S79, summaries of assignments and correlations are shown in
tables S3-S8. CD data for pA-EWA, pA-AWK, and pA-EWK (Figure S80) confirm their similar
weakly helical secondary structure.
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Figure 2-284. NMR Data for pA-EWA. 2D TOCSY data (left), 2D ROESY data (right).

Figure 2-285. NMR Data for pA-AWK. 2D TOCSY data (left), 2D ROESY data (right).
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Figure 2-286. NMR Data for pA-EWK. 2D TOCSY data (left), 2D ROESY data (right).
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Figure 2-287. CD spectra for pA-EWK, pA-AWK, pA-EWA at 100 µM concentration in 20 mM
sodium phosphate pH 7, 25 °C.

A summary of the observed NOEs for pA-AWK, pA-EWA, and pA-EWK appears in
Figure S81. As with pA-EWK, the ROESY spectrum for pA-AWK shows many NOEs between
Trp12 and Lys16 backbone and side-chain protons. However, several important differences
between the ROESY spectra of pA-EWK vs. pA-AWK highlight the impact of Glu8 vs. Ala8 on
Trp-Lys contacts (Figure S81). For example, NOE peaks corresponding to Trp12Hζ3/Lys16Hα,
Trp12Hζ3/Lys16Hδ, and Trp12Hη2/Lys16Hδ are present in the spectrum of pA-AWK but not in
that

of pA-EWK.

In

contrast,

NOE

peaks

corresponding to

Trp12Hε1/Lys16Hγ,

Trp12Hε1/Lys16Hδ, and Trp12Hε1/Lys16Hε are present in the spectrum of pA-EWK but not in
that of pA-AWK. Moreover, normalized peak volumes for the Trp12Hε3/Lys16Hδ,
Trp12Hα/Lys16NH, and Trp12 Hδ1/Lys16Hδ NOEs are larger for pA-EWK than for pA-AWK,
whereas normalized peak volumes for the Trp12Hδ1/Lys16Hε and Trp12Hζ2/Lys16Hε NOEs are
smaller for pA-EWK than for pA-AWK. These changes suggest that replacing Ala8 with Glu8
allows Lys16Hδ to move closer to Hδ1, Hε1, and Hε3 on the right-hand side of the Trp12 indole
ring (as drawn in Figures 2), whereas Lys16NH moves closer to Trp12Hα, possibly due to
localized overwinding of the α-helical backbone between Trp12 and Lys16 to allow for optimized
interaction geometry between Glu8, Trp12, and Lys16.
Similarly, differences between the ROESY spectra of pA-EWK vs. pA-EWA highlight
impact of Lys16 vs. Ala16 on Glu8-Trp12 contacts. The Trp12Hδ1/Glu8Hα NOE is present in
the spectrum of pA-EWA, but not that of pA-EWK. Moreover, normalized peak volumes for
the Trp12Hδ1/Glu8Hβ, Trp12Hδ1/Glu8Hγ, Trp12Hε1/Glu8Hβ, and Trp12Hε1/Glu8Hγ NOEs
are smaller in pA-EWK than in pA-AWK. These observations indicate that the Glu8 side-chain
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protons are close to Hδ1 and Hε1 of Trp12 (as is also the case for Hδ and Hε of Lys16, see
above), but that replacing Ala16 with Lys16 increases the distance between the Glu8 side chain
and the right side of the Trp12 indole ring (as drawn in Figure S81), possibly to compensate for
the localized overwinding of the α-helical backbone between Trp12 and Lys16.

Figure 2-288. Observed NOEs for monomeric α-helical peptides pA-EWK, pA-AWK, and pA-EWA in
20 mM sodium phosphate buffer (pH 7). Lines tipped with asterisks indicate NOEs that are only present
in the indicated peptide. Dotted lines indicate NOEs that are weaker in pA-EWK than in pA-EWA or
pA-AWK. Bold lines indicate NOEs that are stronger in pA-EWK than in pA-EWA or pA-AWK (see
Tables S6-S8).
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Table 2-13. TOCSY correlations for pA-AWK.a
δ (ppm) F1

Assignment F1

δ (ppm) F2

Assignment F2

δ (ppm) F1

Assignment F1

δ (ppm) F2

Assignment F2

8.2
8.21

12Trp NH
12Trp NH

4.56
3.42

12Trp Hα
12Trp Hβ*

1.67
1.68

16Lys Hβb
16Lys Hβb

3.98
2.74

16Lys Hα
16Lys Hεa

4.55

12Trp Hα

4.55

12Trp Hα

1.68

16Lys Hβb

2.82

16Lys Hεb

3.42

12Trp Hβ*

4.55

12Trp Hα

1.68

16Lys Hβb

1.21

16Lys Hγ*

7.31

12Trp Hδ1

4.55

12Trp Hα

1.49

16Lys Hδ*

2.74

16Lys Hεa

7.31

12Trp Hδ1

3.42

12TrpHβ*

1.49

16Lys Hδ*

2.82

16Lys Hεb

7.31

12Trp Hδ1

7.31

12Trp Hγ1

1.48

16Lys Hδ*

1.21

16Lys Hγ*

7.31

12Trp Hδ1

10.2

12Trp Hε1

1.48

16Lys Hδa

3.98

16Lys Hα

10.2

12Trp Hε1

7.31

12Trp Hδ1

2.75

16Lys Hεa

3.98

16Lys Hα

10.2

12Trp Hε1

10.2

12Trp Hε1

2.74

16Lys Hεa

3.98

16Lys Hα

7.66

12Trp Hε3

7.65

12Trp Hε3

2.75

16Lys Hεa

1.6

16Lys Hβa

7.66

12Trp Hε3

7.24

12Trp Hη2

2.75

16Lys Hεa

1.68

16Lys Hβb

7.64

12Trp Hε3

7.24

12Trp Hη2

2.75

16Lys Hεa

1.49

16Lys Hδ*

7.66

12Trp Hε3

7.5

12Trp Hζ2

2.75

16Lys Hεa

2.75

16Lys Hεa

7.64

12Trp Hε3

7.5

12Trp Hζ2

2.75

16Lys Hεa

2.83

16Lys Hεb

7.66

12Trp Hε3

7.16

12Trp Hζ3

2.74

16Lys Hεa

2.83

16Lys Hεb

7.65

12Trp Hε3

7.16

12Trp Hζ3

2.75

16Lys Hεa

1.21

16Lys Hγ*

7.24

12Trp Hη2

7.65

12Trp Hε3

2.82

16Lys Hεb

3.98

16Lys Hα

7.24

12Trp Hη2

7.24

12Trp Hη2

2.81

16Lys Hεb

1.59

16Lys Hβa

7.24

12Trp Hη2

7.5

12Trp Hζ2

2.82

16Lys Hεb

1.68

16Lys Hβb

7.24

12Trp Hη2

7.16

12Trp Hζ3

2.82

16Lys Hεb

1.49

16Lys Hδ*

7.51

12Trp Hζ2

7.65

12Trp Hε3

2.82

16Lys Hεb

2.74

16Lys Hεa

7.5

12Trp Hζ2

7.65

12Trp Hε3

2.82

16Lys Hεb

2.82

16Lys Hεb

7.49

12Trp Hζ2

7.24

12Trp Hη2

2.82

16Lys Hεb

1.22

16Lys Hγ*

7.49

12Trp Hζ2

7.5

12Trp Hζ2

1.22

16Lys Hγ*

3.98

16Lys Hα

7.51

12Trp Hζ2

7.16

12Trp Hζ3

1.22

16Lys Hγ*

1.59

16Lys Hβa

7.49

12Trp Hζ2

7.16

12Trp Hζ3

1.21

16Lys Hγ*

1.68

16Lys Hβb

7.16

12Trp Hζ3

7.65

12Trp Hε3

1.22

16Lys Hγ*

2.74

16Lys Hεa

7.16

12Trp Hζ3

7.24

12Trp Hη2

1.21

16Lys Hγ*

2.82

16Lys Hεb

7.16

12Trp Hζ3

7.5

12Trp Hζ2

1.2

16LysHγ*

1.2

16Lys Hγ*

8.03

16Lys NH

3.98

16Lys Hα

2.91

24Tyr Hβa

4.55

24Tyr Hα

8.03

16Lys NH

1.59

16Lys Hβa

2.95

24Tyr Hβa

4.55

24Tyr Hα

8.03

16Lys NH

1.68

16Lys Hβb

2.93

24Tyr Hβa

4.55

24Tyr Hα

8.03

16Lys NH

1.22

16Lys Hγ*

3.13

24Tyr Hβb

4.54

24Tyr Hα

3.98

16Lys Hα

3.98

16Lys Hα

3.09

24Tyr Hβb

4.55

24Tyr Hα

3.98

16Lys Hα

1.59

16Lys Hβa

7.16

24Tyr Hδ*

7.16

24Tyr Hδ*

3.98

16Lys Hα

1.68

16Lys Hβb

7.17

24Tyr Hδ*

6.85

24Tyr Hε*

3.98

16Lys Hα

1.49

16Lys Hδ*

7.16

24Tyr Hδ*

6.84

24Tyr Hε*

3.98

16Lys Hα

2.74

16Lys Hεa

6.85

24Tyr Hε*

7.17

24Tyr Hδ*

3.98

16Lys Hα

2.82

16Lys Hεb

6.84

24Tyr Hε*

7.17

24Tyr Hδ*

3.98

16Lys Hα

1.2

16Lys Hγ*

6.85

24Tyr Hε*

6.85

24Tyr Hε*

1.6

16Lys Hβa

3.98

16Lys Hα

6.84

24Tyr Hε*

6.84

24Tyr Hε*

1.6

16Lys Hβa

2.74

16Lys Hεa

1.6

16Lys Hβa

2.82

16Lys Hεb

1.6

16Lys Hβa

1.21

16Lys Hγ*

NOE assignments made based on 2D H NMR TOCSY and ROESY experiments on a 5 mM solution of pA-AWK in 20
mM sodium phosphate buffer (pH 7) at room temperature using a 500 MHz Varian INOVA spectrometer.
a

1
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Table 2-14. TOCSY correlations for pA-EWA.a
δ (ppm) F1

Assignment F1

δ (ppm) F2

Assignment F2

δ (ppm) F1

Assignment F1

δ (ppm) F2

Assignment F2

8.18
8.18

8Glu NH
8Glu NH

8.18
4.11

8Glu NH
8Glu Hα

7.16
6.85

24Tyr Hδ*
24Tyr Hε*

6.84
7.17

24Tyr Hε*
24Tyr Hδ*

8.18

8Glu NH

2.17

8Glu Hβa

6.84

24Tyr Hε*

7.17

24Tyr Hδ*

8.18

8Glu NH

2.26

8Glu Hβb

6.85

24Tyr Hε*

6.84

24Tyr Hε*

8.18

8Glu NH

1.98

8Glu Hγ*

4.11

8Glu Hα

8.18

8Glu NH

2.17

8Glu Hβa

8.18

8Glu NH

2.26

8Glu Hβb

8.18

8Glu NH

1.99

8Glu Hγb

8.18

8Glu NH

8.22

12Trp NH

4.51

12Trp Hα

8.22

12Trp NH

3.41

12Trp Hβ*

4.5

12Trp Hα

3.41

12Trp Hβa

7.28

12Trp Hδ1

3.41

12Trp Hβa

7.28

12Trp Hδ1

7.28

12Trp Hδ1

7.28

12Trp Hδ1

10.18

12Trp Hε1

10.18

12Trp Hε1

7.28

12Trp Hδ1

10.18

12Trp Hε1

12Trp Hε1

10.18

7.62

12Trp Hε3

7.61

12Trp Hε3

7.62

12Trp Hε3

7.21

12Trp Hη2

7.62

12Trp Hε3

7.48

12Trp Hζ2

7.62

12Trp Hε3

7.14

12Trp Hζ3

7.21

12Trp Hη2

7.61

12Trp Hε3

7.21

12Trp Hη2

7.21

12Trp Hη2

7.21

12Trp Hη2

7.48

12Trp Hζ2

7.21

12Trp Hη2

7.14

12Trp Hζ3

7.48

12Trp Hζ2

7.61

12Trp Hε3

7.47

12Trp Hζ2

7.61

12Trp Hε3

7.47

12Trp Hζ2

7.21

12Trp Hη2

7.49

12Trp Hζ2

7.49

12Trp Hζ2

7.49

12Trp Hζ2

7.14

12Trp Hζ3

7.14

12Trp Hζ3

7.61

12Trp Hε3

7.15

12Trp Hζ3

7.21

12Trp Hη2

7.14

12Trp Hζ3

7.48

12Trp Hη2

7.14

12Trp Hζ3

7.14

12Trp Hζ3

8.1

16Ala NH

4.11

16Ala Hα

8.1

16Ala NH

1.31

16Ala Hβ*

8.08

23Orn NH

1.63

23Orn Hβa

8.08

23Orn NH

1.74

23Orn Hβb

8.08

23Orn NH

2.96

23Orn Hδ*

8.08

23Orn NH

1.55

23Orn Hγa

8.08

23Orn NH

1.58

23Orn Hγb

8.16

24Tyr NH

4.55

24Tyr Hα

8.16

24Tyr NH

2.94

24Tyr Hβa
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8.16

24Tyr NH

3.11

7.16

24Tyr Hδ*

7.17

24Tyr Hβb
24Tyr Hδ*

NOE assignments made based on 2D H NMR TOCSY and ROESY experiments on a 5 mM solution of pA-EWA in 20
mM sodium phosphate buffer (pH 7) at room temperature using a 500 MHz Varian INOVA spectrometer.
a

1

Table 2-15. TOCSY correlations for pA-EWK.a
δ (ppm) F1
8.21
8.21

Assignment F1

δ (ppm) F2
4.13
2.19

Assignment F2

8Glu NH
8Glu NH

Assignment F1

8Glu Hα
8Glu Hβa

δ (ppm) F1
4.02
4.01

Assignment F2

16Lys Hα
16Lys Hα

δ (ppm) F2
4.02
1.66

8.21

8Glu NH

8.21

8Glu NH

2.28

8Glu Hβb

2.01

8Glu Hγ*

4.01

16Lys Hα

1.72

16Lys Hβb

4.02

16Lys Hα

1.49

4.12

8Glu Hα

2.19

16Lys Hδ*

8Glu Hβa

4.01

16LysHα

2.78

4.12

8Glu Hα

16Lys Hεa

2.28

8Glu Hβb

4.01

16Lys Hα

2.85

16Lys Hεb

4.12

8Glu Hα

2.01

8Glu Hγ*

4.01

16Lys Hα

1.25

16Lys Hγa

8.21

12Trp NH

3.41

12Trp Hβ*

4.01

16Lys Hα

1.29

16Lys Hγb

4.57

12Trp Hα

4.57

12Trp Hα

1.67

16Lys Hβa

2.78

16Lys Hεa

4.56

12Trp Hα

3.41

12Trp Hβ*

1.67

16Lys Hβa

2.85

16Lys Hεb

3.41

12Trp Hβ*

3.41

12Trp Hβ*

1.67

16Lys Hβa

1.25

16Lys Hγa

7.29

12Trp Hδ1

4.57

12Trp Hα

1.67

16Lys Hβa

1.3

16Lys Hγb

16Lys Hα
16Lys Hβa

7.3

12Trp Hδ1

3.41

12Trp Hβ*

1.73

16Lys Hβb

2.78

16Lys Hεa

7.29

12Trp Hδ1

7.29

12Trp Hδ1

1.72

16Lys Hβb

2.85

16Lys Hεb

7.3

12Trp Hδ1

10.19

12Trp Hε1

1.72

16Lys Hβb

1.24

16Lys Hγa

10.19

12Trp Hε1

3.41

12Trp Hβ*

1.72

16Lys Hβb

1.3

16Lys Hγb

10.19

12Trp Hε1

7.3

12Trp Hδ1

1.53

16Lys Hδ*

2.78

16Lys Hεa

10.19

12Trp Hε1

10.19

12Trp Hε1

1.53

16Lys Hδ*

2.85

16Lys Hεb

10.19

12Trp Hε1

7.64

12Trp Hε3

1.53

16Lys Hδ*

1.25

16Lys Hγa

7.64

12Trp Hε3

7.64

12Trp Hε3

1.53

16Lys Hδ*

1.3

16Lys Hγb

7.64

12Trp Hε3

7.23

12Trp Hη2

2.78

16Lys Hεa

1.53

16Lys Hδ*

7.63

12Trp Hε3

7.23

12Trp Hη2

2.79

16Lys Hεa

2.79

16Lys Hεa

7.64

12Trp Hε3

7.49

12Trp Hζ2

2.78

16Lys Hεa

2.85

16Lys Hεb

7.64

12Trp Hε3

7.15

12Trp Hζ3

2.78

16Lys Hεa

1.25

16Lys Hγa

7.63

12Trp Hε3

7.15

12Trp Hζ3

2.78

16Lys Hεa

1.3

16Lys Hγb

7.23

12Trp Hη2

7.64

12Trp Hε3

2.84

16Lys Hεb

1.53

16Lys Hδ*

7.23

12Trp Hη2

7.23

12Trp Hη2

2.84

16Lys Hεb

2.78

16Lys Hεa

7.23

12Trp Hη2

7.49

12Trp Hζ2

2.84

16Lys Hεb

2.84

16Lys Hεb

7.23

12Trp Hη2

7.15

12Trp Hζ3

2.84

16Lys Hεb

1.25

16Lys Hγa

7.48

12Trp Hζ2

7.64

12Trp Hε3

2.84

16Lys Hεb

1.3

16Lys Hγb

7.5

16Lys Hεa

12Trp Hζ2

7.64

12Trp Hε3

1.25

16Lys Hγa

2.78

7.48

12Trp Hζ2

7.23

12Trp Hη2

1.3

16Lys Hγb

2.78

16Lys Hεa

7.49

12Trp Hζ2

7.49

12Trp Hζ2

1.3

16Lys Hγb

2.85

16Lys Hεb

7.48

12Trp Hζ2

7.16

12Trp Hζ3

8.2

24Tyr NH

2.94

24Tyr Hβa

7.15

12Trp Hζ3

7.64

12Trp Hε3

8.2

24Tyr NH

3.1

24Tyr Hβb

7.15

12Trp Hζ3

7.23

12Trp Hη2

4.55

24Tyr Hα

4.55

24Tyr Hα

7.15

12Trp Hζ3

7.49

12Trp Hζ2

4.55

24Tyr Hα

2.94

24Tyr Hβa

8.04

16Lys NH

4.01

16Lys Hα

4.55

24Tyr Hα

3.11

24Tyr Hβb

8.04

16Lys NH

1.66

16Lys Hβa

7.16

24Tyr Hδ*

7.16

24Tyr Hδ*

8.04

16Lys NH

1.73

16Lys Hβb

7.17

24Tyr Hδ*

6.85

24Tyr Hε*
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8.03

16Lys NH

2.78

16Lys Hεa

7.16

24Tyr Hδ*

6.84

24Tyr Hε*

8.03

16Lys NH

2.85

16Lys Hεb

6.85

24Tyr Hε*

7.17

24Tyr Hδ*

8.04

16Lys NH

1.25

16Lys Hγa

6.84

24Tyr Hε*

7.17

24Tyr Hδ*

8.04

16Lys NH

1.3

16Lys Hγb

6.85

24Tyr Hε*

6.85

24Tyr Hε*

4.01

16Lys Hα

8.04

16Lys H

6.84

24Tyr Hε*

6.84

24Tyr Hε*

a
NOE assignments made based on 2D 1H NMR TOCSY and ROESY experiments on a 5 mM solution of pA-EWK in 20
mM sodium phosphate buffer (pH 7) at room temperature using a 500 MHz Varian INOVA spectrometer.
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Table 2-16. NOE assignments for pA-AWK.a
δ (ppm) F1
8.202

Assignment F1
12Trp NH

δ (ppm) F2
4.558

Assignment F2
12Trp Hα

Integrated Peak Volume
45082

8.199

12Trp NH

3.42

12Trp Hβ*

98442

8.197

12Trp NH

1.496

16Lys Hδa

68964

4.567

12Trp Hα

3.418

12Trp Hβ*

48292

3.419

12Trp Hβ*

7.65

12Trp Hε3

63723

7.309

12Trp Hδ1

3.987

16Lys Hα

27897

7.311

12Trp Hδ1

1.229

16Lys Hγ*

20237

7.308

12Trp Hδ1

1.488

16Lys Hδa

57456

7.311

12Trp Hδ1

2.746

16Lys Hεa

14343

10.199

12Trp Hε1

7.503

12Trp Hζ2

28154

7.643

12Trp Hε3

4.557

12Trp Hα

66906

7.643

12Trp Hε3

3.42

12Trp Hβ*

95049

7.659

12Trp Hε3

3.987

16Lys Hα

38341

7.643

12Trp Hε3

3.988

16Lys Hα

40545

7.659

12Trp Hε3

1.488

16Lys Hδa

32298

7.645

12Trp Hε3

1.485

16Lys Hδa

43349

7.242

12Trp Hη2

1.497

16Lys Hδa

16534

7.498

12Trp Hζ2

1.496

16Lys Hδa

25264

7.514

12Trp Hζ2

2.744

16Lys Hεa

13413

7.5

12Trp Hζ2

2.741

16Lys Hεa

10851

7.513

12Trp Hζ2

2.821

16Lys Hεb

7922

7.499

12Trp Hζ2

2.821

16Lys Hεb

8683

7.174

12Trp Hζ3

4.548

12Trp Hα

25074

7.162

12Trp Hζ3

4.548

12Trp Hα

119207

7.163

12Trp Hζ3

3.979

16Lys Hα

139294

8.029

16Lys NH

4.568

12Trp Hα

12374

8.028

16Lys NH

3.986

16Lys Hα

59601

3.986

16Lys Hα

7.651

12Trp Hε3

38664

2.955

24Tyr Hβa

7.168

24Tyr Hδ*

81553

2.935

24Tyr Hβa

7.169

24Tyr Hδ*

85563

2.911

24Tyr Hβa

7.167

24Tyr Hδ*

44295

3.097

24Tyr Hβb

7.169

24Tyr Hδ*

113163

7.174

24Tyr Hδ*

2.934

24Tyr Hβa

166166

7.163

24Tyr Hδ*

2.934

24Tyr Hβa

191533

7.174

24Tyr Hδ*

3.109

24Tyr Hβb

141517

7.163

24Tyr Hδ*

3.108

24Tyr Hβb

163778

NOE assignments made based on 2D H NMR TOCSY and ROESY experiments on a 5 mM solution of pA-AWK in 20
mM sodium phosphate buffer (pH 7) at room temperature using a 500 MHz Varian INOVA spectrometer.
a

1
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Table 2-17. NOE assignments for pA-EWA.a
δ (ppm) F1
8.179

Assignment F1
8Glu NH

δ (ppm) F2
4.109

Assignment F2
8Glu Hα

Integrated Peak Volume
158061

8.179

8Glu NH

8.063

9Ala NH

213495

8.169

8Glu NH

4.245

9Ala Hα

336937

4.110

8Glu Hα

8.182

8Glu NH

151497

2.258

8Glu Hβb

8.185

8Glu NH

38077

1.994

8Glu Hγb

7.272

12Trp Hδ1

10361

8.055

9Ala NH

1.983

8Glu Hγb

135067

8.214

12Trp NH

4.515

12Trp Hα

158247

8.213

12Trp NH

3.406

12Trp Hβ*

283306

8.213

12Trp NH

7.283

12Trp Hδ1

78650

7.281

12Trp Hδ1

8.213

12Trp NH

58320

7.280

12Trp Hδ1

4.513

12Trp Hα

275739

7.284

12Trp Hδ1

1.312

16Ala Hβ*

42052

7.282

12Trp Hδ1

4.127

8Glu Hα

108287

7.285

12Trp Hδ1

2.168

8Glu Hβa

32106

7.284

12Trp Hδ1

2.26

8Glu Hβb

29132

7.284

12Trp Hδ1

1.984

8Glu Hγb

28920

10.175

12Trp Hε1

7.477

12Trp Hζ2

171082

10.177

12Trp Hε1

2.165

8Glu Hβa

13937

10.176

12Trp Hε1

2.261

8Glu Hβb

17440

10.177

12Trp Hε1

1.983

8Glu Hγb

12427

7.607

12Trp Hε3

4.516

12Trp Hα

106629

7.620

12Trp Hε3

3.405

12Trp Hβa

174701

7.608

12Trp Hε3

3.405

12Trp Hβa

206571

7.487

12Trp Hε2

10.177

12Trp Hε1

132616

8.096

16Ala NH

3.405

12Trp Hβa

125996

8.096

16Ala NH

7.612

12Trp He3

83019

1.308

16Ala Hβ*

8.106

16Ala NH

252348

8.158

24Tyr NH

1.741

23Orn Hβb

67715

8.157

24Tyr NH

7.167

24Tyr Hδ*

129240

7.173

24Tyr Hδ*

2.932

24Tyr Hβa

347219

7.163

24Tyr Hδ*

2.933

24Tyr Hβa

353724

7.173

24Tyr Hδ*

3.116

24Tyr Hβb

274030

7.163

24Tyr Hδ*

3.116

24Tyr Hβb

275658

NOE assignments made based on 2D H NMR TOCSY and ROESY experiments on a 5 mM solution of pA-EWA in 20
mM sodium phosphate buffer (pH 7) at room temperature using a 500 MHz Varian INOVA spectrometer.

a

1

183

Table 2-18. NOEs assignments for pA-EWK.a
δ (ppm) F1
8.206

Assignment F1
12Trp NH

δ (ppm) F2
3.41

Assignment F2
12Trp Hβ*

Integrated Peak Volume
205808

3.41

12Trp Hβ*

7.64

12Trp Hε3

81837

7.296

12Trp Hδ1

4.574

12Trp Hα

173185

7.298

12Trp Hδ1

4.023

16Lys Hα

30352

7.297

12Trp Hδ1

1.479

16Lys Hδ*

110836

7.302

12Trp Hδ1

2.792

16Lys Hεa

10641

7.302

12Trp Hδ1

2.852

16Lys Hεb

10855

7.300

12Trp Hδ1

1.255

16Lys Hγa

16864

7.299

12Trp Hδ1

1.31

16Lys Hγb

16298

7.299

12Trp Hδ1

2.185

8Glu Hβa

18624

7.299

12Trp Hδ1

2.284

8Glu Hβb

15431

7.299

12Trp Hδ1

2.007

8Glu Hγ*

21585

10.193

12Trp Hε1

7.493

12Trp Hζ2

103103

10.194

12Trp Hε1

1.528

16Lys Hδ*

24543

10.194

12Trp Hε1

2.776

16Lys Hεa

7219

10.194

12Trp Hε1

1.243

16Lys Hγa

8661

10.194

12Trp Hε1

1.305

16Lys Hγb

7377

10.198

12Trp Hε1

2.182

8Glu Hβa

5806

10.195

12Trp Hε1

2.289

8Glu Hβb

9212

10.194

12Trp Hε1

2.007

8Glu Hγ*

9275

7.646

12Trp Hε3

4.025

16Lys Hα

49757

7.634

12Trp Hε3

4.026

16Lys Hα

51833

7.646

12Trp Hε3

1.478

16Lys Hδ*

91815

7.634

12Trp Hε3

1.478

16Lys Hδ*

97478

7.487

12Trp Hζ2

2.78

16Lys Hεa

9140

7.49

12Trp Hζ2

2.857

16Lys Hεb

12797

8.039

16Lys NH

4.579

12Trp Hα

43420

2.956

24Tyr Hβa

7.169

24Tyr Hδ*

99140

2.937

24Tyr Hβa

7.17

24Tyr Hδ*

102958

3.12

24Tyr Hβb

7.17

24Tyr Hδ*

66381

3.097

24Tyr Hβb

7.17

24Tyr Hδ*

134192

7.176

24Tyr Hδ*

4.551

24Tyr Hα

150166

7.164

24Tyr Hδ*

4.551

24Tyr Hα

163745

7.175

24Tyr Hδ*

2.937

24Tyr Hβa

204171

7.164

24Tyr Hδ*

2.937

24Tyr Hβa

231709

7.175

24Tyr Hδ*

3.109

24Tyr Hβb

180062

7.164

24Tyr Hδ*

3.109

24Tyr Hβb

201782

NOE assignments made based on 2D 1H NMR TOCSY and ROESY experiments on a 5 mM solution of pA-EWK in 20
mM sodium phosphate buffer (pH 7) at room temperature using a 500 MHz Varian INOVA spectrometer.
a
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3

MEASURING A HELICAL LONG-RANGE SALT BRIDGE ENHANCED BY
NONAROMATIC HYDROPHOBIC AMINO ACIDS.

3.1

Introduction

We demonstrate in Chapter 2 that an arene side chain can enhance the interaction between
a Glu and a Lys residue positioned 8 residues apart on the solvent exposed face of a coiled coil.
Several computational studies predicted that positioning a positive ion on one face of an aromatic
ring and negative ion on the opposing face would have a favorable cooperative interaction, which
we also observe in chapter 2.1-5 These studies describe the aromatic ring as an “insulator” or a
medium that stores information between the charges, in other words the electronics found in the
arene ring can be polarized towards the positive ion and away from the negative creating a
synergistic three-way interaction. Interestingly, more recent studies predict a similar interaction
with hydrocarbons where a cyclic hydrocarbon can mediate a salt bridge by polarizing its electron
density (Figure 3-1).
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Figure 3-1. Three-way interaction between a cyclohexane, flourine ion, and a lithium ion. The
mechanism is predicted to be induction where the electron density of the ring is polarized to towards the
lithium cation and away from the fluorine anion.

Elguero et al. was interested in opposing ions interacting with hydrocarbons in order to
better understand and design energy storing devices.6 Interestingly, they predict that positioning
a cation and anion on opposing faces of cyclohexane can promote a cooperative three-way
interaction. They model the electron density of a fluorine anion and a lithium cation on opposing
faces of a cyclohexane and show that the electron density in the ring polarizes towards the lithium
ion and away from the fluorine ion (figure 3-1). Their model predicts a three-way interaction
worth about 5.5 kcal mol-1 in cooperative energy between the ions and cyclohexane. An analogous
study confirms gas phase interaction between a cesium cation and chlorine anion positioned on
opposing faces of a cyclobutane.7 Also, a spherical fullurene C60 crystal structure where a Li+
cation is trapped within the fullerene shows that there is potential for SbCl3- counter ion interaction
on the exterior of the sphere.8 Due to these studies we wondered if a cyclic nonpolar amino acid
could enhance a long range salt bridge between a Glu 10: Lys 18 on the coiled-coil trimeric helix
1CW (Figure 3-2).
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Figure 3-2. Coiled-coil trimeric 1CW with positions 10, 14, and 18 highlighted as the anion, nonpolar,
and cation mutation sites.

3.2

3.2.1

Results and discussion

Long range salt-bridge enhanced by nonpolar amino acids.

To measure the extent that a cyclic nonpolar amino acid can enhance a Glu10:Lys18 salt
bridge we synthesized the 1CW variant EChaK where position 14 is occupied by a
cyclohexylalanine (Cha), position 10 is a Glutamate, and position 18 is a Lysine (Figure 3-2).
Circular dichroism and size exclusion chromatography confirm that E(Cha)K along with its
sequence variants are coiled-coil trimers (supporting information 3.3.4, 3.3.5). Triple mutant cycle
analysis shows that Cha14 enhances the Glu10:Lys18 salt bridge similar to Phe14. This indicates
the aromaticity in not required for the three-way interaction between Glu10:Lys18. To confirm
this, we applied the Cha long-range salt bridge enhancement to GCN-p1 dimeric model system by
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synthesizing EChaKp1 where position 11, 14, and 18 are occupied by Glu, Cha, Lys respectively.
In GCN4-p1 Cha14 also enhances the Glu11:Lys18 salt bridge similar to the extent of Phe14
(Table 3-1).
Table 3-1 Cha enhancement of long range salt bridge.a
Peptide

Sequence

EFK

Ac-•••KVEALEFKVQKLE•••CONH2
Ac-•••KVEALE(Cha)KVQKLE•••CONH2
Ac–•••VAELEFKNYKL•••–CONH2
Ac–•••VAELE(Cha)KNYKL•••–CONH2

EChaK
EFKp1
a

EChaKp1

Salt-bridge with
Ser14
ΔΔΔGf (kcal/mol)
0.87 ± 0.06

Salt-bridge with Phe14 or
Cha14
ΔΔΔGf (kcal/mol)
-0.38 ± 0.07

Influence of
Phe14 or Cha14
ΔΔΔΔGf (kcal/mol)
-1.25 ± 0.09

0.87 ± 0.06

-0.47 ± 0.07

-1.34 ± 0.13

1.20 ± 0.07

-0.38 ± 0.07

-1.58 ± 0.10

1.20 ± 0.07

-0.09 ± 0.06

-1.30 ± 0.09

Data are given ± standard error at 30 µM protein concentration in 20 mM sodium phosphate
buffer (pH 7). Full sequences can are reported in the supporting information.
We then tested if the size and shape of the hydrophobic residue influenced the interaction.
To explore this possibility, we incorporated non-polar Leu at position 14 (Figure 3-3) and assessed
its ability to enhance the Glu10-Lys18 salt bridge relative to non-polar Ala. Some of these variants
were so stable in 20 mM sodium phosphate buffer (pH 7) as to preclude direct assessment of their
folding free energies. To facilitate direct comparison among peptides ELK, and EFK we performed
variable temperature CD experiments on ELK, EFK, and their sequence variants in 20 mM sodium
phosphate buffer (pH 7) with 1 M urea. The impact of Leu is similar to that of Phe or of Cha,
suggesting that the residual Phe-based increase in salt-bridge stability does not require additional
atoms beyond the Cδ’s of Leu. We also found that norleucine (Nle), norvaline (Nva), Val, and 2amino-n-butyric acid (Abu) at position 14 are each superior to Ser and Ala, and are slightly better
than Phe and Leu in their ability to stabilize the Glu10-Lys18 salt-bridge (Fig 3-3). Together, the
observations in Figure 3-1 and chapter 2 suggest that the impact of Phe the Glu10-Lys18 saltbridge depends only on its non-polar character and not on its shape, size, or surface electrostatic
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potential. We also observe that proteinogenic side chains like Leucine and Valine can enhance a
long-range salt bridge in the context of a coiled-coil trimeric alpha helix.

Figure 3-3. Impact of differing hydrophobic acyclic amino acids on the Glu10:Lys18 salt bridge. Phe 14
is included for reference. Data are given ± standard error at 30 µM protein concentration in 20 mM
sodium phosphate buffer (pH 7), and 1M urea. Full sequences along with triple mutant cycle sequence
variants are reported in the supporting information.

3.2.2

Crystal structures

We explored the differences in the side chain rotamers between compounds EFK, ELK,
ENleK, EVK, ENvaK, and EAbuK (figure 3-4A). To explore this, we measured dihedral angles
χ1 (defined by the atoms Nα, Cα, Cβ, and Cγ) and χ2 (Cα, Cβ, Cγ, and Cδ) for each side-chain,
and described each χ1 and χ2 in one of three possible ways: g+ (positive gauche) for angles
between 0° and 120°; g-(negative gauche) for angles between 0° and -120°; and t (trans) for angles
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between 120° and 180° or between -120° and -180°. Glu10 occupies the same geometry in variants
EFK, ELK, EVK, and ENvaK: while ENleK, and EabuK differ (figure 3-4B). The geometry of the
residue 14 position appears to occupy differing rotamers, only Lue14 and Phe14 occupy the t, g+
rotamer while the ENleK, EVK, ENvaK, and EAbuK occupy varying rotamers (figure 3-4C). Like
residue 14, Lys18 in variants ELK and the EFK variant both occupy the same rotamer (g-, t), while
the ENleK, EVK, ENvaK, and EAbuK occupy varying rotamers (figure 3-4D). The caveats
described in Chapter 2 for interpreting the rotamers of surface-exposed side-chains in the
crystalline state also apply here, making it difficult to correlate the structural details described in
Fig. 3-4 with the solution-phase thermodynamic observations shown in Figure 3-3. The Glu10 of
all the vairants exept for EAbuK, and ENleK occupy the g-, g- rotamer. Interestingly, if the crystal
packing is taken into account the Glu10 g- g- rotamer of one helix trimer actually packs very close
to the Lue14 of an adjacent trimer (Figure 3-5E). Although, this interaction is not applicable to in
solution geometry it is tempting to speculate that the crystal packing interface places the Glu10 of
an adjacent trimer at a more optimal position to interact in a three-way interaction with Lue14, and
Lys18.
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Figure 3-4. (A) overlay of a single helix from EFK, ELK, ENleK, EVK, ENvaK, and EAbuK.
(B)Rotamer analysis of Glu10. (C) Rotamer analysis of residue 14. (D) Rotamer analysis of Lys18.

We explored the structural basis for the stabilizing impact of Lue14 on the Glu10:Lys18
salt bridge by crystalizing four variants of peptide ELK, in which Leu vs. Ala is at position 14;
Glu vs. Ala is at position 10; and Lys vs. Ala is at position 18, in all possible combinations (i.e.,
peptides ELK, ELA, ALK, ALA, EAK). These structures are overlaid with the structure of the
EFK peptide in (Figure 3-5A). Interestingly, the Glu10 rotamer changes from t, g+ in ELA to g-,
g- in ELK (Figure 3-5B). This rearrangement packs the Glu10 β hydrogens towards the center of
Lue14 on an adjacent helix trimer (Figure 3-5 E-F). The Leu14 side chains in peptides ELA,
ALK, and ALA adopt the g-,t conformation that is most frequently observed for Leu residues
within proteins;9-11 this conformation projects the δ-methyl groups of Leu14 toward the Nterminus of the helix where they are similarly distant from positions 10 and 18. In contrast,
Leu14 in ELK adopts the less common t,g+ conformation. Interestingly, the t,g+ conformation of
Leu14 closely resembles that of Phe14 in EFK(Figure 3-5C). The Lysine rotamers in ALK and
EAK occupy the g-, g- rotamers. In the variants EFK and ELK the Lysine rotamer switches to a
g-, t rotamer (figure 3-5 D). This switch in rotamer places the Leu14, or Phe14 in close
proximity to Lys18: the Leu14 Cγ is only 3.9 Å from the Lys18 Cδ. We speculate that this
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change in distance is due to the close packing of the crystal contact Glu10 to both Phe14, and
Lue14 (Figure 5E, G, I). However, the caveats described above for interpreting the rotamers of
surface-exposed side-chains in the crystalline state also apply here, making it difficult to
correlate the structural details described in Fig. 3-5 with the solution-phase thermodynamic
observations shown in Fig. 3-3.

Figure 3-5. (A) Single helix overlay of EFK, ELK, EAK, ALK, ALA, and ELA. (B) Rotamer analysis of
Glu10. (C) Rotamer analysis of Luecine14 or Phe 14. (D) Rotamer analysis for Lys18. (E) crystal
interface between 2 trimers for ELK, (F) ELA, (G) ALK, (H) ALA, and (I) EAK.

3.2.3

Conclusions
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In this chapter, we show that long range salt bridge can contribute significant
conformational stability to a coiled-coil alpha helix trimer and dimer if there is a nonpolar amino
acid positioned between the cation and anion. We show that the shape size of the amino acid
does not matter as long as it is bigger than alanine. The data indicate that both leucine and valine
can enhance long range salt bridges in the context of an alpha helix, this suggests a broader
impact for cooperative ion-nonpolar interactions in protein structure. Substantial structural data
show that the Glu10 in one trimer in the crystal lattice positions itself in close proximity to the
leucine 14 on adjacent trimer. Close packing of lysine 18 and leucine 14 is also observed in the
presence of Glu10. This is interesting and causes us to speculate that a nonpolar enhanced salt
bridge might be more favorable if the Lue enhances salt bridge is positioned at the helical-helical
interface.

3.3
3.3.1

Supporting Information
Protein synthesis, characterization, and Purification.
Peptide sequences for EChak, EChaKp1, ELK, ENleK, EVK, ENvaK, and EabuK

along with their sequence variants are shown in table 3-2. EAK, ESK, and EFK data can be
found in chapter 2. All peptides were synthesized as C-terminal amides, by microwave-assisted
solid-phase peptide synthesis as described in Chapter 2 supporting information section 2.4.1.

Table 3-2 Peptide sequences
Peptide

Sequence

1CW
GCN4-P1

Ac–EVEALEKKVAALECKVQALEKKVEALEHGWDGR–CONH2
Ac–RMKQLEDRVEELESKNYHLENEVARLKKLVGER–CONH2
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EChaK
EChaA
AChaK
AChaA

Ac–EVEALEKKVEALEChaKVQKLEKKVEALEHGWDGR–CONH2
Ac–EVEALEKKVEALEChaKVQALEKKVEALEHGWDGR–CONH2
Ac–EVEALEKKVAALEChaKVQKLEKKVEALEHGWDGR–CONH2
Ac–EVEALEKKVAALEChaKVQALEKKVEALEHGWDGR–CONH2

EChaK p1
EChaA p1
AChaK p1
AChaA p1

Ac–RMKQLEDRVAELEChaKNYKLENEVARLKKLVGER–CONH2
Ac–RMKQLEDRVAELEChaKNYALENEVARLKKLVGER–CONH2
Ac–RMKQLEDRVAELEChaKNYKLENEVARLKKLVGER–CONH2
Ac–RMKQLEDRVAELEChaKNYALENEVARLKKLVGER–CONH2

ELK
ELA
ALK
ALA
ENleK
ENleA
ANleK
ANleA
EVK
EVA
AVK
AVA

Ac–EVEALEKKVAELELKVQKLEKKVEALEHGWDGR–CONH2
Ac–EVEALEKKVAELELKVQALEKKVEALEHGWDGR–CONH2
Ac–EVEALEKKVAELELKVQKLEKKVEALEHGWDGR–CONH2
Ac–EVEALEKKVAALELKVQALEKKVEALEHGWDGR–CONH2
Ac–EVEALEKKVEALENleKVQKLEKKVEALEHGWDGR–CONH2
Ac–EVEALEKKVAALENleKVQKLEKKVEALEHGWDGR–CONH2
Ac–EVEALEKKVEALENleKVQALEKKVEALEHGWDGR–CONH2
Ac–EVEALEKKVAALENleKVQALEKKVEALEHGWDGR–CONH2
Ac–EVEALEKKVEALEVKVQKLEKKVEALEHGWDGR–CONH2
Ac–EVEALEKKVEALEVKVQALEKKVEALEHGWDGR–CONH2
Ac–EVEALEKKVAALEVKVQKLEKKVEALEHGWDGR–CONH2
Ac–EVEALEKKVAALEVKVQALEKKVEALEHGWDGR–CONH2

ENvaK
ENvaA
ANvaK
ANvaA

Ac–EVEALEKKVEALENvaKVQKLEKKVEALEHGWDGR–CONH2
Ac–EVEALEKKVEALENvaKVQALEKKVEALEHGWDGR–CONH2
Ac–EVEALEKKVAALENvaKVQKLEKKVEALEHGWDGR–CONH2
Ac–EVEALEKKVAALENvaKVQALEKKVEALEHGWDGR–CONH2

EAbuK
EAbuK
AAbuK
AAbuA

Ac–EVEALEKKVEALEAbuKVQKLEKKVEALEHGWDGR–CONH2
Ac–EVEALEKKVEALEAbuKVQKLEKKVEALEHGWDGR–CONH2
Ac–EVEALEKKVAALEAbuKVQALEKKVEALEHGWDGR–CONH2
Ac–EVEALEKKVAALEAbuKVQALEKKVEALEHGWDGR–CONH2

3.3.2

ESI-TOF mass spec data

Mass spec characterization for EChak, EChaKp1, ELK, ENleK, EVK, ENvaK, and EabuK
along with their sequence variants are shown below.
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Figure 3-6. ESI TOF spectrum for peptide EChaK

Figure 3-7. ESI TOF spectrum for peptide AChaK

Figure 3-8. ESI TOF spectrum for peptide EChaA
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Figure 3-9. ESI TOF spectrum for peptide AChaA

Figure 3-10. ESI TOF data for peptide EchaK p1

Figure 3-11. ESI TOF data for peptide AchaK p1
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Figure 3-12. ESI TOF data for peptide EchaA p1.

Figure 3-13. ESI TOF spectrum for peptide AchaA p1.

Figure 3-14. ESI TOF spectrum for peptide ELK.
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Figure 3-15. ESI TOF spectrum for peptide ALK.

Figure 3-16. ESI TOF spectrum for peptide ELA.

Figure 3-17. ESI TOF spectrum for peptide ALA.
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Figure 3-18. ESI TOF spectrum for AVA.

Figure 3-19. ESI TOF spectrum for AVK.

Figure 3-20. ESI TOF spectrum for EVA.
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Figure 3-21. ESI TOF spectrum for EVK.

Figure 3-22. ESI TOF spectrum for ANleA.

Figure 3-23. ESI TOF spectrum for ANleK.
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Figure 3-24. ESI TOF spectrum for ENleA.

Figure 3-25. ESI TOF spectrum for ENleK.

Figure 3-26. ESI TOF spectrum for ANvaA.
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Figure 3-27. ESI TOF spectrum for ANvaK.

Figure 3-28. ESI TOF spectrum for ENvaA.

Figure 3-29. ESI TOF spectrum for ENvaK.
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Figure 3-30. ESI TOF spectrum for AAbuA.

Figure 3-31. ESI TOF spectrum for AAbuK.

Figure 3-32. ESI TOF spectrum for EAbuA.
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Figure 3-33. ESI TOF spectrum for EAbuK.

3.3.3

Analytical HPLC data

HPLC characterization for EChak, EChaKp1, ELK, ENleK, EVK, ENvaK, and EabuK along
with their sequence variants are shown below.

Figure 3-34. Analytical HPLC Data for EChaK. Protein solution was injected onto a C18 analytical
column and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over
50 minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration (10% B) at
1 mL/min.
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Figure 3-35. Analytical HPLC Data for AChaK. Protein solution was injected onto a C18 analytical
column and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over
50 minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration (10% B) at
1 mL/min.

Figure 3-36. Analytical HPLC Data for EChaA. Protein solution was injected onto a C18 analytical
column and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over
50 minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration (10% B) at
1 mL/min.
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Figure 3-37. Analytical HPLC Data for AChaA. Protein solution was injected onto a C18 analytical
column and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over
50 minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration (10% B) at
1 mL/min.

Figure 3-38. Analytical HPLC Data for ELK. Protein solution was injected onto a C18 analytical column
and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over 50
minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration (10% B) at 1
mL/min.
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Figure 3-39. Analytical HPLC Data for ALK. Protein solution was injected onto a C18 analytical column
and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over 50
minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration (10% B) at 1
mL/min.

Figure 3-40. Analytical HPLC Data for ELA. Protein solution was injected onto a C18 analytical column
and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over 50
minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration (10% B) at 1
mL/min.
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Figure 3-41. Analytical HPLC Data for ALA. Protein solution was injected onto a C18 analytical column
and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over 50
minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration (10% B) at 1
mL/min.

Figure 3-42. Analytical HPLC Data for EChaK p1. Protein solution was injected onto a C18 analytical
column and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over
50 minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration (10% B) at
1 mL/min.
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Figure 3-43. Analytical HPLC Data for AChaK p1. Protein solution was injected onto a C18 analytical
column and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over
50 minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration (10% B) at
1 mL/min.

Figure 3-44. Analytical HPLC Data for EChaA p1. Protein solution was injected onto a C18 analytical
column and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over
50 minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration (10% B) at
1 mL/min.

Figure 3-45. Analytical HPLC Data for AChaA p1. Protein solution was injected onto a C18 analytical
column and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over
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50 minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration (10% B) at
1 mL/min.

Figure 3-46. Analytical HPLC Data for AVA. Protein solution was injected onto a C18 analytical column
and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over 50
minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration (10% B) at 1
mL/min

Figure 3-47. Analytical HPLC Data for EVA. Protein solution was injected onto a C18 analytical column
and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over 50
minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration (10% B) at 1
mL/min
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Figure 3-48. Analytical HPLC Data for AVK. Protein solution was injected onto a C18 analytical column
and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over 50
minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration (10% B) at 1
mL/min

Figure 3-49. Analytical HPLC Data for EVK. Protein solution was injected onto a C18 analytical column
and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over 50
minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration (10% B) at 1
mL/min.
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Figure 3-50. Analytical HPLC Data for ANleA. Protein solution was injected onto a C18 analytical
column and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over
50 minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration (10% B) at
1 mL/min.

Figure 3-51. Analytical HPLC Data for ENleA. Protein solution was injected onto a C18 analytical
column and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over
50 minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration (10% B) at
1 mL/min.

215

Figure 3-52. Analytical HPLC Data for ANleK. Protein solution was injected onto a C18 analytical
column and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over
50 minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration (10% B) at
1 mL/min.

Figure 3-53. Analytical HPLC Data for ENleK. Protein solution was injected onto a C18 analytical
column and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over
50 minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration (10% B) at
1 mL/min.
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Figure 3-54. Analytical HPLC Data for ANvaA. Protein solution was injected onto a C18 analytical
column and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over
50 minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration (10% B) at
1 mL/min.

Figure 3-55. Analytical HPLC Data for ENvaA. Protein solution was injected onto a C18 analytical
column and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over
50 minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration (10% B) at
1 mL/min.
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Figure 3-56. Analytical HPLC Data for ANvaK. Protein solution was injected onto a C18 analytical
column and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over
50 minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration (10% B) at
1 mL/min.

Figure 3-57. Analytical HPLC Data for ENvaK. Protein solution was injected onto a C18 analytical
column and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over
50 minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration (10% B) at
1 mL/min.
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Figure 3-58. Analytical HPLC Data for AAbuA. Protein solution was injected onto a C18 analytical
column and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over
50 minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration (10% B) at
1 mL/min.

Figure 3-59. Analytical HPLC Data for EAbuA. Protein solution was injected onto a C18 analytical
column and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over
50 minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration (10% B) at
1 mL/min.
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Figure 3-60. Analytical HPLC Data for AAbuK. Protein solution was injected onto a C18 analytical
column and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over
50 minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration (10% B) at
1 mL/min.

Figure 3-61. Analytical HPLC Data for EAbuK. Protein solution was injected onto a C18 analytical
column and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over
50 minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration (10% B) at
1 mL/min.

3.3.4

Size Exclusion Chromatography
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Size exclusion chromatography (SEC) was done on a Shimadzu HPLC instrument using a
Zenix-100 SEC analytical column or a Phenomenex Yarra 3u sec-3000 column. Size exclusion
chromatography for EChaK, EChaK p1, ELK, ENleK, ENvaK, EVK, and EAbuK and their
sequence variants were injected as 30 μM samples in 20mM sodium phosphate (pH 7.0) onto the
column on a 25 minute isochratic method of a mobile phase comprised of 20mM sodium
phosphate (pH 7.0). and 0.3M NaCl. Each variant was compared to a trimer and dimer standards
previously characterized.12-13 Retention times for EChaK, ELK, ENleK, ENvaK, EVK, and
EAbuK and their sequence variants were more comparable to the trimer standard that the dimer
or monomer standards. Retention time EChaKp1 and its sequence variants were more
comparable to the Dimer standard than the trimer standard.

Table 3-3 Retention times of helical peptides on a Zenix-100 SEC analytical column
Batch 1 (7/27/17)
Peptide

Calculated MW
(Da.)

Retention time
(min.)

Association
state

Trimer standard

11151

9.15

Trimer

Dimer Standard

8131

10.31

Dimer

AVA

11187

9.26

Trimer

EVA

11358

9.04

Trimer

AVK

11362

9.17

Trimer

EVK

11533

9.17

Trimer

ANleA

11229

9.16

Trimer

ENleA

11400

9.06

Trimer

ANleK

11404

9.19

Trimer

ENleK

11575

9.08

Trimer
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Batch 2 (10/10/17)
Peptide

Calculated MW
(Da.)

Retention time
(min.)

Association
state

Trimer standard

11016

9.04

Trimer

Dimer Standard

8131

10.23

Dimer

ANvaA

11187

9.17

Trimer

ENvaA

11358

9.00

Trimer

ANvaK

11362

9.15

Trimer

ENvaK

11533

9.04

Trimer

AAbuA

11145

9.09

Trimer

EAbuA

11316

8.98

Trimer

AAbuK

11319

9.02

Trimer

EAbuK

11491

9.11

Trimer

Table 3-4 Retention times of helical peptides on a Zenix-100 SEC analytical column
Batch 3
Peptide

MW
(Da)

Retention
Time (min)

Association state

1CW(monomer standard)

11199

8.83

Trimer

GCN4(dimer standard)

8131

9.43

Dimer

PSBD36(monomer
standard)

4001

10.51

Monomer

AChaA p1

7927

10.34

Dimer/Monomer

EChaA p1

8041

9.83

Dimer

AChaK p1

8043

10.33

Dimer/Monomer

EChaK p1

8157

9.79

Dimer

Batch 4
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Peptide

MW
(Da)

Retention
Time (min)

Association state

1CW(trimer standard)

11199

9.04

Trimer

ELK

11575

8.94

Trimer

19-ALK

11404

8.96

Trimer

19-ELA

11401

9.07

Trimer

1CW(trimer standard)

11199

9.11

Trimer

19-ALA

11229

9.23

Trimer

Table 3-5 Retention times of helical peptides on a Phenomenex Yarra 3u sec-3000 column.
Batch 5
Peptide

3.3.5

association state

Calculated
MW (Da)

Retention
Time (min)

1CW (trimer
standard)

11017

10.50

AChaA

11214

10.44

trimer

EChaA

11385

10.33

trimer

AChaK

11389

10.52

trimer

EChaK

11560

10.41

trimer

Folded Free energy measurement, Circular Dichroism spectropolarimetry.

Experimental details and the equations used for acquiring the folded free energies for
EChak, EChaKp1, ELK, ENleK, EVK, ENvaK, EabuK, EAK, ESK, and EFK are the same
as for the compounds found in Chapter 2 details can be found in Section 2.4.5. The wavelengths
scans and thermodynamic fits a EChak, EChaKp1, ELK, ENleK, EVK, ENvaK, and EabuK
are found in figures 3-62 to 3-89.

223

Figure 3-62. CD spectrum (top right) and triplicate variable temperature CD data (top left) for a 30 µM
solution of protein EChaK in 20 mM sodium phosphate (pH 7). Parameters used to fit the variable
temperature CD data to equations S6–S9 are also shown, with standard errors as indicated.

Figure 3-63. CD spectrum (top right) and triplicate variable temperature CD data (top left) for a 30 µM
solution of protein AChaK in 20 mM sodium phosphate (pH 7). Parameters used to fit the variable
temperature CD data to equations S6–S9 are also shown, with standard errors as indicated.
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Figure 3-64. CD spectrum (top right) and triplicate variable temperature CD data (top left) for a 30 µM
solution of protein EChaA in 20 mM sodium phosphate (pH 7). Parameters used to fit the variable
temperature CD data to equations S6–S9 are also shown, with standard errors as indicated.

Figure 3-65. CD spectrum (top right) and triplicate variable temperature CD data (top left) for a 30 µM
solution of protein AChaA in 20 mM sodium phosphate (pH 7). Parameters used to fit the variable
temperature CD data to equations S6–S9 are also shown, with standard errors as indicated.
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Figure 3-66. CD spectrum (top right) and triplicate variable temperature CD data (top left) for a 30 µM
solution of protein EChaK p1 in 20 mM sodium phosphate (pH 7). Parameters used to fit the variable
temperature CD data to equations S6–S9 are also shown, with standard errors as indicated.

Figure 3-67. CD spectrum (top right) and triplicate variable temperature CD data (top left) for a 30 µM
solution of protein EChaA p1 in 20 mM sodium phosphate (pH 7). Parameters used to fit the variable
temperature CD data to equations S6–S9 are also shown, with standard errors as indicated.
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Figure 3-68. CD spectrum (top right) and triplicate variable temperature CD data (top left) for a 30 µM
solution of protein AChaK p1 in 20 mM sodium phosphate (pH 7). Parameters used to fit the variable
temperature CD data to equations S6–S9 are also shown, with standard errors as indicated.

Figure 3-69. CD spectrum (top right) and triplicate variable temperature CD data (top left) for a 30 µM
solution of protein AChaA p1 in 20 mM sodium phosphate (pH 7). Parameters used to fit the variable
temperature CD data to equations S6–S9 are also shown, with standard errors as indicated.
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Figure 3-70. CD spectrum (top right) and triplicate variable temperature CD data (top left) for a 30 µM
solution of protein ALA in 20 mM sodium phosphate (pH 7), and 1M urea. Parameters used to fit the
variable temperature CD data to equations S6–S9 are also shown, with standard errors as indicated.

Figure 3-71. CD spectrum (top right) and triplicate variable temperature CD data (top left) for a 30 µM
solution of protein ALK in 20 mM sodium phosphate (pH 7), and 1M urea. Parameters used to fit the
variable temperature CD data to equations S6–S9 are also shown, with standard errors as indicated.

Figure 3-72. CD spectrum (top right) and triplicate variable temperature CD data (top left) for a 30 µM
solution of protein ELA in 20 mM sodium phosphate (pH 7), and 1M urea. Parameters used to fit the
variable temperature CD data to equations S6–S9 are also shown, with standard errors as indicated.

Figure 3-73. CD spectrum (top right) and triplicate variable temperature CD data (top left) for a 30 µM
solution of protein ELK in 20 mM sodium phosphate (pH 7), and 1M urea. Parameters used to fit the
variable temperature CD data to equations S6–S9 are also shown, with standard errors as indicated.
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Figure 3-74. CD spectrum (top right) and triplicate variable temperature CD data (top left) for a 30 µM
solution of protein AVA in 20 mM sodium phosphate (pH 7), and 1M urea. Parameters used to fit the
variable temperature CD data to equations S6–S9 are also shown, with standard errors as indicated.

Figure 3-75. CD spectrum (top right) and triplicate variable temperature CD data (top left) for a 30 µM
solution of protein AVK in 20 mM sodium phosphate (pH 7), and 1M urea. Parameters used to fit the
variable temperature CD data to equations S6–S9 are also shown, with standard errors as indicated.

Figure 3-76. CD spectrum (top right) and triplicate variable temperature CD data (top left) for a 30 µM
solution of protein EVA in 20 mM sodium phosphate (pH 7), and 1M urea. Parameters used to fit the
variable temperature CD data to equations S6–S9 are also shown, with standard errors as indicated.
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Figure 3-77. CD spectrum (top right) and triplicate variable temperature CD data (top left) for a 30 µM
solution of protein EVK in 20 mM sodium phosphate (pH 7), and 1M urea. Parameters used to fit the
variable temperature CD data to equations S6–S9 are also shown, with standard errors as indicated.

Figure 3-78. CD spectrum (top right) and triplicate variable temperature CD data (top left) for a 30 µM
solution of protein ANleA in 20 mM sodium phosphate (pH 7), and 1M urea. Parameters used to fit the
variable temperature CD data to equations S6–S9 are also shown, with standard errors as indicated.

Figure 3-79. CD spectrum (top right) and triplicate variable temperature CD data (top left) for a 30 µM
solution of protein ANleK in 20 mM sodium phosphate (pH 7), and 1M urea. Parameters used to fit the
variable temperature CD data to equations S6–S9 are also shown, with standard errors as indicated.
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Figure 3-80. CD spectrum (top right) and triplicate variable temperature CD data (top left) for a 30 µM
solution of protein ENleA in 20 mM sodium phosphate (pH 7), and 1M urea. Parameters used to fit the
variable temperature CD data to equations S6–S9 are also shown, with standard errors as indicated.

Figure 3-81. CD spectrum (top right) and triplicate variable temperature CD data (top left) for a 30 µM
solution of protein ENleK in 20 mM sodium phosphate (pH 7), and 1M urea. Parameters used to fit the
variable temperature CD data to equations S6–S9 are also shown, with standard errors as indicated.

Figure 3-82. CD spectrum (top right) and triplicate variable temperature CD data (top left) for a 30 µM
solution of protein ANvaA in 20 mM sodium phosphate (pH 7), and 1M urea. Parameters used to fit the
variable temperature CD data to equations S6–S9 are also shown, with standard errors as indicated.
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Figure 3-83. CD spectrum (top right) and triplicate variable temperature CD data (top left) for a 30 µM
solution of protein ANvaK in 20 mM sodium phosphate (pH 7), and 1M urea. Parameters used to fit the
variable temperature CD data to equations S6–S9 are also shown, with standard errors as indicated.

Figure 3-84. CD spectrum (top right) and triplicate variable temperature CD data (top left) for a 30 µM
solution of protein ENvaA in 20 mM sodium phosphate (pH 7), and 1M urea. Parameters used to fit the
variable temperature CD data to equations S6–S9 are also shown, with standard errors as indicated.

Figure 3-85. CD spectrum (top right) and triplicate variable temperature CD data (top left) for a 30 µM
solution of protein ENvaK in 20 mM sodium phosphate (pH 7), and 1M urea. Parameters used to fit the
variable temperature CD data to equations S6–S9 are also shown, with standard errors as indicated.
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Figure 3-86. CD spectrum (top right) and triplicate variable temperature CD data (top left) for a 30 µM
solution of protein AAbuA in 20 mM sodium phosphate (pH 7), and 1M urea. Parameters used to fit the
variable temperature CD data to equations S6–S9 are also shown, with standard errors as indicated.

Figure 3-87. CD spectrum (top right) and triplicate variable temperature CD data (top left) for a 30 µM
solution of protein AAbuK in 20 mM sodium phosphate (pH 7), and 1M urea. Parameters used to fit the
variable temperature CD data to equations S6–S9 are also shown, with standard errors as indicated.

Figure 3-88. CD spectrum (top right) and triplicate variable temperature CD data (top left) for a 30 µM
solution of protein EAbuA in 20 mM sodium phosphate (pH 7), and 1M urea. Parameters used to fit the
variable temperature CD data to equations S6–S9 are also shown, with standard errors as indicated.
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Figure 3-89. CD spectrum (top right) and triplicate variable temperature CD data (top left) for a 30 µM
solution of protein EAbuK in 20 mM sodium phosphate (pH 7), and 1M urea. Parameters used to fit the
variable temperature CD data to equations S6–S9 are also shown, with standard errors as indicated.

3.3.6

Single crystal diffraction data.

Freeze dried peptides were dissolved in milli Q water at a concentration of 10 mg/ml and
screened against the Rigaku Wizard Cryo 1 and 2 screens. Drops were set with a TPP mosquito
liquid handling robot with protein:condition ratios of 1:2, 1:1, and 2:1 at a total drop volume of
300nl. Conditions that grew high quality crystals are summarized in table 3-6. Crystals was
harvested in ambient temperatures from sitting well plates with a nylon loop and immediately
frozen in liquid N2. The crystal was mounted in a stream of cold N2 and centered in the X-ray
beam using a video camera. Low-temperature (100 K) X-ray diffraction data was collected using
a MACH3 kappa goniometer coupled to a Bruker Apex II CCD detector with a Bruker-Nonius
FR591 rotating anode X-ray source producing Cu Kα radiation (λ = 1.54178 Å). The Bruker
Proteum-3 suite was used to process (integrate and scale) the data.
Structures were determined by molecular replacement with Phaser (CCP4 program suite)
using the coordinates of the a coiled-coil trimer structure previously determined. The initial
electron density map indicated two helices each being a helix in a coiled coil trimer; side-chain
density was clearly interpretable. Model building was carried out using COOT.14 Refinement
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was performed with Phenix.15 Data and refinement statistics are summarized in Tables 3-7, 3-8,
3-9, and 3-10.
Table 3-5 Crystal drop conditions
Protein

Precipitant

Buffer

pH

ALA

40% v/v PEG 300

100 mM Sodium phosphate dibasic/
Citric acid

7.5

ELA

40% v/v PEG 300

100 mM Sodium phosphate dibasic/
Citric acid

4.2

ALK

40% v/v PEG 300

100 mM Sodium phosphate dibasic/
Citric acid

4.2

ELK

50% v/v PEG 200

100 mM HEPES free acid/ Sodium
hydroxide

7.5

EAK

50% v/v PEG 200

100 mM Sodium phosphate dibasic/
Potassium phosphate monobasic

6.2

EFK

40% v/v PEG 300

100 mM Sodium phosphate dibasic/
Citric acid

4.2

EVK

40% v/v PEG 600

100 mM Sodium citrate tribasic/ Citric
acid

5.5

ENvaK

40% v/v PEG 600

100 mM Sodium citrate tribasic/ Citric
acid

5.5

ENleK

40% v/v PEG 600

100 mM Sodium citrate tribasic/ Citric
acid

5.5

Salt
0.2M NaCl

0.2M NaCl

Table 3-6 Data and refinement statistics
ALA

ELA

ALK

R3

R3

R3

a, b, c

37.86, 37.86, 105.85

38.04, 38.04, 104.28

38.18, 38.18, 102.77

α,β,γ

90, 90, 120

90, 90, 120

90, 90, 120

31.32-1.90

34.77-1.70

31.48-1.68

Space group
Unit Cell

Data collection
Resolution
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R merge (%)

13.8 (34.7)

29.8(26.9)

37.3 (48.5)

I/σ(I)

7.7 (1.1)

20.2 (2.5)

10.2 (1.2)

completeness

99.2 (92.5)

99.2 (88.3)

99.8 (99.1)

Redundancy

3.7 (2.3)

7.6 (3.5)

3.9 (2.1)

Resolution

31.32-1.90

34.77-1.70

31.48-1.68

# of reflections

4461

6237

6377

Rwork/Rfree

15.5/19.3

17.1/21.6

17.3/22.9

# of atoms

636

634

644

Ave B factor

17.4

15.4

15.2

Bond lengths (Å)

0.007

0.006

0.006

Bond angles (°)

0.69

1.09

0.88

EAK

EFK

ELK

R3

R3

R3

a, b, c

39.01, 39.01, 98.16

38.89, 38.89, 103.47

39.06, 39.06, 101.52

α,β,γ

90, 90, 120

90, 90, 120

90, 90, 120

Resolution

32.72-2.30

34.49-2.15

33.85-1.90

R merge (%)

19.9 (36.4)

19.3 (40.6)

19.1 (53.2)

Refinement

Rmsd

Table 3-7 Data and refinement statistics

Space group
Unit Cell

Data collection
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I/σ(I)

8.5 (1.6)

9.4 (2.1)

9.9 (1.4)

completeness

99.56 (100)

99.7 (100)

99.1 (94.8)

Redundancy

5.8 (4.4)

7.7 (4.4)

4.9 (2.5)

Resolution

32.72-2.30

34.49-2.15

33.85-1.95

# of reflections

2481

3180

4591

Rwork/Rfree

18.4/24.6

17.6/24.4

17.6/22.7

# of atoms

576

604

620

Ave B factor

28.3

20.5

15.4

Bond lengths (Å) 0.008

0.008

0.011

Bond angles (°)

0.96

1.31

EVK

ENVAK

ENLEK

R3

R3

R3

a, b, c

38.14, 38.14, 104.49

38.32, 38.32, 104.59

39.07, 39.07, 113.33

α,β,γ

90, 90, 120

90, 90, 120

90, 90, 120

34.84-1.5

34.87-1.70

37.78.-2.20

Refinement

Rmsd
1.05

Table 3-8 Data and refinement statistics

Space group
Unit Cell

Data collection
Resolution
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R merge (%)

15.8 (25.1)

10.5 (34.0)

11.6 (32.0)

I/σ(I)

18.3 (1.9)

17.5 (1.9)

16.2 (2.1)

completeness

99.9 (97.6)

99.8 (98.3)

99.5 (95.4)

Redundancy

6.1 (2.8)

7.3 (4.7)

4.6 (2.2)

Resolution

34.84-1.5

34.87-1.70

37.78.-2.20

# of reflections

9118

6357

3261

Rwork/Rfree

17.5/19.7

16.1/18.9

19.7/26.6

# of atoms

670

667

559

Ave B factor

14.7

15.2

37.7

Bond lengths (Å)

0.006

0.006

0.008

Bond angles (°)

1.03

1.00

1.03

Refinement

Rmsd

Table 3-9 Data and refinement statistics
EABUK
Space group

R3

Unit Cell
a, b, c

39.37, 39.37, 98.12

α,β,γ

90, 90, 120

Data collection
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Resolution

32.72-1.6

R merge (%)

9.3 (28.4)

I/σ(I)

16.3 (1.4)

completeness

99.9 (98.7)

Redundancy

3.6 (2.4)

Refinement
Resolution

32.72-1.6

# of reflections

7495

Rwork/Rfree

19.2/21.4

# of atoms

638

Ave B factor

20.28

Rmsd
Bond lengths (Å)

0.007

Bond angles (°)

1.04

3.4
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4

AN ANION−Π INTERACTION STRONGLY STABILIZES THE Β-SHEET
PROTEIN WW.

4.1

Introduction

Interactions between cationic amino acids and the face of an electron rich aromatic amino
acids (cation-π) are ubiquitous in protein structure.1-5 Experimental and computational work
indicate that anions can have analogous interactions with the face of an electron deficient arene.612

However, the energetic benefit of anion π interactions is a subject of debate,13-14 especially for

anion-π interactions with the electron-rich amino acid side chains Phe, Tyr, and Trp.15
Unsurprisingly, one would expect the facewise interaction between an electron-rich arene
and an anion to be unfavorable because of electrostatic repulsion,11 though arene polarization can
partially compensate for less than optimal electrostatic interactions.7 Interestingly, analysis of
protein structures in the Protein Data Bank (PDB) show that facewise contacts of anions with the
aryl side chains of Phe, Trp, or Tyr do occur despite the debate whether this type of interaction is
stabilizing.15-19
Alternative studies suggest an anion interacting with the electron poor C-H edge of electron
rich arene occurs more often and has a more favorable energetic impact.7, 18-19 For example,
Kallenbach and co-workers found that an i-position Glu and an i + 4 Phe interaction contributes
about -0.5 kcal mol-1 in conformational stability to an alpha helix model peptide; relatively weak
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NOEs show that the Glu and Phe side chains are in close proximity, possibly consistent with an
interaction between the aryl protons of Phe and the negatively charged oxygens of Glu.20-21

4.2

Results and discussion

A statistical probe of protein structures in the PDB for facewise anion π interactions
showed, among others, two interactions where in a reverse turn an i-residue anion interacts with
an i+2 aromatic residue.17 The first example, fibronectin is a protein that plays a role in cell
adhesion by binding integrin proteins.22 The fibronectin crystal structure (PDB 2QBW) shows
that Asp179, found in a reverse turn, is interacting with the face of Tyr181 (Figure 4-1A).23 β-

galactosidase, an enzyme that breaks down polysaccharides, also has a reverse turn in its structure
(PDB 1JZ8) where Asp997 interacts with the face of Trp 999 (Figure 4-1B).24-25 We wondered if
we could assess the energetic contribution of an anion-π interaction with the well-characterized
WW domain. The WW domain (WW) is a 33 amino acid protein that has three antiparallel beta
sheets connected by two reverse turns. 26-31 The first reverse turn in WW contains positions 16 and
18 whose side chains are in close proximity (Figure 4-1C, PDB 2f21). We thought that placing a
negatively charged amino acid at position 16 and an aromatic amino acid at position 18 might
facilitate a face-wise anion−π interaction similar to that observed in the context of fibronectin, and
β-galactosidase.
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Figure 4-1. (A) Fibronectin face wise anion-π interaction between Asp179 and Tyr181, PDB ID 2QBW.
(B) β-galactosidase face wise anion-π interaction between Asp997 and Trp999, PDB ID 1JZ8. (C) Close
proximity of residues 16 and 18 in a reverse turn within the Pin WW domain (PDB: 2f21). We made the
substitutions shown at the positions indicated.

We tested this hypothesis by making WW variant DY in which position 16 is an Asp and
position 18 is a Tyr, along with sequence-matched control compounds SY, DN, and SN, where we
switched Asp16 to Ser and Tyr18 to Asn, respectively, in all possible combinations. We chose
these replacements because Ser16 and Asn18 cannot participate in an anion−π interaction and
because they closely resemble the residues that occupy these positions in the parent WW sequence
from which these variants were derived, these varients also complete a double mutant cycle
allowing us to measure the Asp:Tyr interaction (see Chapter 1.2.1).32
Variable temperature CD experiments allowed us to assess the conformational stability of
DY relative to SY, DN, and SN (Table 4-1). Mutating Ser16 to Asp increases WW conformational
stability by −0.26 ± 0.04 kcal mol-1 when Asn occupies position 18 (which would preclude any
contribution from an anion−π interaction). In contrast, when Tyr occupies position 18, the S16D
mutation stabilizes WW by a moderately larger amount (ΔΔGf = −0.52 ± 0.03 kcal/mol),
suggesting that an Asp16–Tyr18 interaction contributes slightly to the stability of DY relative to
DN (ΔΔΔGf = −0.26 ± 0.04 kcal/mol; see Table 4-1).
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We wondered if other proteinogenic arenes might more readily engage in a stabilizing
interaction with Asp16. To test this hypothesis, we prepared WW variants SW, DW, SH, DH, SF,
and DF, in which Trp, His, or Phe have replaced Tyr18. Variable temperature CD data for SW
were inconsistent with a two-state folding protein, preventing us from determining the strength of
the Asp16–Trp18 interaction. Comparison of SH and DH vs SN and DN indicates that the Asp16–
His18 interaction is only marginally stabilizing (ΔΔΔGf = −0.12 ± 0.02 kcal/mol, Table 4-1). In
contrast, the Asp16–Phe18 interaction contributes nearly 5 times more conformational stability
than the Asp16-Tyr18 interaction (−1.31 ± 0.05 kcal/mol, compare ΔGf values for SF and DF vs
SN and DN in Table 4-1).
These results show that the Asp16–Phe18 interaction stabilizes WW, But the exact
orientation of Asp16 relative to Phe18 remains unclear. If the Asp16-Phe18 interaction has a
facewise orientation Asp16 packs close to the center Phe18, then replacing Phe with electron-poor
pentafluorophenylalanine (F5Phe; one-letter abbreviation is Z) should result in a more
energetically favorable interaction. In contrast, an edgewise interaction of Asp16 with F5Phe
should be much less favorable, due to the electron rich fluorines of F5Phe repelling the Asp16
carboxylate.
We tested this hypothesis by preparing WW variants DZ and SZ, in which we replaced
Phe18 with F5Phe. Surprisingly, the Asp16–F5Phe18 interaction contributes −1.33 ± 0.03 kcal/mol
to the stability of DZ relative to SZ, the same amount at the Asp16:Phe18 interaction. This result
potentially indicates an edgewise orientation of Asp16 relative to Phe18 in DF and a facewise
orientation of Asp16 relative to F5Phe18 in DZ and could indicate that anion−π protein interactions
are dynamic and permit local conformational changes that optimize interaction energetics.
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Finally, we explored the role of aromaticity in the Asp16–Phe18 interaction by preparing
variants DX and SX, where we incorporated the nonaromatic residue cyclohexylalanine (Cha;
one-letter abbreviation is X) at position 18. The interaction of Asp16 with Cha18 does not
contribute a significant amount to WW stability (0.08 ± 0.02 kcal/mol), indicating aromaticity of
the side chain at position 18 is essential for an anion-π interaction with position 16

Table 4-1. Folded Free energies of WW proteins SN, DN and their Sequence Variants at 60 °Ca
Protein

Position 16

Position 18

Tm (°C)

SN

Ser

Asn

65.7± 0.1

-0.53± 0.01

DN

Asp

Asn

68.7± 0.1

-0.80± 0.01

SY

Ser

Tyr

58.3± 0.3

0.15± 0.03

DY

Asp

Tyr

64.2± 0.2

-0.37± 0.02

SH

Ser

His

60.8± 0.1

-0.06± 0.01

DH

Asp

His

65.4± 0.1

-0.45± 0.01

SF

Ser

Phe

52.8± 0.2

1.05± 0.04

DF

Asp

Phe

65.9± 0.1

-0.53± 0.01

SZ

Ser

F5Phe

49.7± 0.1

1.33± 0.03

DZ

Asp

F5Phe

62.6± 0.1

-0.26± 0.01

SX

Ser

Cha

58.4± 0.1

0.22± 0.01
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ΔG(kcal/mol) ΔΔΔG(kcal/mol)

-0.26± 0.04

-0.12± 0.02

-1.31± 0.05

-1.33± 0.03

DX

Asp

Cha

61.3± 0.1

-0.13± 0.01

-0.08± 0.02

a

Folded free energies are given ± standard error in kcal/mol at 60 °C (333.15 K) in 20 μM sodium
Phosphate buffer (pH7). Z = pentaflourophenylalanine; X = cyclohexylalanine

4.3

Conclusions

Here, we have shown that anionic Asp can interact favorably with Phe to increase the
stability of the WW domain. Our results complement previous computational predictions6, 9-10, 3335

along with earlier studies of an α-helical model system,20-21 suggesting that the anion−π

interaction should be considered as an important addition to the tool box of noncovalent
interactions used to understand protein folding, to design new proteins, and to develop smallmolecule effectors of protein function.

4.4
4.4.1

Supporting information
Protein Synthesis

WW peptide variants SN, DN, SY, DY, SY, DY, SF, DF, DZ, SZ, SX, DX (sequences shown in
main text, Z = pentafluorophenylalanine, X = cyclohexylalanine) were synthesized as C-terminal
acids (Fmoc-Gly-Wang resin, EMD Millipore), by microwave-assisted solid-phase peptide
synthesis, using a standard Fmoc Nα protection strategy as described previously in chapter 2
section 2.4.1.

4.4.2

Protein Purification and Characterization
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Immediately prior to purification, the crude protein was dissolved in 1:1 H2O/MeCN. Proteins
were purified by preparative reverse-phase high performance liquid chromatography (HPLC) on a
C18 column using a linear gradient of water in acetonitrile with 0.1% v/v TFA. Fractions
containing the desired protein product were pooled, frozen, and lyophilized. Proteins were
identified by electrospray ionization time of flight mass spectrometry (ESI-TOF); mass spectra
appear below in Figures S1–S12. Protein purity was assessed by Analytical HPLC (Figures S13–
S24).
ESI-TOF spectra for proteins WW peptide variants SN, DN, SY, DY, SY, DY, SF, DF, DZ,
SZ, SX, DX are shown in Figures 4-2–4-11.

Figure 4-2. ESI TOF spectrum for SN. Expected [M+3H]3+/3 = 1251.619 Da. Observed [M+3H]3+/3 =
1251.607 Da.
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Figure 4-3. ESI TOF spectrum for DN. Expected [M+4H+]/4 = 945.965 Da. Observed [M+4H+]/4 =
945.948 Da.

Figure 4-4. ESI TOF spectrum for SY. Expected [M+4H+]/4 = 951.221 Da. Observed [M+4H+]/4 =
951.218 Da.

Figure 4-5. ESI TOF spectrum for DY. Expected [M+4H+]/4 = 958.220 Da. Observed [M+4H+]/4 =
958.215 Da.
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Figure 4-6. ESI TOF spectrum for SF. Expected [M+3H+]/3 = 1262.6272 Da. Observed [M+3H+]/3 =
1262.6244 Da.

Figure 4-7. ESI TOF spectrum for DF. Expected [M+3H+]/3 = 1271.9588 Da. Observed [M+3H+]/3 =
1271.9511 Da.

Figure 4-8. ESI TOF spectrum for SZ. Expected [M+3H+]/3 = 1292.6115 Da. Observed [M+3H+]/3 =
1292.6085 Da (Z= pentaflourophenylalanine).
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Figure 4-9. ESI TOF spectrum for DZ. Expected [M+3H+]/3 = 1301.9431 Da. Observed [M+3H+]/3 =
1301.9408 Da (Z= pentaflourophenylalanine).

Figure 4-10. ESI TOF spectrum for SX. Expected [M+4H+]/4 = 948.7341 Da. Observed [M+4H+]/4 =
948.7248 Da (X=cyclohexylalanine).

Figure 4-11. ESI TOF spectrum for DX. Expected [M+4H+]/4 = 955.7328 Da. Observed [M+4H+]/4 =
955.7174 Da (X=cyclohexylalanine).
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HPLC traces for proteins SN, DN, SY, DY, SF, DF, SZ, DZ, SX, DX are shown in Figures 4-12–
4-21.

Figure 4-12. Analytical HPLC Data for SN. Protein solution was injected onto a C18 analytical column
and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over 50
minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration (10% B) with a
flow rate of 1 mL/min.

Figure 4-13. Analytical HPLC Data for DN. Protein solution was injected onto a C18 analytical column
and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over 50
minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration (10% B) with a
flow rate of 1 mL/min.
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Figure 4-14. Analytical HPLC Data for SY. Protein solution was injected onto a C18 analytical column
and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over 50
minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration (10% B) with a
flow rate of 1 mL/min.

Figure 4-15. Analytical HPLC Data for DY. Protein solution was injected onto a C18 analytical column
and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over 50
minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration (10% B) with a
flow rate of 1 mL/min.
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Figure 4-16. Analytical HPLC Data for SF. Protein solution was injected onto a C18 analytical column
and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over 50
minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration (10% B) with a
flow rate of 1 mL/min.

Figure 4-17. Analytical HPLC Data for DF. Protein solution was injected onto a C18 analytical column
and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over 50
minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration (10% B) with a
flow rate of 1 mL/min.
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Figure 4-18. Analytical HPLC Data for SZ. Protein solution was injected onto a C18 analytical column
and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over 50
minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration (10% B) with a
flow rate of 1 mL/min. (Z = pentaflourophenylalanine)

Figure 4-19. Analytical HPLC Data for DZ. Protein solution was injected onto a C18 analytical column
and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over 50
minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration (10% B) with a
flow rate of 1 mL/min. (Z = pentaflourophenylalanine)
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Figure 4-20. Analytical HPLC Data for SX. Protein solution was injected onto a C18 analytical column
and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over 50
minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration (10% B) with a
flow rate of 1 mL/min. (X = cyclohexylalanine)

Figure 4-21. Analytical HPLC Data for DX. Protein solution was injected onto a C18 analytical column
and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over 50
minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration (10% B) with a
flow rate of 1 mL/min. (X = cyclohexylalanine)

4.4.3

Circular Dichroism Spectropolarimetry
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Measurements were made with an Aviv 420 Circular Dichroism Spectropolarimeter, using
quartz cuvettes with a path length of 0.1 cm. Protein solutions were prepared in 20 mM sodium
phosphate buffer, pH 7, and protein concentrations were determined spectroscopically based on
tyrosine and tryptophan absorbance at 280 nm in 8 M guanidine hydrochloride + 20 mM sodium
phosphate (εTrp = 5690 M-1cm-1, εTyr = 1280 M-1cm-1).36 CD spectra of 50 μM solutions of SN,
DN, SY, DY, SF, DF, SZ, DZ, SX, and DX were obtained from 260 to 200 nm at 25°C. Variable
temperature CD data were obtained at least in triplicate by monitoring the molar ellipticity at 227
nm of 50 µM solutions of in 20 mM sodium phosphate (pH 7) from 1 to 95°C at 2 °C intervals,
with 120 s equilibration time between data points and 30 s averaging time.
The folding equilibria of SN, DN, SY, DY, SF, DF, SZ, DZ, SX, and DX do not involve
self-association into quaternary structures; rather, an unfolded monomer proceeds to a folded
monomer via a single high-energy transition state, with the position of the equilibrium determined
by folding equilibrium constant Kf:

(S10)
We used the following equation to fit the variable temperature CD data:
[θ] =

(uo +u1 T)+(fo +f1 T)Kf
1+Kf

(S11)

T is the temperature in Kelvin; uo and u1 are the intercept and slope of the post-transition baseline,
respectively; fo and f1 are the intercept and slope of the pre-transition baseline, respectively; and
Kf is the folding equilibrium constant as defined by equations S12 and S13:
−∆Gf

K f = exp �
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RT

�

(S12)

(S13)
where R is the universal gas constant (0.0019872 kcal/mol/K), and the fit parameters are Tm (the
midpoint of the unfolding transition; the temperature at which ΔGf = 0), ΔH(Tm), the change in
enthalpy upon folding at Tm; and ΔCp, the change in heat capacity upon folding. In some cases,
standard errors indicated that certain parameters (typically ΔCp and/or u1) were unlikely to be
significant (p-value > 0.01). When this happened, we fit the data again with modified equations
that eliminated the insignificant parameters.
We used parameters from the fits of the variable temperature CD data for SN, DN, SY,
DY, SF, DF, SZ, DZ, SX, and DX variants to calculate the folding free energy values presented
in the main text. CD spectra and variable temperature CD data for SN, DN, SY, DY, SF, DF, SZ,
DZ, SX, and DX are shown in Figures 4-21–4-40, along with the parameters that were used to
generate global fits for each compound. The standard error for each fitted parameter is also shown.
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Figure 4-22. (A) CD spectrum and (B)–(D) variable temperature CD data for 50 µM solutions of protein
SN in 20 mM sodium phosphate, pH 7. Parameters used to fit the variable temperature CD data to
equations S6–S9 are also shown, with standard errors as indicated; R2 = 0.9999.
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Figure 4-23. (A) CD spectrum and (B)–(D) variable temperature CD data for 50 µM solutions of protein
DN in 20 mM sodium phosphate, pH 7. Parameters used to fit the variable temperature CD data to
equations S6–S9 are also shown, with standard errors as indicated; R2 = 0.9999.
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Figure 4-24. (A) CD spectrum and (B)–(D) variable temperature CD data for 50 µM solutions of protein
SY in 20 mM sodium phosphate, pH 7. Parameters used to fit the variable temperature CD data to
equations S6–S9 are also shown, with standard errors as indicated; R2 = 0.9994.
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Figure 4-25. (A) CD spectrum and (B)–(I) variable temperature CD data for 50 µM solutions of protein
DY in 20 mM sodium phosphate, pH 7. Parameters used to fit the variable temperature CD data to
equations S6–S9 are also shown, with standard errors as indicated; R2 = 0.9988.
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Figure 4-26. (A) CD spectrum and (B)–(D) variable temperature CD data for 50 µM solutions of protein
SNR in 20 mM sodium phosphate, pH 7. Parameters used to fit the variable temperature CD data to
equations S6–S9 are also shown, with standard errors as indicated; R2 = 0.9999.
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Figure 4-27. (A) CD spectrum and (B)–(D) variable temperature CD data for 50 µM solutions of protein
DNR in 20 mM sodium phosphate, pH 7. Parameters used to fit the variable temperature CD data to
equations S6–S9 are also shown, with standard errors as indicated; R2 = 0.9997.

263

Figure 4-28. (A) CD spectrum and (B)–(D) variable temperature CD data for 50 µM solutions of protein
SYR in 20 mM sodium phosphate, pH 7. Parameters used to fit the variable temperature CD data to
equations S6–S9 are also shown, with standard errors as indicated; R2 = 0.9996.
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Figure 4-29. (A) CD spectrum and (B)–(D) variable temperature CD data for 50 µM solutions of protein
DYR in 20 mM sodium phosphate, pH 7. Parameters used to fit the variable temperature CD data to
equations S6–S9 are also shown, with standard errors as indicated; R2 = 0.9996.
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Figure 4-30. (A) CD spectrum and (B)–(D) variable temperature CD data for 50 µM solutions of protein
SH in 20 mM sodium phosphate, pH 7. Parameters used to fit the variable temperature CD data to
equations S6–S9 are also shown, with standard errors as indicated; R2 = 0.9999.
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Figure 4-31. (A) CD spectrum and (B)–(D) variable temperature CD data for 50 µM solutions of protein
DH in 20 mM sodium phosphate, pH 7. Parameters used to fit the variable temperature CD data to
equations S6–S9 are also shown, with standard errors as indicated; R2 = 0.9999.
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Figure 4-32. (A) CD spectrum and (B)–(D) variable temperature CD data for 50 µM solutions of protein
SF in 20 mM sodium phosphate, pH 7. Parameters used to fit the variable temperature CD data to
equations S6–S9 are also shown, with standard errors as indicated; R2 = 0.9992.
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Figure 4-33. (A) CD spectrum and (B)–(D) variable temperature CD data for 50 µM solutions of protein
DF in 20 mM sodium phosphate, pH 7. Parameters used to fit the variable temperature CD data to
equations S6–S9 are also shown, with standard errors as indicated; R2 = 0.9999.
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Figure 4-34. (A) CD spectrum and (B)–(D) variable temperature CD data for 50 µM solutions of protein
SZ in 20 mM sodium phosphate, pH 7. Parameters used to fit the variable temperature CD data to
equations S6–S9 are also shown, with standard errors as indicated; R2 = 0.9994.
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Figure 4-35. (A) CD spectrum and (B)–(D) variable temperature CD data for 50 µM solutions of protein
DZ in 20 mM sodium phosphate, pH 7. Parameters used to fit the variable temperature CD data to
equations S6–S9 are also shown, with standard errors as indicated; R2 = 0.9997.
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Figure 4-36. (A) CD spectrum and (B)–(D) variable temperature CD data for 50 µM solutions of protein
SX in 20 mM sodium phosphate, pH 7. Parameters used to fit the variable temperature CD data to
equations S6–S9 are also shown, with standard errors as indicated. R2 = 0.9997.
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Figure 4-37. (A) CD spectrum and (B)–(D) variable temperature CD data for 50 µM solutions of protein
SX in 20 mM sodium phosphate, pH 7. Parameters used to fit the variable temperature CD data to
equations S6–S9 are also shown, with standard errors as indicated. R2 = 0.9999.
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Figure 4-38. (A) CD spectrum and (B)–(D) variable temperature CD data for 50 µM solutions of protein
SD in 20 mM sodium phosphate, pH 7. Parameters used to fit the variable temperature CD data to
equations S6–S9 are also shown, with standard errors as indicated. R2 = 0.9998.
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Figure 4-39. (A) CD spectrum and (B)–(D) variable temperature CD data for 50 µM solutions of protein
FN in 20 mM sodium phosphate, pH 7. Parameters used to fit the variable temperature CD data to
equations S6–S9 are also shown, with standard errors as indicated. R2 = 0.9999.
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Figure 4-40. (A) CD spectrum and (B)–(D) variable temperature CD data for 50 µM solutions of protein
FD in 20 mM sodium phosphate, pH 7. Parameters used to fit the variable temperature CD data to
equations S6–S9 are also shown, with standard errors as indicated. R2 = 0.9999.
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5

THE CYSI-LYSI+3-LYSI+4 TRIAD: A GENERAL APPROACH FOR PEG-BASED
STABILIZATION OF Α-HELICAL PROTEINS.

5.1

Introduction

Attaching polyethylene glycol oligomers (PEGs) to protein surface side chains (i.e.
PEGylation) is an important strategy for protecting protein drugs from immunogenicity,
aggregation, proteolysis, and for increasing their serum half-life.1-3 Early protein PEGylation
strategies were generally non-specific, where current chemoselective side-chain modification
strategies now allow specific placement of a single PEG at any position on a protein surface.4-8
However, this site-specific protein PEGylation raises the questions: where should we put PEG?
Do some PEGylation sites provide more pharmacokinetic protection than others? If so, can we
develop rational guidelines for recognizing optimal PEGylation sites in advance, thereby
accelerating the development of PEGylated protein drugs?
Because unfolded or misfolded proteins are more aggregation-prone,9-10 more susceptible
to proteolysis,11-13 and more readily recognized by antibodies,14-15 we hypothesize that optimal
PEGylation sites should be characterized by the ability of the attached PEG to increase protein
conformational stability. To support this hypothesis, the Price lab has demonstrated that PEGbased stabilization of a reverse turn in the β-sheet-containing WW domain of the human protein
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Pin 1 is associated with enhanced resistance to proteolysis.16 However, it is unclear whether
PEGylation can stabilize other secondary structures such as α-helices.
Here we explore the energetic impact of PEGylating a trimeric α-helical coiled coil. We
find that modifying a solvent-exposed Cys with a PEG-maleimide increases the conformational
stability of the coiled coil due to a favorable three-way interaction between the PEG-maleimide
and two Lys residues at the i+3 and i+4 positions, relative to Cys. Analogous positioning of this
Cysi-Lysi+3-Lysi+4 triad in the C-terminal α-helix of the villin headpiece domain results in similar
PEG-based increases to conformational stability. Our findings suggest that the Cysi-Lysi+3-Lysi+4
triad is a simple, general, structure based sequence motif for identifying or installing stabilizing
maleimide-based PEGylation sites within α-helical proteins.

5.2

Results and Discussion

Early studies showed that N-terminal PEGylation of coiled-coil peptides can promote
helical secondary structure;17-18 but can be either stabilizing18 or destabilizing17 to coiled-coil
quaternary structure for reasons that are unclear. Xu and coworkers19 used a 2000 Da PEGmaleimide to modify a centrally located solvent-exposed Cys residue within the designed trimeric
coiled coil 1CW (Figure 5-1).20 The resulting PEGylated peptide p1CW was more helical than its
non-PEGylated counterpart, and retained the ability to form a cooperatively folded trimeric coiled
coil.19 Small-angle X-ray scattering studies of p1CW revealed that the PEG in p1CW is more
compact than would be expected for a free PEG in solution, possibly due to favorable PEG-peptide
interactions.21-22 Molecular dynamic simulations by two different groups23-24 suggested the
possible role of interactions between positively charged Lys residues and electronegative oxygen
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atoms of the PEG oligomer in mediating PEG-based increases in helicity. One study implicated
Lys7, Lys15, and Lys21 as particularly important.23

Figure 5-1. Ribbon diagram (rendered in Pymol) of the parent coiled-coil trimer from which 1CW was
derived. Installation of a Cys at position 14 (highlighted in green) facilitates site-specific PEGylation
with a 2000 Da PEG maleimide.

If these predictions are accurate, replacing Lys7, Lys15, or Lys21 with Ala (i.e. Ala
mutation) should lessen the impact of PEGylation on helicity. To test this hypothesis, we used
solid-phase peptide synthesis to prepare peptide 1CW and alanine mutants 7A, 15A, 21A, in which
Lys residues at positions 7, 15, or 21, respectively, have been changed to Ala (see supporting
information Table S4). We then prepared PEGylated peptides p1CW, p7A, p15A, and p21A by
modifying Cys14 in 1CW, 7A, 15A, 21A with a 2000 Da PEG-maleimide. The CD spectra of
these peptides have minima at 222 nm and 208 nm, consistent with α-helical secondary structure
and coiled-coil quaternary structure. Analysis of these spectra with the program K2D325 indicates
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that PEGylated p1CW is 2% more helical than 1CW in 20 mM sodium phosphate buffer, pH 7.
Interestingly, Ala mutation of Lys7, Lys15, or Lys21 does not lessen the impact of PEGylation on
helicity: p7A, p15A, and p21A are each 6%, 5%, and 9% more helical, respectively, than their
non-PEGylated counterparts, a greater increment than we observed for p1CW relative to 1CW.
These results suggest that any interactions between PEG and Lys7, Lys15, or Lys21 do not contribute
to the enhanced helicity of p1CW.
In principle, Lys-PEG interactions could affect coiled-coil quaternary structural stability,
independent of their effect on α-helical secondary structure. To test this hypothesis, we used
sedimentation equilibrium experiments to verify the trimeric association state of 7A, p7A, 15A,
p15A, 21A, and p21A. We assessed the conformational stability of these compounds by fitting
variable temperature CD data to equations derived from a two-state folding model for a coiled-coil
trimer (see supporting information for details).
We find that the p1CW coiled coil is less stable than 1CW: a 30 µM solution of 1CW has
a melting temperature (Tm) of 78.3 °C, whereas a 30 µM solution of p1CW has a Tm of 76.8 °C,
corresponding to decrease in stability of 0.26 ± 0.07 kcal mol-1 at the reference temperature of
70°C. Ala mutation at position 7 does not substantially change the impact of PEGylation on coiledcoil stability, suggesting that PEG-Lys7 interactions do not play a significant role. In contrast, Ala
mutation at positions 15 and 21 makes PEGylation even more unfavorable than observed for
p1CW (see supporting information Table S4, compare p15A vs. 15A, ΔΔGf = 0.44 ± 0.03 kcal
mol-1; compare p21A and 21A, ΔΔGf = 0.58 ± 0.03), suggesting that interactions between the
PEG-maleimide and Lys15 or Lys21 do contribute to the stability of p1CW, though not enough to
stabilize p1CW relative to 1CW. We wondered whether these Lys/PEG-maleimide interactions
might have a greater stabilizing impact if the Lys residues were located closer in space to
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PEGylated Cys14. To test this hypothesis, we generated peptides 17K, 18K, and their PEGylated
counterparts (p17K and p18K), in which wild-type residues at i+3 position 17 or i+4 position 18,
respectively, have been changed to Lys (see supporting information Table S4). We chose these
positions because they are only one helical turn away from Cys14, along the same solvent-exposed
face of the helix. We also prepared 17/18K and PEGylated p17/18K, in which Lys residues occupy
both positions 17 and 18.
CD spectra and sedimentation equilibrium experiments confirm that 17K, p17K, 18K,
p18K, 17/18K, and p17/18K each form coiled-coil trimers. Maleimide-based PEGylation has no
impact on the conformational stability of p17K and p18K relative to 17K and 18K, respectively
(see supporting information Table S5). In contrast, the p17/18K coiled coil is -0.85 ± 0.06 kcal
mol-1 more stable than the 17/18K coiled coil. Because there are three PEG oligomers in each
trimeric p17/18K coiled coil, we can infer that each PEG-maleimide imparts ~ -0.28 kcal/mol to
coiled-coil stability. Peptides 1CW, p1CW, 17K, p17K, 18K, p18K, 17/18K, and p17/18K
comprise a triple mutant cycle. As we have done previously,26 we can use variable temperature
CD data for these compounds to parse the stabilizing impact of maleimide-based PEGylation on
p17/18K into several components, including the intrinsic impact of the PEG-maleimide on coiledcoil stability; two-way interactions between Lys17 or Lys18 and the PEG-maleimide; and a threeway interaction among the PEG-maleimide, Lys17, and Lys18 (each component represents the total
contribution of the three PEG-maleimides).
Triple mutant cycle analysis reveals that maleimide-based PEGylation of Cys14 is
intrinsically destabilizing (ΔΔGf = 0.26 kcal mol-1), but this effect is offset by favorable Lys/PEGmaleimide interactions in p17/18K (Figure 5-2). Two-way interactions between Lys17 or Lys18
and the PEG-maleimide contribute a total of ~ -0.27 and -0.22 kcal mol-1, respectively, to coiled-
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coil quaternary structural stability. An additional -0.62 kcal mol-1 of synergistic stabilization
comes from a three-way interaction among the PEG-maleimide, Lys17, and Lys18, suggesting that
optimal PEG-based stabilization requires the presence of Lys residues at both the i+3 and i+4
positions relative to the PEGylated i-position Cys.

Figure 5-2. Triple mutant cycle analysis of 1CW, p1CW 17K, p17K, 18K, p18K 17/18K, and p17/18K:
parsing of PEG-based stabilization of p17/18K relative to 17/18K into the intrinsic impact of maleimidebased PEGylation along with interactions among the PEG-maleimide, Lys17, and Lys18.

We wondered whether the length of PEG affects the increase in conformational stability
associated with attaching the PEG-maleimide to the Cysi-Lysi+3-Lysi+4 triad in p17/18K. To test
this hypothesis, we prepared peptides p17/18K-1kDa and m17/18K, in which a 1000 Da PEGmaleimide and a non-PEGylated maleimide have been attached to the Cys at position 14 in 17/18K,
respectively (Figure 5-3). Variable temperature CD experiments reveal that p17/18K-1kDa is
slightly more stable than its counterpart p17/18K (which harbors a 2000 Da PEG), though the
exact difference in stability is challenging to extract from the CD data because p17/18K-1kDa
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does not reach a fully unfolded conformation even at the highest temperature sampled. We
estimate that p17/18K-1kDa is -1.2 ± 0.1 kcal mol-1 more stable than non-PEGylated 17/18K and
is -0.33 ± 0.06 kcal mol-1 more stable than p17/18K. Surprisingly, non-PEGylated maleimidemodified m17/18K is the most stable variant of all; we estimate that m17/18K is -2.3 ± 0.1 kcal
mol-1 more stable than non-PEGylated 17/18K and is -1.4 ± 0.1 kcal mol-1 more stable than
p17/18K (again, these stability differences are estimates as m17/18K does not reach a fully
unfolded conformation at the highest temperature sampled).

Figure 5-3. Variable temperature CD data for 17/18K, p17/18K, p17/18K-1kDa (which harbors a 1000
Da PEG-maleimide), and m17/18K (which has a Cys-linked maleimide, but no PEG).

Notwithstanding predictions of previous molecular dynamics simulations to the
contrary,25,26 these results strongly suggest that the increased conformational stability of p17/18K
relative to non-PEGylated 17/18K does not come from favorable interactions between Lys17,
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Lys18, and the electronegative oxygen atoms of PEG. Instead, the stabilization appears to come
from favorable interactions between Lys17, Lys18, and the maleimide group, possibly between the
cationic ε-ammonium groups of Lys17 and Lys18 and the carbonyl oxygen atoms of the maleimide.
Adding PEG to the maleimide decreases the stability of these interactions in a length dependent
manner, with longer oligomers leading to less substantial stabilization, possibly by increasing the
conformational entropy of the PEG-functionalized maleimide group. However, we note that
attaching the 2000 Da PEG-maleimide to the Cysi-Lysi+3-Lysi+4 triad in 17/18K is still a stabilizing
modification overall (ΔΔGf = -0.85 ± 0.06 kcal mol-1), suggesting that the Cysi-Lysi+3-Lysi+4 triad
is a better site for PEG-maleimide modification than locations that lack the i+3 and i+4 Lys
residues.
We wondered whether attaching the 2000 Da PEG-maleimide to the Cysi-Lysi+3-Lysi+4
triad in other helical contexts might result in similar stabilization. To test this hypothesis, we turned
to a truncated variant of the villin headpiece domain (VHP), an extensively characterized 35residue protein in which three α-helices pack around a core composed of non-polar and aromatic
amino acids (Figure 5-4A,B).27-29 We began with destabilized variant 10/12L, instead of wildtype VHP (Figure 5-4A),28 because we feared the high thermal stability of VHP would make
characterizing PEG-based stabilization difficult. The third turn of the C-terminal helix of 10/12L
contains two adjacent Lys residues: Lys29 and Lys30. Replacing Gln26 with Cys gives protein
VHP1, which harbors the complete Cysi-Lysi+3-Lysi+4 triad. We generated PEGylated pVHP1 by
modifying Cys26 in VHP1 with a 2000 Da PEG-maleimide.
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Figure 5-4. (A) Sequences of proteins VHP, 10/12L, VHP1, pVHP1, VHP2, and pVHP2; box denotes
Cys modified with a 2000 Da PEG-maleimide (B) Ribbon diagram of VHP (PDB ID: 1VII), with
hydrophobic core side-chain atoms shown as spheres. (C) and (D) Ribbon diagrams showing placement
of the Cysi-Lysi+3-Lysi+4 triad at flanking and backside positions, respectively, in the C-terminal helix of
VHP1 and VHP2.

The Tm of PEGylated pVHP1 is 3.4 ± 0.1 °C higher than that of unmodified VHP1,
corresponding to an increase in conformational stability of -0.18 ± 0.01 kcal mol-1. This result
demonstrates maleimide-based PEGylation of the Cysi-Lysi+3-Lysi+4 triad can stabilize proteins
other than p17/18K. However, the increased stability of pVHP1 relative to VHP1 is somewhat
lower than we observed previously for p17/18K relative to 17/18K (~-0.28 kcal/mol per triad),
possibly because the Cysi-Lysi+3-Lysi+4 triad in pVHP1 flanks the hydrophobic core of the protein
(Figure 5-4C), where steric clashes with PEG might limit stabilization.
We explored this possibility by shifting the Cysi-Lysi+3-Lysi+4 triad one position toward the
C-terminal end of the helix to generate VHP2 and PEGylated pVHP2. The Cysi-Lysi+3-Lysi+4
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triad in these variants occupies the solvent-exposed “backside” of the helix, as far from the
hydrophobic core as possible (Figure 5-4D). Maleimide-based PEGylation increases the Tm of
pVHP2 by 9.1 ± 0.4 °C relative to VHP2, corresponding to an increase in conformational stability
of -0.29 ± 0.01 kcal mol-1, an increment that more closely matches what we observed in p17/18K,
suggesting that modifying the Cysi-Lysi+3-Lysi+4 triad with a PEG-maleimide is a general way to
stabilize α-helical proteins.

5.3

Conclusions

We have shown that favorable interactions between an i position PEG-maleimide and two
i+3 and i+4 position Lys residues stabilizes two different α-helical proteins. Our results suggest
that the Cysi-Lysi+3-Lysi+4 triad is a simple sequence motif for identifying or installing stabilizing
maleimide-based PEGylation sites within α-helical proteins. Many important therapeutic proteins
contain α-helices (e.g. erythropoietin, granulocyte colony stimulating factor, interferon α, etc.);
application of the Cysi-Lysi+3-Lysi+4 in these contexts should accelerate the development of
PEGylated protein drugs with enhanced conformational stability (and therefore enhanced
resistance to proteolysis, aggregation, and immunogenicity). Moreover, the fact that modifying the
Cysi-Lysi+3-Lysi+4 triad with maleimide alone results in even greater increases to conformational
stability suggests that a Cysi-Lysi+3-Lysi+4 triad, positioned carefully in an α-helix could be an ideal
site for using maleimide chemistry to immobilize helical proteins on solid supports or to
functionalize them with fluorophores or drug conjugates.
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5.4

Contributions

Contributions of Brijesh Pandey, a former post-doctoral researcher in the Price lab, were
significant to this Chapter; When the data were published Mason and Brijesh shared first
authorship.30 Brijesh demonstrated the PEG based Helix stability in the 1CW model system
(Figures 5-1, 5-2). Mason demonstrated PEG-based helix stability in the VHP system and did the
length dependence study showing that the maleimide linker contributed the most stability to the
1CW coiled coil (Figure 5-3, 5-4).

5.5

5.5.1

Supporting Information

Protein Synthesis
Peptides 1CW, 7A, 15A, 21A, 17K, 18K, 17/18K, VHP1, VHP2, and their PEGylated

counterparts p1CW, p7A, p15A, p21A, p17K, p18K, p17/18K, pVHP1, and pVHP2 (Table S1)
were synthesized as C-terminal amides, by microwave-assisted solid-phase peptide synthesis,
using a standard Fmoc Nα protection strategy as described previously in chapter 2 section 2.4.1.16
We prepared PEGylated proteins p1CW, p7A, p15A, p21A, p17K, p18K, p17/18K,
pVHP1, and pVHP2 by functionalizing the Cys14 in proteins 1CW, 7A, 15A, 21A, 17K, 18K,
17/18K, VHP1, VHP2 with a 2 kDa monomethoxy PEG maleimide (average PEG M.W. = 2000
Da; Jenkem Technology, ZZ099P356) according to the following general protocol: Following
initial purification of 25 µmol crude 1CW variant, half of the resulting purified material (assumed
to be ~12.5 µmol) was dissolved in 2mL of milli-Q water. The maleimide-functionalized 2 kDa
monomethoxy PEG (62.5 µmol, 5 eq) was then added to the solution and stirred at room
temperature for 2 hours. The resulting solution was then stored at -20°C until subjected to further
purification and characterization. We used a similar approach to prepare peptide p17/18K-1kDa,
except we used a 1 kDa monomethoxy PEG-maleimide.
We prepared peptide m17/18K by functionalizing Cys14 in peptide 17/18K with 3maleimidopropionic acid (M.W. = 169.135, AK scientific) according the following procedure:
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500uL of purified 17/18K (195uM) was diluted to a 1mL solution of 20mM tris (pH = 6.9),
approximately 20eq. of maleimidopropionoic acid (0.32mg), and 10 eq. of TCEP HCl (0.27mg,
Thermo Scientific). The resulting solution was stirred at room temperature for 24 hours and then
subjected to reverse phase HLPC chromatography.
5.5.2

Protein Purification and Characterization

Immediately prior to purification, the crude protein was dissolved in 1:1 H2O/MeCN. Proteins
were purified by preparative reverse-phase high performance liquid chromatography (HPLC) on a
C18 column using a linear gradient of water in acetonitrile with 0.1% v/v TFA. Fractions
containing the desired protein product were pooled, frozen, and lyophilized. Proteins were
identified by electrospray ionization time of flight mass spectrometry (ESI-TOF); mass spectra
appear below in Figures S1–S29. Protein purity was assessed by Analytical HPLC (Figures S30–
S49).

ESI-TOF spectra for proteins 1CW, 7A, 15A, 21A, 17K, 18K, 17/18K, VHP1, VHP2, their
PEGylated counterparts p1CW, p7A, p15A, p21A, p17K, p18K, p17/18K, pVHP1, pVHP2,
p17/18K-1kDa, and m17/18K are shown in Figures 5-5–5-33.

Figure 5-5. ESI TOF spectrum for 1CW. Expected [M+3H]3+/3 = 1249.6689 Da. Observed [M+3H]3+/3
= 1249.6645 Da.
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Figure 5-6. ESI TOF spectrum for p1CW with 38 PEG units. Expected [M+4H++2NH4+]/6 = 940.1915
Da. Observed [M+4H++2NH4+]/6 = 940.184 Da.

Figure 5-7. ESI TOF spectrum for p1CW with 48 PEG units. Expected [M+4H++2NH4+]/6 = 1013.5686
Da. Observed [M+4H++2NH4+]/6 = 1013.58 Da.

Figure 5-8. ESI TOF spectrum for 7A. Expected [M+3H]3+/3 = 1230.6469 Da. Observed [M+3H]3+/3 =
1230.6470 Da.
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Figure 5-9. ESI TOF spectrum for p7A with 40 PEG units. Expected [M+3H++2NH4+]/5 = 1134.2272
Da. Observed [M+3H++2NH4+]/5 = 1134.2217 Da.

Figure 5-10. ESI TOF spectrum for p7A with 36 PEG units. Expected [M+3H++2NH4+]/5 = 1099.0062
Da. Observed [M+3H++2NH4+]/5 = 1098.964 Da.

Figure 5-11. ESI TOF spectrum for 15A. Expected [M+3H]3+/3 = 1230.6469 Da. Observed [M+3H]3+/3
= 1230.6387 Da.
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Figure 5-12. ESI TOF spectrum for p15A with 43 PEG units. Expected [M+4H++2NH4+]/6 = 967.3704
Da. Observed [M+4H++2NH4+]/6 = 967.3447 Da.

Figure 5-13. ESI TOF spectrum for p15A with 40 PEG units. Expected [M+3H++2NH4+]/5 = 1134.2272
Da. Observed [M+3H++2NH4+]/5 = 1134.2217 Da.

Figure 5-14. ESI TOF spectrum for K21A. Expected [M+3H]3+/3 = 1230.6469 Da. Observed
[M+3H]3+/3 = 1230.6631 Da.
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Figure 5-15. ESI TOF spectrum for p21A with 40 PEG units. Expected [M+3H++2NH4+]/5 = 1134.2272
Da. Observed [M+3H++2NH4+]/5= 1134.2217 Da.

Figure 5-16. ESI TOF spectrum for p21A with 43 PEG units. Expected [M+5H++2NH4+]/7 = 829.3186
Da. Observed [M+5H++2NH4+]/7 = 829.3045Da.

Figure 5-17. ESI TOF spectrum for 17K. Expected [M+3H]3+/3 = 1249.6811 Da. Observed [M+3H]3+/3
= 1249.6999 Da.

294

Figure 5-18. ESI TOF spectrum for p17K with 45 PEG units. Expected [M+4H++2NH4+]/6 = 991.5616
Da. Observed [M+4H++2NH4+]/6 = 991.5709 Da.

Figure 5-19. ESI TOF spectrum for p17K with 44 PEG units. Expected [M+4H++2NH4+]/6 = 984.2238
Da. Observed [M+4H++2NH4+]/6 = 984.2355 Da.

Figure 5-20. ESI TOF spectrum for 18K. Expected [M+3H]3+/3 = 1268.6882 Da. Observed [M+3H]3+/3
= 1268.7061 Da.
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Figure 5-21. ESI TOF spectrum for p18K with 40 PEG units. Expected [M+4H++2NH4+]/6 = 964.3766
Da. [M+4H++2NH4+]/6 = 964.3656 Da.

Figure 5-22. ESI TOF spectrum for p18K with 41 PEG units. Expected [M+4H++2NH4+]/6 = 971.7143
Da. [M+4H++2NH4+]/6 = 971.7190 Da.

Figure 5-23. ESI TOF spectrum for 17K/18K. Expected [M+3H]3+/3 = 1268.7004 Da. Observed
[M+3H]3+/3 = 1268.7243Da.
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Figure 5-24. ESI TOF spectrum for p17K/18K with 45 PEG units. Expected [M+4H++2NH4+]/6 =
1001.0712 Da. Observed [M+4H++2NH4+]/6 = 1001.0757 Da.

Figure 5-25. ESI TOF spectrum for p17K/18K with 46 PEG units. Expected [M+4H++2NH4+]/6 =
1008.4089 Da. Observed [M+4H++2NH4+]/6 = 1008.4161 Da.

Figure 5-26. ESI TOF spectrum for VHP1. Expected [M+3H]3+/3 = 1341.0635 Da. Observed
[M+3H]3+/3 = 1341.0614.
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Figure 5-27. ESI TOF spectrum for pVHP1 with a 45 unit PEG. Expected [M+4H++2NH4+]/6 =
1037.2528 Da. Observed [M+4H++2NH4+]/6 = 1037.2518 Da.

Figure 5-28. ESI TOF spectrum for pVHP1. Expected with a 44 unit PEG. Expected [M+4H++2NH4+]/6
= 1029.9151 Da. Observed [M+4H++2NH4+]/6 = 1029.8636.

Figure 5-29. ESI TOF spectrum for VHP2. Expected [M+4H+]/4 = 1009.3166 Da. Observed [M+4H+]/4
= Da.
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Figure 5-30. ESI TOF spectrum for pVHP2 with 41 PEG units. Expected [M+4H++2NH4+]/6 =
1010.0800 Da. Observed [M+4H++2NH4+]/6 = 1010.0807 Da.

Figure 5-31. ESI TOF spectrum for pVHP2 with 42 PEG units. Expected [M+4H++2NH4+]/6 =
1017.4177 Da. Observed [M+4H++2NH4+]/6 = 1017.4135 Da.

Figure 5-32. ESI TOF spectrum for p17/18K-1kDa. Expected [M+2H++K++Na++NH4+]/5 = 1003.9497
Observed [M+2H++K++Na++NH4+]/5 =1003.9694
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Figure 5-33. ESI TOF spectrum for m17/18K. Expected [M+4H+]/4 = 994.03665 Da. Observed
[M+4H+]/4 = 994.0503 Da.

HPLC traces for proteins 1CW, 7A, 15A, 21A, 17K, 18K, 17/18K, VHP1, VHP2, and
their PEGylated counterparts p1CW, p7A, p15A, p21A, p17K, p18K, p17/18K, pVHP1,
pVHP2, p17/18K-1kDa, and m17/18K are shown in Figures 5-34–5-53.

Figure 5-34. Analytical HPLC Data for 1CW. Protein solution was injected onto a C18 analytical column
and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over 50
minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration (10% B) with a
flow rate of 1 mL/min.
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Figure 5-35. Analytical HPLC Data for p1CW. Protein solution was injected onto a C18 analytical
column and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over
50 minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration (10% B)
with a flow rate of 1 mL/min.

Figure 5-36. Analytical HPLC Data for 7A. Protein solution was injected onto a C18 analytical column
and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over 50
minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration (10% B) with a
flow rate of 1 mL/min.
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Figure 5-37. Analytical HPLC Data for p7A. Protein solution was injected onto a C18 analytical column
and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over 50
minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration (10% B) with a
flow rate of 1 mL/min.

Figure 5-38. Analytical HPLC Data for 15A. Protein solution was injected onto a C18 analytical column
and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over 50
minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration (10% B) with a
flow rate of 1 mL/min.
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Figure 5-39. Analytical HPLC Data for p15A. Protein solution was injected onto a C18 analytical
column and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over
50 minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration (10% B)
with a flow rate of 1 mL/min.

Figure 5-40. Analytical HPLC Data for 21A. Protein solution was injected onto a C18 analytical column
and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over 50
minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration (10% B) with a
flow rate of 1 mL/min.
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Figure 5-41. Analytical HPLC Data for p21A. Protein solution was injected onto a C18 analytical
column and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over
50 minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration (10% B)
with a flow rate of 1 mL/min.

Figure 5-42. Analytical HPLC Data for 17K. Protein solution was injected onto a C18 analytical column
and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over 50
minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration (10% B) with a
flow rate of 1 mL/min.

Figure 5-43. Analytical HPLC Data for p17K. Protein solution was injected onto a C18 analytical
column and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over
50 minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration (10% B)
with a flow rate of 1 mL/min.
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Figure 5-44. Analytical HPLC Data for 18K. Protein solution was injected onto a C18 analytical column
and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over 50
minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration (10% B) with a
flow rate of 1 mL/min.

Figure 5-45. Analytical HPLC Data for p18K. Protein solution was injected onto a C18 analytical
column and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over
50 minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration (10% B)
with a flow rate of 1 mL/min.
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Figure 5-46. Analytical HPLC Data for 17K/18K. Protein solution was injected onto a C18 analytical
column and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over
50 minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration (10% B)
with a flow rate of 1 mL/min.

Figure 5-47. Analytical HPLC Data for p17K/18K. Protein solution was injected onto a C18 analytical
column and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over
50 minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration (10% B)
with a flow rate of 1 mL/min.
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Figure 5-48. Analytical HPLC Data for VHP1. Protein solution was injected onto a C18 analytical
column and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over
50 minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration (10% B)
with a flow rate of 1 mL/min.

Figure 5-49. Analytical HPLC Data for pVHP1. Protein solution was injected onto a C18 analytical
column and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over
50 minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration (10% B)
with a flow rate of 1 mL/min.
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Figure 5-50. Analytical HPLC Data for VHP2. Protein solution was injected onto a C18 analytical
column and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over
50 minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration (10% B)
with a flow rate of 1 mL/min.

Figure 5-51. Analytical HPLC Data for pVHP2. Protein solution was injected onto a C18 analytical
column and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over
50 minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration (10% B)
with a flow rate of 1 mL/min.
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Figure 5-52. Analytical HPLC Data for p17/18K-1kDa. Protein solution was injected onto a C18
analytical column and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1%
TFA) over 50 minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration
(10% B) with a flow rate of 1 mL/min.

Figure 5-53. Analytical HPLC Data for m17/18K. Protein solution was injected onto a C18 analytical
column and eluted using a linear gradient of 10-60% B (A=H2O, 0.1% TFA; B= MeCN, 0.1% TFA) over
50 minutes, followed by a 10 minute rinse (95% B), and a 10 minute column re-equilibration (10% B)
with a flow rate of 1 mL/min.
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5.5.3

Variable Temperature CD experiments

Details and equations used for the Thermodynmic measurements of 1CW, p1CW, 7A,
p7A, 15A, p15A, 21A, p21A, 17K, p17K, 18K, p18K, 17K/18K, p17K/18K, p17K/18K-1kDa
and m17/18K can be found in Chapter 2 section 2.4.5. Details and equations used for the
Thermodynmic measurements for VHP1, pVHP1, VHP2, and pVHP2 (50 μM) can be found in
chapter 4 section 4.4.3.
We used the parameters generated by fitting the variable temperature CD data for 1CW
and VHP variants to calculate the folding free energy values presented in the main text. CD spectra
and variable temperature CD data for 1CW, p1CW, 7A, p7A, 15A, p15A, 21A, p21A, 17K,
p17K, 18K, p18K, 17K/18K, p17K/18K, p17/18K-1kDa, m17/18K, VHP1, pVHP1, VHP2,
pVHP2 are shown in Figures 5-54–5-64, along with the parameters that were used to generate
global fits for each compound. The standard error for each fitted parameter is also shown.
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Figure 5-54. CD spectra (lines, top left), variable temperature CD data (circles, top right) for 30 µM
solutions of proteins 1CW (black) and p1CW (red) in 20 mM sodium phosphate, pH 7. Parameters used
to fit the variable temperature CD data to equations S6–S9 are also shown, with standard errors as
indicated.

Figure 5-55. CD spectra (lines, top left), variable temperature CD data (circles, top right) for 30 µM
solutions of proteins 7A (black) and p7A (red) in 20 mM sodium phosphate, pH 7. Parameters used to fit
the variable temperature CD data to equations S6–S9 are also shown, with standard errors as indicated.
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Figure 5-56. CD spectra (lines, top left), variable temperature CD data (circles, top right) for 30 µM
solutions of proteins 15A (black) and p15A (red) in 20 mM sodium phosphate, pH 7. Parameters used to
fit the variable temperature CD data to equations S6–S9 are also shown, with standard errors as indicated.
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Figure 5-57. CD spectra (lines, top left), variable temperature CD data (circles, top right) for 30 µM
solutions of proteins 21A (black) and p21A (red) in 20 mM sodium phosphate, pH 7. Parameters used to
fit the variable temperature CD data to equations S6–S9 are also shown, with standard errors as indicated.
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Figure 5-58. CD spectra (lines, top left), variable temperature CD data (circles, top right) for 30 µM
solutions of proteins 17K (black) and p17K (red) in 20 mM sodium phosphate, pH 7. Parameters used to
fit the variable temperature CD data to equations S6–S9 are also shown, with standard errors as indicated.

Figure 5-59. CD spectra (lines, top left), variable temperature CD data (circles, top right) for 30 µM
solutions of proteins 18K (black) and p18K (red) in 20 mM sodium phosphate, pH 7. Parameters used to
fit the variable temperature CD data to equations S6–S9 are also shown, with standard errors as indicated.
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Figure 5-60. CD spectra (lines, top left), variable temperature CD data (circles, top right) for 30 µM
solutions of proteins 17K/18K (black) and p17K/18K (red) in 20 mM sodium phosphate, pH 7.
Parameters used to fit the variable temperature CD data to equations S6–S9 are also shown, with standard
errors as indicated.

Figure 5-61. CD spectra (lines, top left), variable temperature CD data (circles, top right) for 30 µM
solutions of proteins 17K/18K (black) and p17K/18K-1kDa (red) in 20 mM sodium phosphate, pH 7.
Parameters used to fit the variable temperature CD data to equations S6–S9 are also shown, with standard
errors as indicated.
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Figure 5-62. CD spectra (lines, top left), variable temperature CD data (circles, top right) for 30 µM
solutions of proteins 17K/18K (black) and m17K/18K (red) in 20 mM sodium phosphate, pH 7.
Parameters used to fit the variable temperature CD data to equations S6–S9 are also shown, with standard
errors as indicated.
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Figure 5-63. CD spectra (lines, top left), variable temperature CD data (circles, top right) for 50 µM
solutions of proteins VHP1 (black) and pVHP1 (red) in 20 mM sodium phosphate, pH 7. Parameters
used to fit the variable temperature CD data to equations S11–S13 are also shown, with standard errors as
indicated.

Figure 5-64. CD spectra (lines, top left), variable temperature CD data (circles, top right) for 50 µM
solutions of proteins VHP2 (black) and pVHP2 (red) in 20 mM sodium phosphate, pH 7. Parameters
used to fit the variable temperature CD data to equations S11–S13 are also shown, with standard errors as
indicated.

5.5.4 Sedimentation Equilibrium experiments
Sedimentation equilibrium experiments were performed using a Beckman XLA
ultracentrifuge. Peptide solutions were loaded into 1.2 cm cells, and sedimentation was
monitored by absorbance at 280 nm. Sedimentation equilibria were analyzed at several speeds
ranging from 12 to 45 krpm, and data were collected at 0.001 cm intervals along the length of the
cell at each speed. After changing speeds, samples were allowed to equilibrate for 24 hours at
the new speed prior to data collection, which was also repeated 2 hours later to verify that the
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consecutive data sets were superimposable, signaling that the system was at equilibrium.
Apparent molecular weight was determined by least-squares regression of the equilibrium radial
absorbance data using MS Excel and Solver. Data were fit to models either for a single species,
or for an equilibrium between monomer and n-mer (equations S14 and S15, respectively):

A(r) = baseline + Ao exp �
A(r) = Ao exp �

M(1−νρ)ω2 (r2 −r2o )
2RT

M(1−νρ)ω2 (r2 −r2o )
2RT

� + KA𝑛𝑛𝑜𝑜 exp �

�

nM(1−νρ)ω2 (r2 −r2o )
2RT

In equation S14, A(r) is the absorbance (at 280 nm) at radial position r (in cm); Ao is the

(S14)

� (S15)

absorbance ( at 280 nm) at an arbitrary reference radial position ro; M is the apparent molecular
weight of the peptide; ν is the partial specific volume of the peptide (in cm3 g-1); ρ is the density
of the sample (calculated using SEDNTERP; ρ = 1.00046 g cm-3 for a 20 mM sodium phosphate
solution at pH 7); ω is the radial velocity (in s-1) of the rotor; R is the universal gas constant
(8.3144 x 107 erg mol-1 K-1); T is the temperature (in Kelvin), and “baseline” is a correction for
absorbance resulting from non-sedimenting components of the sample.
The variables in equation S15 have the same meaning, except Ao is the absorbance (at
280 nm) due to monomer at the arbitrary reference radial position; K is the equilibrium constant
for the association between the monomer and the n-mer; n is the aggregation number for the
species in equilibrium with the monomer; M is the molecular weight of the monomer, assuming
appropriately ionized side-chains at pH 7.
The partial specific volumes (ν) for each non-PEGylated 1CW variant were calculated
following the method of Durschlag and Zipper31 and are shown in Table 5-1. For PEGylated
1CW variants, we estimated ν according to the following equation (S16):
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ν=�

ν1 𝑀𝑀1 +ν2 𝑀𝑀2
𝑀𝑀1 +𝑀𝑀2

�

(S16)

where, ν1 is the partial specific volume of a 1CW variant modified at Cys14 with a maleimidePEG containing only one PEG unit; M1 is the calculated molecular weight of this peptide; ν2 is
the partial specific volume of a 44-unit PEG oligomer (~44 PEG units; ν2 = 0.836 cm3 g-1,
measured previously for a 2000 Da PEG32); and M2 is the molecular weight of the 44-unit PEG
oligomer (1938 Da).
Table 5-1. Molecular Weight and Partial Specific Volumes for 1CW variants and their PEGylated counterparts.

Peptide

Calculated
M (g mol-1)

Calculated
ν (cm3 g-1)

Observed M
single species fit
(g mol-1)

Mobs/Mcalc

Aggregation
state

p1CW

5909.8

0.7687

15.7 ± 0.1 × 103

2.7

trimer

7A

3687.1

0.7327

11.9 ± 0.1 × 103

3.2

trimer

p7A

5851.7

0.7675

13.5 ± 0.1 × 103

2.3

trimer

15A

3687.1

0.7327

10.5 ± 0.3 × 103

2.8

trimer

p15A

5851.7

0.7675

14.0 ± 0.1 × 103

2.4

trimer

21A

3687.1

0.7327

9.2 ± 0.1 × 103

2.5

trimer

p21A

5851.7

0.7675

14.2 ± 0.1 × 103

2.4

trimer

17K

3746.3

0.7389

10.2 ± 0.1 × 103

2.7

trimer

p17K

5910.8

0.7711

16.1 ± 0.2 × 103

2.7

trimer

18K

3803.3

0.7375

10.6 ± 0.1 × 103

2.8

trimer

p18K

5967.9

0.7699

14.7 ± 0.1 × 103

2.5

trimer

17K/18K

3804.4

0.7412

11.3 ± 0.1 × 103

3.0

trimer

p17K/18K

5968.9

0.7723

15.3 ± 0.1 × 103

2.6

trimer
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As a rule, equilibrium sedimentation data were fit to the single species model first; the
equilibrium models were attempted if the single species fit was unsatisfactory. The quality of a
particular fit was judged based on the R2 value (closer to 1 is better), the fit standard deviation
(lower is better), and the appearance of the residual plots, which show the difference between the
data and the fit at each radial position (smaller and more random deviations from residual = 0 are
better). If the single-species and equilibrium models were of similar quality according to these
criteria, we used the simpler model to describe the peptides shown in Table 5-1. The best model
selected for each peptide according to these criteria is highlighted with a magenta box in Figures
5-65–5-76. In each case, alternative models are also presented to show how we arrived at the
conclusions presented in Table 5-1.
In most cases, the observed apparent molecular weights shown in Table 5-1 are smaller
than the molecular weights expected for a trimer composed of three copies of a 1CW variant or
its PEGylated counterpart. These differences may be a result of charged-based non-ideality, in
which charge-charge repulsion decreases the apparent molecular weight of peptide assemblies by
shifting the equilibrium distribution of the peptide away from the bottom of the cell. The
difference may also reflect errors in the calculated values of density (ρ) or partial specific volume
(ν) that were used in each fit. In most cases, a small 3-6% change in ρ or ν could account for the
deviation of the experimental apparent molecular weight from the calculated molecular weight of
the trimer. For PEGylated compounds, the difference may also reflect the polydisperse nature of
the PEG oligomer; some protein-PEG conjugates will have PEG oligomers that are longer or
shorter than the average nominal 45-unit length. We note that previously published
sedimentation equilibrium experiments from Xu and coworkers19 gave observed molecular
weights for 1CW and p1CW of 10177 Da and 17147 Da. These values are respectively 9% and
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3% smaller than expected; Xu and coworkers nonetheless conclude that 1CW and p1CW are
helix-bundle trimers.
The smaller size of the observed molecular weights relative to the calculated trimer
molecular weights in Table 5-1 could also be consistent with 1CW variants that are equilibrating
between two or more distinct species under the conditions of the experiment. To test this
hypothesis, we attempted to fit the sedimentation data for each variant to a monomer-dimer,
monomer-trimer, and monomer-tetramer equilibrium model according to equation S15. In so
doing, we used the monomer molecular weights listed in Table 5-1 as constants, along with n =
2, 3, or 4 as desired. In each case, the monomer-dimer and monomer-tetramer fits were of
substantially lower quality than the monomer-trimer fit, which itself was of slightly lower quality
than the single species fit. Given the potential uncertainty that results from charge-based nonideality; errors in ρ and v; and a polydisperse PEG conjugate, we conclude that the single species
fit and monomer-trimer equilibrium fit lead to the same conclusion: that each of the 1CW
variants shown in Table 5-1 forms a helix-bundle trimer in solution.
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Figure 5-65. Sedimentation equilibrium data for p1CW in 20 mM sodium phosphate, pH 7. Data were
fit to four different models; the best-fitting model is highlighted in magenta.
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Figure 5-66. Sedimentation equilibrium data for 7A in 20 mM sodium phosphate, pH 7. Data were fit to
four different models; the best-fitting model is highlighted in magenta.
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Figure 5-67. Sedimentation equilibrium data for p7A in 20 mM sodium phosphate, pH 7. Data were fit
to four different models; the best-fitting model is highlighted in magenta.
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Figure 5-68. Sedimentation equilibrium data for 15A in 20 mM sodium phosphate, pH 7. Data were fit
to four different models; the best-fittting model is highlighted in magenta.
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Figure 5-69. Sedimentation equilibrium data for p15A in 20 mM sodium phosphate, pH 7. Data were fit
to four different models; the best-fittting model is highlighted in magenta.
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Figure 5-70. Sedimentation equilibrium data for 21A in 20 mM sodium phosphate, pH 7. Data were fit
to four different models; the best-fittting model is highlighted in magenta.
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Figure 5-71. Sedimentation equilibrium data for p21A in 20 mM sodium phosphate, pH 7. Data were fit
to four different models; the best-fittting model is highlighted in magenta.
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Figure 5-72. Sedimentation equilibrium data for 17K in 20 mM sodium phosphate, pH 7. Data were fit
to four different models; the best-fittting model is highlighted in magenta.
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Figure 5-73. Sedimentation equilibrium data for p17K in 20 mM sodium phosphate, pH 7. Data were fit
to four different models; the best-fittting model is highlighted in magenta.
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Figure 5-74. Sedimentation equilibrium data for 18K in 20 mM sodium phosphate, pH 7. Data were fit
to four different models; the best-fittting model is highlighted in magenta.
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Figure 5-75. Sedimentation equilibrium data for p18K in 20 mM sodium phosphate, pH 7. Data were fit
to four different models; the best-fittting model is highlighted in magenta.
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Figure 5-76. Sedimentation equilibrium data for 17K/18K in 20 mM sodium phosphate, pH 7. Data were
fit to four different models; the best-fittting model is highlighted in magenta.
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Figure 5-77. Sedimentation equilibrium data for p17K/18K in 20 mM sodium phosphate, pH 7. Data
were fit to four different models; the best-fittting model is highlighted in magenta.
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5.5.5

Triple Mutant Cycle Analysis
As described in the main text, we used least-squares regression to fit the thermodynamic

data for 17/18K, p17/18K, 17K, p17K, 18K, p18K, 1CW, and p1CW to the following
equation:
∆𝐺𝐺𝑓𝑓 = ∆𝐺𝐺𝑓𝑓𝑜𝑜 + �∆∆𝐺𝐺C14C(PEG) ∙ 𝑊𝑊14C(PEG) � + �∆∆𝐺𝐺Q17K ∙ 𝑊𝑊17K � + �∆∆𝐺𝐺A18K ∙ 𝑊𝑊18K �

+�∆∆∆𝐺𝐺14C(PEG),17K ∙ 𝑊𝑊14C(PEG) ∙ 𝑊𝑊17K � + �∆∆∆𝐺𝐺14C(PEG),18K ∙ 𝑊𝑊14C(PEG) ∙ 𝑊𝑊18K �
+�∆∆∆𝐺𝐺17K,18K ∙ 𝑊𝑊17K ∙ 𝑊𝑊18K �

+�∆∆∆∆𝐺𝐺14C(PEG),17K,18K ∙ 𝑊𝑊14C(PEG) ∙ 𝑊𝑊17K ∙ 𝑊𝑊18K �

(S17)

where ΔGf is the folding free energy of a given variant of 1CW; ΔGf° is the folding free energy
of 1CW; ΔΔGC14C(PEG), ΔΔGQ17K, and ΔΔGA18K describe the intrinsic energetic consequences of
the Cys14 to Cys14(PEG), Gln17 to Lys17, and Ala18 to Lys18 mutations, respectively;
ΔΔΔG14C(PEG),17K, ΔΔΔG14C(PEG),18K, and ΔΔΔG17K,18K, describe the two-way interaction energies
between Cys14(PEG) and Lys17, between Cys14(PEG) and Lys18, and between Lys17 and Lys18,
respectively, relative to the corresponding two-way interaction energies in 1CW between Cys14
and Gln17, between Cys14 and Ala18, and between Gln17 and Ala18, respectively;
ΔΔΔΔG14C(PEG),17K,18K describes the three-way interaction energy between Cys14(PEG), Lys17,
and Lys18 relative to the corresponding three-way interaction energy in 1CW between Cys14,
Gln17, and Ala18; W14C(PEG) is 0 when position 14 is Cys or 1 when it is Cys(PEG); W17K = 0
when position 17 is Gln or 1 when it is Lys; W18K = 0 when position 18 is Ala or 1 when it is
Lys. Parameters obtained from this analysis are given in Table 5-2
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Table 5-2. Triple mutant cycle analysis of folding free energy data for 1CW variants at 70 °C
(338.15 K).
Energetic Contribution
(kcal mol-1)
-16.43

ΔGf °
ΔΔGC14C(PEG)

0.26

ΔΔGQ17K

-0.06

ΔΔGA18K

1.33

ΔΔΔG14C(PEG),17K

-0.27

ΔΔΔG14C(PEG),18K

-0.22

ΔΔΔG17K,18K

0.06

ΔΔΔΔG14C(PEG),17K,18

-0.57

Table 5-3. CD spectra and variable temperature CD data for PEGylated and non-PEGylated
variants of 1CW at 70 °C.a
Peptide

Sequence

[]222

%

Tm

ΔGf

helicity (°C) (kcal mol-1) (kcal mol-1)

1CW Ac-EVEALEKKVAALECKVQALEKKVEALEHGWDGR-CONH2 -25.2 ± 0.3

67

78.3

-16.43 ± 0.05

p1CW Ac-EVEALEKKVAALECKVQALEKKVEALEHGWDGR-CONH2 -26.5 ± 0.4

69

76.8

-16.17 ± 0.05

Ac-EVEALEAKVAALECKVQALEKKVEALEHGWDGR-CONH2 -23.9 ± 0.4

62

74.5

-15.41 ± 0.03

p7A Ac-EVEALEAKVAALECKVQALEKKVEALEHGWDGR-CONH2 -26.0 ± 0.3

68

73.1

-15.20 ± 0.03

7A

ΔΔGf

15A Ac-EVEALEKKVAALECAVQALEKKVEALEHGWDGR-CONH2 -24.5 ± 0.3

65

68.5

-14.01 ± 0.02

p15A Ac-EVEALEKKVAALECAVQALEKKVEALEHGWDGR-CONH2 -26.8 ± 0.3

70

66.7

-13.57 ± 0.02

21A Ac-EVEALEKKVAALECKVQALEAKVEALEHGWDGR-CONH2 -24.6 ± 0.3

67

73.2

-15.23 ± 0.02

p21A Ac-EVEALEKKVAALECKVQALEAKVEALEHGWDGR-CONH2 -29.6 ± 0.3

76

71.0

-14.65 ± 0.01

0.26 ± 0.07

0.21 ± 0.04

0.44 ± 0.03

0.58 ± 0.03

| | | | | | |
1 5 10 15 20 25 30
aData

collected at 30 µM peptide concentration in 20 mM sodium phosphate, pH 7 at 25 °C. % helicity estimated using the

program K2D3. ΔGf and ΔΔGf were calculated at 70 °C. []222 is in units of 103 deg dmol cm-2 res-1. C denotes a Cys residue
modified with a 2000 Da PEG-maleimide (see Figure 1).
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Table 5-3. Variable temperature CD data for 1CW, 17K, 18K, 17/18K, and their PEGylated
counterparts at 70 °C.a
ΔGf (kcal

ΔΔGf (kcal

mol-1)

mol-1)

Peptide

Sequence

Tm (°C)

1CW

Ac-EVEALEKKVAALECKVQALEKKVEALEHGWDGR-CONH2

78.3

-16.43 ± 0.05

p1CW

Ac-EVEALEKKVAALECKVQALEKKVEALEHGWDGR-CONH2

76.8

-16.17 ± 0.05

17K

Ac-EVEALEKKVAALECKVKALEKKVEALEHGWDGR-CONH2

79.3

-16.49 ± 0.04

p17K

Ac-EVEALEKKVAALECKVKALEKKVEALEHGWDGR-CONH2

79.5

-16.50 ± 0.04

18K

Ac-EVEALEKKVAALECKVQKLEKKVEALEHGWDGR-CONH2

73.1

-15.10 ± 0.03

p18K

Ac-EVEALEKKVAALECKVQKLEKKVEALEHGWDGR-CONH2

73.3

-15.06 ± 0.03

17/18K

Ac-EVEALEKKVAALECKVKKLEKKVEALEHGWDGR-CONH2

73.8

-15.23 ± 0.03

p17/18K Ac-EVEALEKKVAALECKVKKLEKKVEALEHGWDGR-CONH2

79.2

-16.08 ± 0.04

0.26 ± 0.07

-0.01 ± 0.06

0.04 ± 0.04

-0.85 ± 0.06

| | | | | | |
1 5 10 15 20 25 30
aData

are for 30 µM peptide solutions in 20 mM sodium phosphate, pH 7. ΔGf and ΔΔGf were calculated at 70 °C. C denotes

a Cys residue modified with a 2000 Da PEG-maleimide (see Figure 1).
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